P01282450A01
Pain_NN management_NN ,_, nutritional_JJ support_NN ,_, and_CC psychosocial_JJ support_NN are_VBB fundamental_JJ services_NNS that_PNR enhance_VVB patients_NNS '_GE ability_NN to_TO cope_VVI with_II their_PNG cancer_NN and_CC its_PNG therapy_NN ._.
P01350716A05
Seven_MC trials_NNS of_II beta-blockers_NNS and_CC 15_MC of_II sclerotherapy_NN were_VBD published_VVN as_II full_JJ papers_NNS ._.
P01421653A15
CONCLUSIONS_NNS :_: Although_CS more_RR well-designed_VVNJ clinical_JJ trials_NNS comparing_VVG pamidronate_NN with_II standard_JJ therapies_NNS and_CC other_JJ available_JJ agents_NNS are_VBB necessary_JJ ,_, initial_JJ results_NNS indicate_VVB that_CST pamidronate_NN is_VBZ an_DD effective_JJ and_CC promising_VVGJ alternative_NN for_II use_NN in_II the_DD treatment_NN of_II HCM_NN ._.
P01462793A01
BACKGROUND_NN :_: More_RR than_CSN 11_MC million_MC people_NNS in_II the_DD United_VVNJ States_NNS have_VHB moderate_JJ or_CC severe_JJ migraine_NN resulting_VVG in_II much_DD suffering_VVGN and_CC millions_NNS of_II lost_VVNJ work_NN days_NNS annually_RR ._.
P01533416A11
Thirty-eight_MC of_II 44_MC effect_NN sizes_NNS indicated_VVD that_CST SMT_NN was_VBD better_JJR than_CSN the_DD comparison_NN treatment_NN ._.
P01538563A14
There_EX has_VHZ been_VBN an_DD exponential_JJ increase_NN in_II knowledge_NN regarding_VVG the_DD interactions_NNS among_II the_DD components_NNS of_II the_DD stress_NN system_NN and_CC between_II the_DD stress_NN system_NN and_CC other_JJ brain_NN elements_NNS involved_VVN in_II the_DD regulation_NN of_II emotion_NN ,_, cognitive_JJ function_NN ,_, and_CC behavior_NN ,_, as_CC+ well_CC+ as_CC with_II the_DD axes_NNS responsible_JJ for_II reproduction_NN ,_, growth_NN ,_, and_CC immunity_NN ._.
P01595772A01
Gastroesophageal_JJ reflux_NN disease_NN (_( GERD_NN )_) remains_VVZ a_DD ubiquitous_JJ problem_NN ,_, although_CS therapeutic_JJ options_NNS continue_VVB to_TO evolve_VVI ._.
P01616217A13
Medical_JJ interventions_NNS that_PNR effectively_RR halt_VVB the_DD progression_NN or_CC prevent_VVB the_DD development_NN of_II diabetic_JJ retinopathy_NN are_VBB needed_VVN ._.
P01658404A08
Because_CS PID_NN is_VBZ polymicrobial_JJ in_II cause_NN ,_, recommended_VVNJ antimicrobial_JJ regimens_NNS are_VBB broad-spectrum_NN in_II coverage_NN ._.
P01726215A18
The_DD modest_JJ ,_, reversible_JJ risk_NN of_II neutropenia_NN ,_, affecting_VVG less_RR than_CSN 1_MC %_SYM of_II patients_NNS ,_, makes_VVZ the_DD benefit_NN :_SYM risk_NN ratio_NN a_DD reasonable_JJ one_PN ._.
P01767696A02
Central_JJ to_II the_DD debate_NN are_VBB the_DD results_NNS of_II the_DD major_JJ placebo-controlled_VVNJ clinical_JJ trials_NNS of_II pharmacologic_JJ treatment_NN of_II hypercholesterolemia_NN ._.
P01828529A09
In_II the_DD case_NN of_II comparative_JJ studies_NNS the_DD relative_JJ risks_NNS of_II severe_JJ reactions_NNS in_II low-risk_NN versus_CC high-risk_NN patients_NNS and_CC with_II LOCM_NN compared_VVN with_II HOCM_NN were_VBD treated_VVN for_II homogeneity_NN ,_, and_CC pooled_VVNJ odds_NNS ratios_NNS and_CC 95_MC %_SYM confidence_NN intervals_NNS (_( CI_NN )_) were_VBD calculated_VVN by_II combining_VVGN the_DD logarithms_NNS of_II the_DD odds_NNS ratios_NNS weighted_VVN by_II their_PNG variances_NNS ._.
P01934395A12
The_DD consensus_NN was_VBD that_CST a_DD very_RR restrictive_JJ and_CC cautious_JJ attitude_NN to_II the_DD newer_JJR settings_NNS is_VBZ appropriate_JJ at_II this_DD time_NN ._.
P02050423A02
Although_CS there_EX are_VBB differences_NNS in_II pathogens_NNS by_II age_NN ,_, the_DD importance_NN of_II nosocomial_JJ pneumonia_NN is_VBZ apparent_JJ in_II the_DD adult_NN population_NN as_CC+ well_CC+ as_CC in_II the_DD pediatric_JJ patient_NN groups_NNS ._.
P02206035A07
In_II the_DD United_VVNJ States_NNS ,_, lovastatin_NN will_VM be_VBB used_VVN in_II a_DD double-blind_JJ ,_, placebo-controlled_VVNJ ,_, primary_JJ prevention_NN trial_NN involving_VVG 8,000_MC patients_NNS without_II clinical_JJ evidence_NN of_II CAD_NN ,_, slight_JJ to_II moderate_JJ elevations_NNS of_II total_JJ cholesterol_NN ,_, and_CC low-_JJ and_CC high-density_NN lipoprotein_NN cholesterol_NN to_TO establish_VVI whether_CST 5_MC years_NNS of_II treatment_NN will_VM decrease_VVB the_DD rate_NN of_II fatal_JJ CAD_NN or_CC nonfatal_JJ myocardial_JJ infarction_NN ._.
P02491421A14
In_II many_DD patients_NNS with_II renal_JJ disease_NN ,_, ACE_NN inhibitors_NNS dramatically_RR reduce_VVB proteinuria_NN ,_, but_CC whether_CST they_PN also_RR reduce_VVB the_DD rate_NN of_II progression_NN of_II renal_JJ disease_NN remains_VVZ unproved_VVN ._.
P02656825A15
7._MC Finally_RR ,_, in_II this_DD era_NN of_II quality_NN assurance_NN ,_, professional_JJ review_NN and_CC cost_NN containment_NN ,_, it_PN behooves_VVZ each_DD physician_NN to_TO ask_VVI whether_CST the_DD data_NNS provided_VVN by_II the_DD particular_JJ tests_NNS were_VBD worth_II the_DD cost_NN ,_, inconvenience_NN and_CC risk_NN for_II that_DD particular_JJ patient_NN ._.
P02864682A09
The_DD success_NN of_II captopril_NN ,_, the_DD first_JJ oral_JJ agent_NN of_II this_DD class_NN ,_, promises_VVZ to_TO hold_VVI true_JJ for_II other_JJ ACE_NN inhibitors_NNS (_( such_II+ as_II enalapril_NN )_) ,_, which_PNR have_VHB similar_JJ activities_NNS but_CC differing_VVGJ pharmacokinetic_JJ properties_NNS and_CC will_VM soon_RR be_VBB available_JJ for_II clinical_JJ use_NN ._.
P03414608A08
The_DD ATP_NN 's_GE report_NN established_VVD criteria_NNS that_PNR define_VVB candidates_NNS with_II high_JJ blood_NN cholesterol_NN levels_NNS who_PNR should_VM receive_VVB medical_JJ intervention_NN and_CC provided_VVD guidelines_NNS on_II how_CST to_TO detect_VVI ,_, set_VVI goals_NNS ,_, treat_VVI ,_, and_CC monitor_VVI these_DD patients_NNS over_II time_NN ._.
P07474194A07
CONCLUSIONS_NNS --_: Sympathetic_JJ nervous_JJ system_NN activation_NN in_II patients_NNS with_II chronic_JJ heart_NN failure_NN is_VBZ a_DD major_JJ contributor_NN to_II the_DD severity_NN of_II disease_NN as_CC+ well_CC+ as_CC its_PNG progression_NN over_II time_NN ._.
P07486487A12
The_DD pooled_VVNJ sensitivity_NN was_VBD 66_MC %_SYM (_( 95_MC %_SYM CI_NN ,_, 57_MC %_SYM to_II 74_MC %_SYM )_) ,_, and_CC the_DD pooled_VVNJ specificity_NN was_VBD 98_MC %_SYM (_( CI_NN ,_, 96_MC %_SYM to_II 99.5_MC %_SYM )_) ._.
P07503088A01
Some_DD aspects_NNS of_II thyroid_NN nodule_NN evaluation_NN and_CC management_NN remain_VVB controversial_JJ ._.
P07527326A07
Titrating_VVGN quinapril_NN dosages_NNS from_II 10_MC to_II 40_MC mg_NN /_SYM day_NN increased_VVD response_NN rates_NNS without_II increasing_VVGN the_DD incidence_NN or_CC severity_NN of_II adverse_JJ events_NNS ._.
P07563563A09
Thereafter_RR ,_, the_DD panel_NN resolved_VVD conflicting_VVGJ recommendations_NNS and_CC released_VVD a_DD revised_VVNJ statement_NN at_II the_DD end_NN of_II the_DD conference_NN ._.
P07587242A08
Experts_NNS in_II closed_VVNJ loop_NN systems_NNS were_VBD then_RR added_VVN to_II the_DD group_NN to_TO review_VVI the_DD summary_NN provided_VVN by_II the_DD task_NN force_NN ._.
P07596718A18
Five_MC trials_NNS reporting_VVG deaths_NNS from_II tuberculosis_NN showed_VVD a_DD BCG_NN protective_JJ effect_NN of_II 0.65_MC (_( 95_MC %_SYM CI_NN ,_, 0.12_MC to_II 0.86_MC )_) ,_, five_MC studies_NNS reporting_VVG on_II meningitis_NN showed_VVD a_DD protective_JJ effect_NN of_II 0.64_MC (_( 95_MC %_SYM CI_NN ,_, 0.30_MC to_II 0.82_MC )_) ,_, and_CC three_MC studies_NNS of_II disseminated_VVNJ tuberculosis_NN showed_VVD a_DD protective_JJ effect_NN of_II 0.78_MC (_( 95_MC %_SYM CI_NN ,_, 0.58_MC to_II 0.88_MC )_) ._.
P07606076A04
DATA_NNS EXTRACTION_NN :_: The_DD most_RRT recent_JJ clinical_JJ trials_NNS that_PNR evaluated_VVD cytotoxic_JJ chemotherapy_NN or_CC hormonal_JJ therapy_NN in_II patients_NNS with_II node-negative_JJ breast_NN cancer_NN were_VBD chosen_VVN ._.
P07639445A03
Five_MC major_JJ areas_NNS were_VBD identified_VVN and_CC searched_VVN :_: cardiomyopathies_NNS ,_, atrial_JJ fibrillation_NN ,_, the_DD long_JJ QT_NN syndrome_NN ,_, cardiac_JJ transplantation_NN ,_, and_CC vasovagal_JJ syncope_NN ._.
P07650455A11
One_MC technique_NN ,_, atherectomy_NN ,_, has_VHZ been_VBN shown_VVN to_TO be_VBI no_RR more_RR effective_JJ ,_, and_CC more_RR expensive_JJ ,_, than_CSN conventional_JJ balloon_NN angioplasty_NN ._.
P07663033A01
OBJECTIVE_NN :_: To_TO discuss_VVI the_DD role_NN of_II amiodarone_NN for_II the_DD maintenance_NN of_II normal_JJ sinus_NN rhythm_NN in_II patients_NNS with_II atrial_JJ fibrillation_NN (_( AF_NN )_) and_CC review_VVI the_DD clinical_JJ trial_NN data_NNS evaluating_VVG the_DD efficacy_NN and_CC safety_NN of_II amiodarone_NN in_II patients_NNS with_II AF_NN ._.
P07674695A10
The_DD most_RRT recent_JJ data_NNS from_II the_DD 4S_NN trial_NN have_VHB unequivocally_RR demonstrated_VVN the_DD benefits_NNS of_II treatment_NN with_II HMG_NN coenzyme-A_NN reductase_NN inhibitors_NNS in_II reducing_VVGN the_DD risk_NN of_II future_JJ coronary_JJ events_NNS and_CC improving_VVGN the_DD overall_JJ survival_NN in_II patients_NNS with_II established_VVNJ CHD_NN ._.
P07700062A05
Are_VBB ACE_NN inhibitors_NNS beneficial_JJ in_II mild-to-moderate_JJ heart_NN failure_NN ?_.
P07726699A06
To_II our_PNG knowledge_NN ,_, no_DD randomized_VVNJ ,_, placebo-controlled_VVNJ trials_NNS of_II amiodarone_NN therapy_NN for_II atrial_JJ fibrillation_NN have_VHB been_VBN published_VVN ._.
P07752668A09
There_EX are_VBB also_RR promising_VVGJ data_NNS suggesting_VVG that_CST beta-blockade_NN is_VBZ useful_JJ in_II endothelial_JJ protection_NN and_CC atheroma_NN prevention_NN ,_, and_CC benefits_VVZ patients_NNS with_II hypertrophic_JJ cardiomyopathy_NN and_CC heart_NN failure_NN ._.
P07786840A10
More_RR recently_RR ,_, preliminary_JJ results_NNS from_II the_DD third_JJ Gruppo_NN Italiano_NN per_II lo_DD Studio_NN della_II Sopravvivenza_NN nell'Infarto_NN Miocardico_NN (_( GISSI-3_NN )_) ,_, the_DD Fourth_JJ International_JJ Study_NN of_II Infarct_NN Survival_NN (_( ISIS-4_NN )_) ,_, and_CC the_DD Chinese_NN Captopril_NN Trial_NN suggested_VVD that_CST angiotensin-converting_VVGJ enzyme_NN (_( ACE_NN )_) inhibitor_NN mortality_NN benefits_NNS post-myocardial_JJ infarction_NN would_VM be_VBB detected_VVN in_II these_DD megatrials_NNS as_II early_JJ as_II 35_MC days_NNS after_II the_DD event_NN ._.
P07805271A02
The_DD American_JJ Heart_NN Association_NN assembled_VVD a_DD group_NN of_II experts_NNS in_II a_DD multidisciplinary_JJ consensus_NN conference_NN to_TO develop_VVI this_DD statement_NN ._.
P07826548A10
The_DD panel_NN believes_VVZ that_CST whereas_CS many_DD different_JJ drugs_NNS can_VM produce_VVB effective_JJ blood_NN pressure_NN reduction_NN ,_, the_DD modern_JJ primary_JJ goal_NN of_II antihypertensive_JJ drug_NN therapy_NN is_VBZ to_TO select_VVI a_DD regimen_NN most_RRT likely_RR to_TO prolong_VVI the_DD quality_NN and_CC duration_NN of_II life_NN ._.
P07850886A09
Peluso_NNP and_CC colleagues_NNS (_( 1993_MC )_) have_VHB performed_VVN a_DD recent_JJ meta-analysis_NN of_II available_JJ therapies_NNS in_II fibromyalgia_NN syndrome_NN and_CC found_VVD that_CST the_DD effect-size_NN (_( a_DD standardized_VVNJ measure_NN of_II the_DD efficacy_NN of_II a_DD given_VVNJ therapy_NN )_) of_II several_JJ non-medication_NN therapies_NNS such_II+ as_II electroacupuncture_NN exceeded_VVD that_PND of_II traditional_JJ medication_NN therapies_NNS ._.
P07867364A10
CONCLUSION_NN :_: Recommendations_NNS for_II the_DD design_NN ,_, conduct_NN and_CC analysis_NN of_II future_JJ trials_NNS of_II sepsis_NN therapies_NNS were_VBD summarized_VVN ._.
P07882203A09
At_II the_DD conclusion_NN ,_, the_DD students_NNS will_VM have_VHB encountered_VVN all_DB the_DD information_NN necessary_JJ to_TO solve_VVI the_DD case_NN and_CC ,_, in_II so_RR doing_VVGN ,_, will_VM have_VHB gained_VVN knowledge_NN that_PNR in_II a_DD conventional_JJ curriculum_NN would_VM usually_RR have_VHB been_VBN disseminated_VVN by_II lecture_NN ._.
P07905143A11
This_DD overview_NN indicates_VVZ that_CST fibrinolytic_JJ therapy_NN is_VBZ beneficial_JJ in_II a_DD much_RR wider_JJR range_NN of_II patients_NNS than_CSN is_VBZ currently_RR given_VVN such_DD treatment_NN routinely_RR ._.
P07922426A04
These_DD considerations_NNS have_VHB led_VVN to_II pressure-limited_VVNJ mechanical_JJ ventilation_NN strategies_NNS ,_, including_VVG pressure-controlled_VVNJ ,_, inverse-ratio_NN ventilation_NN ._.
P07939748A04
The_DD presentation_NN of_II advanced_VVNJ disease_NN is_VBZ also_RR unusual_JJ ,_, in_II that_CST the_DD vast_JJ majority_NN of_II patients_NNS do_VDB not_RR have_VHB measurable_JJ disease_NN suitable_JJ for_II traditional_JJ studies_NNS of_II new_JJ chemotherapy_NN agents_NNS ._.
P07966873A01
OBJECTIVE_NN --_: This_DD article_NN reviews_VVZ the_DD incidence_NN of_II arterial_JJ thromboembolism_NN in_II patients_NNS with_II heart_NN failure_NN who_PNR are_VBB not_RR receiving_VVG anticoagulants_NNS ._.
P08011827A20
More_RR reliable_JJ administration_NN of_II antimicrobial_JJ agents_NNS according_II+ to_II recognized_VVNJ guidelines_NNS should_VM prevent_VVB some_DD postoperative_JJ wound_NN infections_NNS while_CS lowering_VVG the_DD total_JJ quantity_NN of_II these_DD drugs_NNS used_VVN ._.
P08017749A09
The_DD clinical_JJ presentations_NNS of_II nonvalvular_JJ endovascular_JJ infections_NNS are_VBB subtle_JJ and_CC diagnoses_NNS are_VBB difficult_JJ to_TO make_VVI ,_, often_RR requiring_VVG not_RR only_RR a_DD high_JJ index_NN of_II suspicion_NN but_CC also_RR the_DD use_NN of_II sophisticated_VVNJ radiologic_JJ techniques_NNS ._.
P08055409A10
The_DD clinical_JJ judgment_NN of_II the_DD practising_VVGJ clinician_NN ,_, however_RR ,_, must_VM always_RR be_VBB incorporated_VVN into_II any_DD diagnostic_JJ or_CC therapeutic_JJ decision_NN ._.
P08080494A10
Unfortunately_RR ,_, these_DD conditions_NNS are_VBB extremely_RR frequent_JJ and_CC carry_VVB high_JJ mortality_NN rates_NNS ._.
P08085692A07
Single_JJ and_CC combined_VVNJ chemotherapeutic_JJ agents_NNS produce_VVB high_JJ response_NN rates_NNS ._.
P08120703A06
DATA_NNS SYNTHESIS_NN :_: The_DD spontaneous_JJ rate_NN of_II primary_JJ control_NN --_: without_II antibiotics_NNS or_CC tympanocentesis_NN --_: was_VBD 81_MC %_SYM (_( 95_MC %_SYM confidence_NN interval_NN ,_, 69_MC %_SYM to_II 94_MC %_SYM )_) ._.
P08147551A11
Perhaps_RR more_RR accurate_JJ clinical_JJ and_CC laboratory_NN predictors_NNS are_VBB needed_VVN to_TO identify_VVI patients_NNS who_PNR may_VM benefit_VVB from_II a_DD given_VVNJ treatment_NN strategy_NN ._.
P08173141A17
Failure_NN to_TO respond_VVI to_II treatment_NN of_II recurrent_JJ ventricular_JJ tachycardia_NN /_SYM fibrillation_NN to_II usual_JJ antiarrhythmic_JJ therapy_NN in_II patients_NNS with_II acute_JJ myocardial_JJ infarction_NN ,_, idiopathic_JJ dilated_VVNJ cardiomyopathy_NN ,_, and_CC congestive_JJ heart_NN failure_NN should_VM alert_VVB the_DD clinician_NN to_TO consider_VVI administering_VVG intravenous_JJ Mg_NN ._.
P08207176A07
EVIDENCE_NN :_: Many_DD prospective_JJ ,_, randomized_VVNJ ,_, controlled_VVNJ trials_NNS comparing_VVG placebo_NN with_II antibiotic_NN and_CC comparing_VVG one_MC antibiotic_NN with_II another_PND have_VHB been_VBN conducted_VVN ._.
P08221424A15
The_DD CMA_NN 's_GE guidelines_NNS on_II this_DD topic_NN should_VM be_VBB evaluated_VVN to_TO see_VVI whether_CST they_PN are_VBB effective_JJ in_II controlling_VVGN physician-industry_NN interactions_NNS ._.
P08234776A08
The_DD creation_NN of_II this_DD ideal_JJ ICD_NN will_VM obviously_RR require_VVB continued_VVNJ technological_JJ advances_NNS ;_: however_RR ,_, given_VVN the_DD tremendous_JJ improvements_NNS realized_VVN over_II the_DD first_JJ three_MC generations_NNS of_II ICD_NN systems_NNS ,_, optimism_NN for_II the_DD future_NN seems_VVZ warranted_VVN ._.
P08281682A07
Data_NNS on_II each_DD procedure_NN were_VBD recorded_VVN on_II a_DD unique_JJ modular_JJ database_NN that_PNR captured_VVD the_DD reason_NN for_II (_( and_CC interim_JJ result_NN after_II )_) each_DD device_NN use_NN ._.
P08305784A06
Clinical_JJ trials_NNS were_VBD assessed_VVN primarily_RR for_II comparative_JJ efficacy_NN and_CC toxicity_NN ._.
P08329800A23
Based_VVN on_II the_DD CONSENSUS_NN II_MC results_NNS ,_, enalapril_NN therapy_NN immediately_RR following_VVG AMI_NN can_VM not_RR be_VBB recommended_VVN ._.
P08357116A08
For_II most_DD patients_NNS ,_, therapy_NN can_VM be_VBB initiated_VVN with_II a_DD full_JJ replacement_NN dosage_NN (_( 1.6_MC micrograms_NNS /_SYM kg_NN body_NN weight_NN )_) ,_, which_PNR is_VBZ usually_RR 75_MC to_II 100_MC micrograms_NNS /_SYM day_NN for_II women_NNS and_CC 100_MC to_II 150_MC micrograms_NNS /_SYM d_NN for_II men_NNS ._.
P08379605A13
After_II one_MC negative_JJ result_NN of_II a_DD 3-year_NN examination_NN ,_, the_DD interval_NN can_VM be_VBB increased_VVN to_II 5_MC years_NNS ._.
P08410406A02
DESIGN_NN AND_CC DATA_NNS IDENTIFICATION_NN :_: English-language_NN literature_NN search_NN using_VVG MEDLINE_NN ,_, Index_NN Medicus_NN ,_, and_CC bibliographic_JJ reviews_NNS of_II texts_NNS and_CC all_DD pertinent_JJ articles_NNS to_TO perform_VVI a_DD quantitative_JJ and_CC methodologic_JJ analysis_NN of_II all_DD studies_NNS from_II 1983_MC (_( the_DD original_JJ publication_NN )_) assessing_VVG the_DD association_NN under_II study_NN ._.
P08439699A08
Trials_NNS were_VBD assessed_VVN by_II design_NN ,_, sample_NN size_NN ,_, types_NNS of_II seizures_NNS of_II the_DD subjects_NNS ,_, and_CC clinical_JJ response_NN ._.
P08472581A13
In_II recognition_NN of_II these_DD complex_JJ issues_NNS (_( including_VVG potential_JJ conflicts_NNS among_II ICUs_NNS ,_, hospital_NN administration_NN ,_, individual_JJ physicians_NNS ,_, and_CC the_DD various_JJ medical_JJ and_CC surgical_JJ programs_NNS feeding_VVG patients_NNS into_II special_JJ care_NN units_NNS )_) ,_, the_DD Society_NN of_II Critical_JJ Care_NN Medicine_NN has_VHZ organized_VVN a_DD Task_NN Force_NN on_II the_DD legal_JJ and_CC ethical_JJ justification_NN for_II triage_NN ._.
P08520092A11
CONCLUSIONS_NNS :_: Desogestrel_NN ,_, norgestimate_NN ,_, and_CC gestodene_NN appear_VVB to_TO offer_VVI clinical_JJ advantages_NNS because_II+ of_II their_PNG decreased_VVNJ androgenicity_NN ._.
P08544272A14
Sucralfate_NN may_VM be_VBB as_RR effective_JJ in_II reducing_VVGN bleeding_VVGN as_II gastric_JJ pH-altering_VVGJ drugs_NNS and_CC is_VBZ associated_VVN with_II lower_JJR rates_NNS of_II pneumonia_NN and_CC mortality_NN ._.
P08564995A04
Much_DD progress_NN has_VHZ been_VBN made_VVN in_II altering_VVGN practices_NNS such_II+ as_II under-prescribing_VVGN and_CC underdosing_VVGN that_PNR have_VHB adversely_RR affected_VVD adequate_JJ control_NN of_II pain_NN in_II children_NNS ._.
P08576513A20
Research_NN questions_NNS might_VM be_VBB guided_VVN by_II the_DD biopsychosocial_JJ conceptual_JJ context_NN described_VVN above_RR ._.
P08591547A22
The_DD candidate_NN obtains_VVZ information_NN by_II "_`` mouse-clicking_VVGN ,_, "_'' so_CS it_PN is_VBZ not_RR necessary_JJ to_TO be_VBI a_DD computer_NN expert_NN to_TO use_VVI the_DD system_NN ._.
P08593127A12
Possible_JJ adverse_JJ effects_NNS of_II the_DD fibric-acid_NN derivatives_NNS include_VVB abdominal_JJ discomfort_NN ,_, nausea_NN ,_, flatulence_NN ,_, increased_VVNJ lithogenicity_NN of_II bile_NN ,_, liver_NN enzyme_NN elevations_NNS and_CC creatine_NN kinase_NN elevations_NNS ._.
P08601930A08
RESULTS_NNS :_: A_DD total_NN of_II 8676_MC admissions_NNS with_II unstable_JJ angina_NN or_CC non-Q-wave_NN MI_NN were_VBD enumerated_VVN and_CC ,_, of_II these_PND ,_, 3318_MC patients_NNS were_VBD selected_VVN for_II the_DD prospective_JJ study_NN ._.
P08604723A17
Other_JJ treatment_NN modalities_NNS ,_, including_VVG tissue_NN transplants_NNS and_CC cytokine-modulating_VVGJ drugs_NNS ,_, are_VBB emerging_VVG for_II the_DD potential_JJ therapy_NN of_II OA_NN ._.
P08608668A13
Patients_NNS who_PNR present_VVB 1-6_MC months_NNS after_II angioplasty_NN with_II typical_JJ anginal_JJ symptoms_NNS have_VHB a_DD high_JJ likelihood_NN of_II having_VVGN angiographic_JJ restenosis_NN ._.
P08615705A02
It_PN is_VBZ unknown_VVN how_CST the_DD effectiveness_NN and_CC costs_NNS of_II such_DB an_DD approach_NN (_( "_`` stepped_VVNJ care_NN "_'' )_) compare_VVB in_II typical_JJ clinical_JJ practice_NN to_II those_PND of_II initial_JJ therapy_NN with_II lovastatin_NN ._.
P08625645A02
To_TO examine_VVI the_DD available_JJ evidence_NN that_PNR supports_VVZ or_CC refutes_VVZ goal-directed_VVNJ therapy_NN toward_II supranormal_JJ oxygen_NN transport_NN in_II optimizing_VVGN the_DD outcome_NN of_II critically_RR ill_JJ sepsis_NN syndrome_NN patients_NNS ._.
P08633831A06
RESULTS_NNS :_: Forty-two_MC studies_NNS were_VBD reviewed_VVN for_II possible_JJ inclusion_NN ._.
P08653655A03
At_II the_DD same_JJ time_NN ,_, many_DD interventions_NNS are_VBB associated_VVN with_II increased_VVNJ risks_NNS in_II the_DD elderly_NN ,_, so_CS+ that_CS individualization_NN of_II treatment_NN is_VBZ essential_JJ in_II all_DD patients_NNS ._.
P08658222A21
A_DD large_JJ American_JJ intergroup_NN trial_NN is_VBZ underway_VVN testing_VVG the_DD concept_NN of_II postoperative_JJ adjuvant_NN chemoradiation_NN ._.
P08673987A05
The_DD role_NN of_II cyclooxygenase-2_NN (_( COX-2_NN )_) versus_CC COX-1_NN inhibiting_VVGJ agents_NNS was_VBD also_RR examined_VVN ._.
P08677863A05
Clinicians_NNS must_VM therefore_RR decide_VVB what_DB their_PNG practice_NN will_VM be_VBB on_II the_DD basis_NN of_II data_NNS that_PNR are_VBB currently_RR available_JJ ._.
P08686979A02
The_DD review_NN consists_VVZ of_II two_MC parts_NNS ._.
P08703521A03
AIM_NN :_: The_DD aim_NN of_II the_DD study_NN was_VBD to_TO assess_VVI the_DD effectiveness_NN of_II corticosteroid_NN injections_NNS in_II the_DD treatment_NN of_II lateral_JJ epicondylitis_NN (_( tennis_NN elbow_NN )_) by_II systematic_JJ review_NN of_II the_DD available_JJ randomized_VVNJ clinical_JJ trials_NNS ._.
P08729587A01
Both_CC the_DD European_JJ Atherosclerosis_NN Society_NN and_CC the_DD US_NNP National_JJ Cholesterol_NN Education_NN Program_NN have_VHB issued_VVN revised_VVNJ guidelines_NNS for_II the_DD prevention_NN of_II coronary_JJ heart_NN disease_NN (_( CHD_NN )_) ,_, based_VVN on_II a_DD multitude_NN of_II recent_JJ epidemiological_JJ and_CC angiographic_JJ studies_NNS ._.
P08736614A24
In_II comparison_NN with_II haloperidol_NN ,_, it_PN appears_VVZ to_TO be_VBI associated_VVN with_II a_DD lower_JJR prevalence_NN of_II acute_JJ extrapyramidal_JJ adverse_JJ effects_NNS in_II dosages_NNS <_SYM or_CC =_SYM 10_MC mg_NN /_SYM day_NN ,_, the_DD most_RRT potentially_RR important_JJ component_NN of_II which_PNR is_VBZ its_PNG reportedly_RR insignificant_JJ likelihood_NN of_II promoting_VVGN akathisia_NN ._.
P08754362A14
Amiodarone_NN unlike_II other_JJ antiarrhythmic_JJ drugs_NNS does_VDZ not_RR seem_VVB depress_VVI left_VVD ventricular_JJ function_NN ,_, and_CC may_VM be_VBB the_DD best_JJT drug_NN in_II patients_NNS with_II CHF_NN and_CC symptomatic_JJ arrhythmias_NNS ._.
P08780375A04
The_DD literature_NN was_VBD searched_VVN through_II Medline_NN and_CC an_DD extensive_JJ bibliography_NN of_II references_NNS was_VBD provided_VVN to_II the_DD panel_NN and_CC the_DD conference_NN audience_NN ._.
P08792953A07
DATA_NNS SYNTHESIS_NN :_: Production_NN of_II viscous_JJ respiratory_JJ secretion_NN is_VBZ a_DD hallmark_NN phenomenon_NN of_II cystic_JJ fibrosis_NN ,_, leading_VVG to_II a_DD variety_NN of_II symptoms_NNS ._.
P08826564A01
OBJECTIVE_NN :_: To_TO review_VVI the_DD pathophysiology_NN of_II hypertension_NN and_CC complications_NNS in_II patients_NNS with_II diabetes_NN mellitus_NN ,_, specifically_RR focusing_VVG on_II diabetic_JJ nephropathy_NN ;_: to_TO evaluate_VVI the_DD current_JJ clinical_JJ literature_NN regarding_VVG the_DD appropriate_JJ management_NN of_II hypertension_NN in_II this_DD patient_NN group_NN ;_: and_CC to_TO offer_VVI treatment_NN recommendations_NNS ._.
P08827194A19
And_CC it_PN would_VM be_VBB even_RR more_RR peculiar_JJ if_CS various_JJ other_JJ antidepressant_NN medications_NNS chemically_RR unrelated_VVN to_II fluoxetine_NN also_RR ,_, by_II chance_NN alone_JJ ,_, benefited_VVD all_PND of_II these_DD same_JJ disorders_NNS via_II still_RR other_JJ independent_JJ mechanisms_NNS ._.
P08837541A11
RECOMMENDATIONS_NNS :_: Bone_NN mineral_NN density_NN should_VM be_VBB measured_VVN only_RR to_TO assist_VVI in_II making_VVGN a_DD clinical_JJ management_NN choice_NN ._.
P08841011A01
Role_NN of_II ACE_NN inhibitors_NNS in_II the_DD management_NN of_II asymptomatic_JJ or_CC symptomatic_JJ left_JJ ventricular_JJ (_( LV_NN )_) dysfunction_NN after_II acute_JJ myocardial_JJ infarction_NN (_( AMI_NN )_) is_VBZ well_RR established_VVN ._.
P08853610A07
Although_CS successful_JJ for_II some_PND ,_, this_DD approach_NN increases_VVZ risk_NN for_II ineffective_JJ interventions_NNS accompanied_VVN by_II side_NN effects_NNS ._.
P08873639A05
OUTCOMES_NNS :_: Prevention_NN of_II loss_NN of_II bone_NN mineral_NN density_NN and_CC fracture_NN ;_: increased_VVNJ bone_NN mass_NN ;_: and_CC improved_VVNJ quality_NN of_II life_NN ._.
P08876861A08
The_DD attenuation_NN of_II ventricular_JJ remodeling_VVGN that_PNR occurs_VVZ with_II ACE_NN inhibition_NN does_VDZ not_RR fully_RR explain_VVB the_DD results_NNS of_II clinical_JJ trials_NNS in_II patients_NNS after_II MI_NN ._.
P08888782A14
Early_JJ intervention_NN has_VHZ been_VBN shown_VVN to_TO reduce_VVI the_DD rate_NN of_II vertebral_JJ and_CC hip_NN fractures_NNS by_II 50_MC -_CC 70_MC %_SYM ._.
P08893123A27
Therapy_NN must_VM be_VBB individualized_VVN according_II+ to_II the_DD patient_NN 's_GE disease_NN course_NN and_CC other_JJ patient-specific_JJ factors_NNS ._.
P08900335A03
Most_PND of_II the_DD atherosclerotic_JJ regression_NN trials_NNS were_VBD too_RR small_JJ and_CC of_II too_RR short_JJ duration_NN to_TO demonstrate_VVI a_DD significant_JJ difference_NN in_II hard_JJ coronary_JJ events_NNS between_II patients_NNS receiving_VVG cholesterol-lowering_VVGJ intervention_NN and_CC controls_NNS ._.
P08903273A12
Return_NN to_II sinus_NN rhythm_NN may_VM be_VBB difficult_JJ to_TO achieve_VVI early_JJ after_II surgery_NN ,_, so_CS opting_VVGN for_II rate_NN control_NN is_VBZ the_DD best_RRT initial_JJ approach_NN ._.
P08913409A03
;_: published_VVNJ articles_NNS and_CC abstracts_NNS ;_: and_CC review_NN chapters_NNS from_II medical_JJ textbooks_NNS ._.
P08918275A05
The_DD population_NN studied_VVN comprised_VVD subgroups_NNS of_II patients_NNS with_II atherosclerotic_JJ vascular_JJ disease_NN manifested_VVN as_II either_CC recent_JJ ischaemic_JJ stroke_NN ,_, recent_JJ myocardial_JJ infarction_NN ,_, or_CC symptomatic_JJ peripheral_JJ arterial_JJ disease_NN ._.
P08934387A13
Lipid-lowering_VVGJ drugs_NNS improve_VVB endothelium-dependent_JJ vasodilation_NN in_II the_DD coronary_JJ and_CC forearm_NN circulation_NN of_II patients_NNS with_II hyperlipidemia_NN and_CC atherosclerosis_NN ._.
P08968429A04
It_PN is_VBZ our_PNG opinion_NN ,_, however_RR ,_, that_CST there_EX are_VBB no_DD data_NNS that_PNR support_VVB the_DD extrapolation_NN of_II these_DD untoward_JJ effects_NNS to_II the_DD more_RR contemporary_JJ ,_, long-acting_VVGJ dihydropyridines_NNS (_( eg_NN ,_, amlodipine_NN )_) or_CC ,_, especially_RR ,_, to_II the_DD non-dihydropyridine_NN (_( heart_NN rate-lowering_VVGN )_) calcium_NN antagonists_NNS ,_, such_II+ as_II diltiazem_NN or_CC verapamil_NN ._.
P08974727A09
Weight-bearing_VVGJ exercise_NN is_VBZ important_JJ throughout_II life_NN ._.
P08990407A06
TIMI_NN grade_NN 2_MC or_CC 3_MC flow_NN at_II 90_MC minutes_NNS when_CS compared_VVN with_II accelerated_VVNJ alteplase_NN ._.
P09002496A13
CONCLUSIONS_NNS :_: The_DD results_NNS of_II this_DD meta-analysis_NN indicate_VVB that_CST in_II patients_NNS undergoing_VVG CABG_NN surgery_NN ,_, treatment_NN with_II acadesine_NN before_II and_CC during_II surgery_NN can_VM reduce_VVB early_RR cardiac_JJ death_NN ,_, MI_NN ,_, and_CC combined_VVNJ adverse_JJ cardiovascular_JJ outcomes_NNS ._.
P09023821A08
The_DD panel_NN composed_VVD a_DD draft_JJ statement_NN that_PNR was_VBD read_VVN in_II its_PNG entirety_NN and_CC circulated_VVN to_II the_DD experts_NNS and_CC the_DD audience_NN for_II comment_NN ._.
P09029428A15
Simply_RR developing_VVGN and_CC publishing_VVGN guidelines_NNS has_VHZ not_RR resulted_VVN in_II improvement_NN in_II practice_NN ._.
P09036802A07
Platelet_NN hyperactivity_NN ,_, reduced_VVNJ fibrinolytic_JJ capacity_NN ,_, increased_VVNJ concentrations_NNS of_II hemostatic_JJ proteins_NNS ,_, and_CC endothelial_JJ dysfunction_NN promote_VVB thrombosis_NN at_II the_DD site_NN of_II plaque_NN rupture_NN ._.
P09054283A09
Educational_JJ interventions_NNS with_II physicians_NNS led_VVD to_II increased_VVNJ use_NN of_II patient_NN preferences_NNS ,_, but_CC sophisticated_VVNJ educational_JJ techniques_NNS were_VBD needed_VVN to_TO motivate_VVI physicians_NNS to_TO change_VVI their_PNG behavior_NN ._.
P09063282A02
STUDY_NN SELECTION_NN /_SYM DATA_NNS ABSTRACTION_NN :_: MEDLINE_NN searches_NNS for_II literature_NN on_II prevention_NN and_CC screening_VVGN with_II regard_NN to_II older_JJR adults_NNS as_CC+ well_CC+ as_CC each_DD individual_JJ condition_NN reviewed_VVN ;_: bibliographical_JJ reviews_NNS of_II textbooks_NNS ,_, journal_JJ articles_NNS ,_, government_NN and_CC advocacy_NN organization_NN task_NN force_NN reports_NNS ,_, and_CC recommendations_NNS ._.
P09072935A03
STUDY_NN SELECTION_NN :_: Probabilities_NNS for_II individual_JJ clinical_JJ outcomes_NNS were_VBD derived_VVN from_II various_JJ sources_NNS ,_, including_VVG the_DD largest_JJT screening_VVGJ study_NN of_II community_NN volunteers_NNS to_II data_NNS ,_, analyses_NNS of_II Medicare_NN claims_NNS ,_, and_CC recently_RR published_VVNJ meta-analyses_NNS of_II the_DD outcomes_NNS of_II alternative_JJ treatment_NN strategies_NNS ._.
P09092324A01
PURPOSE_NN :_: To_TO review_VVI the_DD literature_NN on_II risk_NN stratification_NN after_II acute_JJ myocardial_JJ infarction_NN in_II the_DD reperfusion_NN era_NN and_CC to_TO propose_VVI an_DD algorithm_NN for_II early_JJ and_CC continual_JJ risk_NN assessment_NN ._.
P09101399A10
For_II example_NN ,_, in_II the_DD GISSI_NN 3_MC study_NN ,_, treatment_NN with_II lisinopril_NN was_VBD associated_VVN with_II a_DD decreased_VVNJ 6-week_NN mortality_NN in_II both_CC IDD_NN (_( 11.8_MC %_SYM versus_CC 21.1_MC ,_, p_NN <_SYM 0.05_MC )_) and_CC non-IDD_NN (_( 8.0_MC %_SYM versus_CC 10.6_MC %_SYM ,_, p_NN <_SYM 0.05_MC )_) patients_NNS corresponding_VVG to_II a_DD 44.1_MC %_SYM and_CC 24.5_MC %_SYM reduction_NN ,_, respectively_RR ._.
P09110119A02
For_II example_NN 1_MC out_II+ of_II 5_MC ,_, and_CC even_RR as_RR many_JJ as_CSN 1_MC out_II+ of_II 3_MC ,_, fatal_JJ cardiovascular_JJ events_NNS can_VM be_VBB prevented_VVN by_II some_DD treatments_NNS ._.
P09112710A23
These_DD impressions_NNS justify_VVB additional_JJ research_NN efforts_NNS on_II this_DD topic_NN ._.
P09118820A13
Evidence_NN is_VBZ now_RR available_JJ to_TO show_VVI a_DD beneficial_JJ effect_NN of_II bezafibrate_NN on_II retarding_VVGN atherosclerotic_JJ processes_NNS and_CC in_II reducing_VVGN risk_NN of_II coronary_JJ heart_NN disease_NN ._.
P09132880A12
However_RR ,_, there_EX are_VBB still_RR many_DD methodological_JJ questions_NNS regarding_VVG the_DD validity_NN and_CC sensitivity_NN of_II quality_NN of_II life_NN measurement_NN an_DD optimal_JJ study_NN design_NN calls_VVZ for_II caution_NN in_II the_DD interpretation_NN of_II current_JJ results_NNS and_CC makes_VVZ refinement_NN of_II methodological_JJ issues_NNS a_DD desirable_JJ goal_NN ._.
P09158559A12
Of_II the_DD 639_MC patients_NNS who_PNR may_VM have_VHB received_VVN electrolyte-free_JJ solutions_NNS ,_, 16_MC patients_NNS (_( 2.5_MC %_SYM )_) reported_VVD adverse_JJ effects_NNS ,_, 8_MC of_II which_PNR were_VBD severe_JJ ._.
P09165992A16
The_DD results_NNS of_II the_DD 26_MC randomised_VVNJ trials_NNS that_PNR have_VHB been_VBN carried_VVN out_II to_II date_NN ,_, suggest_VVB that_CST NSAIDs_NNS might_VM be_VBB effective_JJ for_II short-term_NN symptomatic_JJ relief_NN in_II patients_NNS with_II uncomplicated_VVNJ low_JJ back_NN pain_NN ,_, but_CC are_VBB less_RR effective_JJ or_CC ineffective_JJ in_II patients_NNS with_II low_JJ back_NN pain_NN with_II sciatica_NN and_CC patients_NNS with_II sciatica_NN with_II nerve_NN root_NN symptoms_NNS ._.
P09187830A14
Pilot_NN studies_NNS suggest_VVB that_CST QOL_NN can_VM be_VBB enhanced_VVN prior_II+ to_II transplant_NN ,_, and_CC that_CST health-related_VVNJ QOL_NN prior_II+ to_II transplant_NN may_VM predict_VVB survival_NN and_CC clinical_JJ outcomes_NNS ._.
P09198254A06
Estrogen_NN replacement_NN therapy_NN is_VBZ associated_VVN with_II decreased_VVNJ atherosclerosis_NN in_II several_JJ animal_NN models_NNS ._.
P09207617A10
When_CS all_DD 17_MC reports_NNS were_VBD combined_VVN ,_, beta-blockade_NN significantly_RR reduced_VVD all-cause_NN mortality_NN (_( random_JJ effect_NN odds_NNS ratio_NN [_( OR_NN ]_) 0.69_MC ,_, 95_MC %_SYM confidence_NN interval_NN [_( CI_NN ]_) 0.54_MC to_II 0.88_MC )_) ._.
P09214253A08
For_II acute_JJ mono-_JJ and_CC oligoarthritis_NN ,_, rheumatologists_NNS performed_VVD arthrocentesis_NN more_RR appropriately_RR than_CSN nonrheumatologists_NNS and_CC produced_VVD shorter_JJR durations_NNS of_II hospitalization_NN ._.
P09220052A08
A_DD pharmacoeconomic_JJ analysis_NN estimated_VVD that_CST continuation_NN of_II digoxin_NN in_II patients_NNS with_II stable_JJ congestive_JJ heart_NN failure_NN could_VM save_VVB the_DD healthcare_NN system_NN an_DD estimated_VVNJ $_SYM 400_MC million_MC ,_, based_VVN on_II costs_NNS from_II one_MC hospital_NN ._.
P09222261A05
Physician_NN advice_NN to_TO stop_VVI smoking_VVGN substantially_RR increases_VVZ the_DD likelihood_NN of_II smoking_VVGJ cessation_NN and_CC long-term_NN abstinence_NN ._.
P09230868A09
The_DD ABCs_NNS recently_RR have_VHB been_VBN seriously_RR challenged_VVN on_II the_DD basis_NN of_II results_NNS of_II both_CC experimental_JJ and_CC clinical_JJ studies_NNS ._.
P09235072A20
The_DD primary_JJ outcome_NN is_VBZ the_DD development_NN of_II NIDDM_NN according_II+ to_II WHO_NN criteria_NNS (_( fasting_VVGJ plasma_NN glucose_NN level_NN 140_MC mg_NN /_SYM dL_NN or_CC 2-hour_NN plasma_NN glucose_NN 200_MC mg_NN /_SYM dL_NN after_II a_DD 75_MC g_NN OGTT_NN )_) ._.
P09257080A08
Since_CS causes_NNS of_II sudden_JJ death_NN are_VBB heterogeneous_JJ ,_, the_DD clinician_NN should_VM pursue_VVB a_DD multifactorial_JJ approach_NN to_II its_PNG prevention_NN ._.
P09264420A10
Treatment_NN of_II this_DD population_NN is_VBZ likely_RR to_TO realize_VVI the_DD greatest_JJT cumulative_JJ long-term_NN benefit_NN in_II the_DD prevention_NN of_II acute_JJ major_JJ coronary_JJ events_NNS ._.
P09274899A01
PURPOSE_NN :_: To_TO review_VVI information_NN on_II the_DD implications_NNS of_II insulin_NN resistance_NN for_II type_NN II_MC diabetes_NN mellitus_NN (_( non-insulin-dependent_JJ diabetes_NN mellitus_NN )_) and_CC coronary_JJ heart_NN disease_NN ,_, and_CC to_TO derive_VVI guidance_NN from_II this_DD information_NN for_II the_DD management_NN of_II these_DD conditions_NNS ._.
P09286833A06
DATA_NNS SYNTHESIS_NN :_: While_CS nearly_RR all_DD medical_JJ schools_NNS offer_VVB some_DD formal_JJ teaching_VVGN about_II end-of-life_NN care_NN ,_, there_EX is_VBZ considerable_JJ evidence_NN that_CST current_JJ training_VVGN is_VBZ inadequate_JJ ,_, most_RRT strikingly_RR in_II the_DD clinical_JJ years_NNS ._.
P09294665A11
To_II date_NN ,_, no_DD other_JJ antiarrhythmic_JJ drug_NN has_VHZ shown_VVN benefit_NN ,_, while_CS several_PND have_VHB been_VBN shown_VVN to_TO be_VBI harmful_JJ ._.
P09299869A10
EVIDENCE_NN AND_CC INFORMATION_NN SOURCES_NNS :_: The_DD method_NN used_VVN for_II preparing_VVGN this_DD review_NN was_VBD an_DD informal_JJ consensus_NN development_NN ._.
P09309458A20
Attention_NN to_II factors_NNS that_PNR may_VM predispose_VVB an_DD individual_NN to_TO fall_VVI ,_, such_II+ as_II her_PNG balance_NN ,_, eyesight_NN ,_, stairs_NNS ,_, and_CC bathtubs_NNS that_PNR are_VBB difficult_JJ to_TO get_VVI into_II and_CC out_II+ of_II ,_, are_VBB all_PND items_NNS that_PNR need_VVB attention_NN ._.
P09327800A07
VALUES_NNS :_: High_JJ priority_NN was_VBD given_VVN to_II prevention_NN of_II adverse_JJ maternal_JJ and_CC neonatal_JJ outcomes_NNS in_II pregnancies_NNS with_II established_VVNJ hypertension_NN and_CC in_II those_PND at_II high_JJ risk_NN of_II gestational_JJ hypertension_NN through_II the_DD provision_NN of_II effective_JJ nonpharmacologic_JJ management_NN ._.
P09337293A02
All_DD organizations_NNS recommend_VVB against_II any_DD efforts_NNS to_TO detect_VVI early_JJ lung_NN cancer_NN because_CS each_PND of_II four_MC randomized_VVNJ controlled_VVNJ trials_NNS (_( RCTs_NNS )_) has_VHZ failed_VVN to_TO demonstrate_VVI a_DD significant_JJ reduction_NN in_II lung_NN cancer_NN mortality_NN as_II a_DD result_NN of_II screening_VVGN ._.
P09337449A02
DATA_NNS SOURCES_NNS :_: A_DD MEDLINE_NN search_NN encompassing_VVG the_DD years_NNS 1966-1996_MC was_VBD used_VVN to_TO identify_VVI pertinent_JJ literature_NN for_II discussion_NN ._.
P09347000A13
Caution_NN is_VBZ warranted_VVN in_II interpreting_VVGN these_DD results_NNS because_RR :_: 1_MC )_) the_DD treatment_NN is_VBZ not_RR blinded_VVN and_CC this_PND could_VM affect_VVB some_DD outcomes_NNS ;_: 2_MC )_) except_II+ for_II one_MC small_JJ trial_NN postneonatal_JJ survival_NN ,_, lung_NN function_NN ,_, and_CC neurodevelopment_NN have_VHB not_RR been_VBN reported_VVN from_II HVS_NN trials_NNS ;_: and_CC 3_MC )_) the_DD benefits_NNS and_CC disadvantages_NNS have_VHB not_RR been_VBN reported_VVN in_II infants_NNS born_VVN at_II different_JJ gestational_JJ ages_NNS or_CC different_JJ birth_NN weights_NNS ._.
P09357708A02
Small_JJ groups_NNS of_II senior_JJ medical_JJ students_NNS under_II the_DD direction_NN of_II a_DD multidisciplinary_JJ team_NN (_( behavioral_JJ scientist_NN ,_, information_NN specialist_NN ,_, physician_NN )_) facilitate_VVB discussions_NNS of_II clinical_JJ articles_NNS using_VVG checklists_NNS designed_VVN to_TO evaluate_VVI their_PNG quality_NN ._.
P09366779A08
Finally_RR ,_, the_DD relevance_NN of_II this_DD information_NN (_( or_CC lack_NN thereof_RR )_) to_II clinical_JJ practice_NN needs_VVZ to_TO be_VBI determined_VVN ._.
P09374952A01
OBJECTIVES_NNS :_: To_TO review_VVI prospective_JJ epidemiological_JJ studies_NNS and_CC randomized_VVNJ clinical_JJ trials_NNS regarding_VVG the_DD role_NN of_II antioxidant_NN vitamins_NNS (_( vitamins_NNS E_NN and_CC C_NN and_CC beta-carotene_NN )_) in_II the_DD prevention_NN of_II cardiovascular_JJ diseases_NNS ._.
P09388153A11
As_II a_DD result_NN ,_, society_NN could_VM expect_VVB to_TO gain_VVI 1.7_MC million_MC new_JJ quitters_NNS at_II an_DD average_JJ cost_NN of_II $_SYM 3779_MC per_II quitter_NN ,_, $_SYM 2587_MC per_II life-year_NN saved_VVN ,_, and_CC $_SYM 1915_MC for_II every_DD QALY_NN saved_VVN ._.
P09393381A02
Studies_NNS were_VBD identified_VVN through_II a_DD MEDLINE_NN search_NN of_II all_DD English-language_NN publications_NNS between_II 1970_MC and_CC 1996_MC in_II which_PNR the_DD words_NNS estrogen_NN and_CC cognition_NN or_CC estrogen_NN and_CC memory_NN appeared_VVD ._.
P09397232A11
Primary_JJ angioplasty_NN may_VM have_VHB a_DD role_NN in_II selected_VVNJ patients_NNS ._.
P09414540A11
The_DD inclusion_NN criteria_NNS were_VBD fairly_RR broad_JJ because_II+ of_II the_DD quality_NN of_II the_DD studies_NNS located_VVN ._.
P09416913A03
The_DD fact_NN that_CST many_DD practitioners_NNS do_VDB not_RR pursue_VVB a_DD proven_VVNJ treatment_NN strategy_NN in_II patients_NNS who_PNR qualify_VVB must_VM be_VBB redressed_VVN through_II education_NN and_CC reinforcement_NN of_II existing_VVGJ recommendations_NNS ._.
P09426711A02
The_DD experimental_JJ observation_NN that_CST low-fat_NN diets_NNS and_CC soy_NN protein_NN extracts_NNS may_VM influence_VVB the_DD progression_NN of_II established_VVNJ tumors_NNS ,_, rather_II+ than_II inhibiting_VVGN etiologic_JJ factors_NNS ,_, is_VBZ particularly_RR intriguing_VVG because_CS it_PN may_VM serve_VVB to_TO help_VVI explain_VVI the_DD paradox_NN whereby_CST the_DD incidence_NN of_II clinical_JJ prostate_NN cancer_NN shows_VVZ wide_JJ geographic_JJ variation_NN ,_, yet_CC the_DD evidence_NN persists_VVZ that_CST the_DD incidence_NN of_II microfocal_JJ tumors_NNS is_VBZ essentially_RR the_DD same_JJ worldwide_JJ ._.
P09438745A03
Additional_JJ data_NNS sources_NNS included_VVD bibliographies_NNS of_II papers_NNS identified_VVN on_II MEDLINE_NN and_CC bibliographies_NNS in_II textbooks_NNS on_II substance_NN abuse_NN ._.
P09445511A09
The_DD risk_NN of_II methemoglobinemia_NN (_( defined_VVN as_II methemoglobin_NN concentration_NN >_SYM 5_MC %_SYM and_CC requiring_VVGN medical_JJ intervention_NN )_) was_VBD estimated_VVN from_II all_DD prospective_JJ studies_NNS ._.
P09457159A16
Individuals_NNS infected_VVN with_II the_DD hepatitis_NN C_NN virus_NN should_VM not_RR donate_VVB blood_NN ,_, organs_NNS ,_, tissues_NNS ,_, or_CC semen_NN ._.
P09469146A07
DATA_NNS EXTRACTION_NN :_: The_DD following_VVGJ information_NN was_VBD extracted_VVN from_II the_DD 11_MC studies_NNS :_: characteristics_NNS of_II the_DD study_NN population_NN ,_, number_NN of_II participants_NNS (_( and_CC number_NN followed_VVN to_II completion_NN )_) ,_, length_NN of_II follow-up_NN ,_, type_NN of_II intervention_NN ,_, outcome_NN measures_NNS and_CC results_NNS ._.
P09476302A01
Improvement_NN of_II symptoms_NNS and_CC ,_, accordingly_RR ,_, quality_NN of_II life_NN ,_, as_CC+ well_CC+ as_CC prolongation_NN of_II life_NN ,_, are_VBB the_DD objectives_NNS of_II drug_NN therapy_NN in_II congestive_JJ heart_NN failure_NN patients_NNS ._.
P09479406A11
Designing_VVG tolerable_JJ ,_, effective_JJ regimens_NNS will_VM require_VVB careful_JJ monitoring_VVGN for_II compliance_NN ,_, adverse_JJ effects_NNS ,_, and_CC potential_JJ drug_NN interactions_NNS ._.
P09483156A06
To_TO make_VVI recommendations_NNS for_II the_DD future_JJ development_NN and_CC organisation_NN of_II neonatal_JJ screening_VVGN for_II inborn_NN errors_NNS of_II metabolism_NN in_II the_DD UK_NNP ._.
P09483159A28
Other_JJ studies_NNS that_PNR provide_VVB some_DD natural_JJ history_NN data_NNS suggest_VVB that_CST mild_JJ degrees_NNS of_II amblyopia_NN may_VM resolve_VVB spontaneously_RR ._.
P09483162A02
To_TO try_VVI to_TO identify_VVI the_DD optimal_JJ time_NN at_II which_PNR to_TO start_VVI assessing_VVGN new_JJ and_CC fast-evolving_VVGJ health_NN technologies_NNS ._.
P09483436A22
But_CC what_PND is_VBZ the_DD better_JJR solution_NN for_II thrombosis_NN and_CC which_PND for_II plaque_NN disruption_NN ?_.
P09484275A08
For_II accurate_JJ staging_VVGN and_CC to_TO reduce_VVI the_DD risk_NN of_II recurrence_NN in_II the_DD axilla_NN ,_, level_NN 1_MC and_CC level_NN 2_MC nodes_NNS should_VM be_VBB removed_VVN ._.
P09484278A18
Tamoxifen_NN should_VM normally_RR be_VBB administered_VVN daily_RR for_II 5_MC years_NNS ._.
P09484281A18
Intramuscular_JJ administration_NN of_II opioids_NNS is_VBZ not_RR recommended_VVN ._.
P09496407A07
It_PN is_VBZ most_RRT commonly_RR caused_VVN by_II dermatophytes_NNS ,_, but_CC yeasts_NNS and_CC molds_NNS can_VM also_RR be_VBB involved_VVN ._.
P09499674A15
Finally_RR ,_, the_DD Italian_JJ Federation_NN of_II Centers_NNS for_II the_DD Surveillance_NN of_II Anticoagulant_NN (_( FCSA_NN )_) therapies_NNS was_VBD founded_VVN in_II 1989_MC ._.
P09505959A06
Scientific_JJ evidence_NN was_VBD given_VVN precedence_NN over_II clinical_JJ anecdotal_JJ experience_NN ._.
P09516096A11
If_CS applied_VVN appropriately_RR ,_, they_PN can_VM ensure_VVB that_CST management_NN of_II patients_NNS is_VBZ based_VVN on_II clinically_RR useful_JJ diagnostic_JJ tests_NNS and_CC treatments_NNS that_PNR have_VHB been_VBN shown_VVN to_TO be_VBI effective_JJ and_CC not_RR harmful_JJ ._.
P09526814A02
The_DD diabetic_JJ dyslipidemia_NN in_II these_DD patients_NNS is_VBZ characterized_VVN by_II moderately_RR high_JJ levels_NNS of_II (_( 1_MC )_) serum_NN cholesterol_NN and_CC triglycerides_NNS ;_: (_( 2_MC )_) small_JJ ,_, dense_JJ low-density_NN lipoprotein_NN (_( LDL_NN )_) particles_NNS ;_: and_CC (_( 3_MC )_) low_JJ high-density_NN lipoprotein_NN (_( HDL_NN )_) cho-lesterol_NN concentrations_NNS ._.
P09537220A13
A_DD short-term_NN reduction_NN on_II markers_NNS like_II ventricular_JJ ectopic_JJ beats_NNS ,_, for_II example_NN ,_, does_VDZ not_RR translate_VVB into_II a_DD long-term_NN decrease_NN in_II arrhythmia-related_VVNJ mortality_NN ._.
P09539499A08
The_DD currently_RR available_JJ data_NNS concerning_VVG the_DD efficacy_NN ,_, safety_NN ,_, and_CC cost_NN provide_VVB a_DD compelling_VVGJ argument_NN for_II embracing_VVGN abciximab_NN therapy_NN in_II the_DD treatment_NN of_II patient_NN subsets_NNS where_PNR it_PN will_VM be_VBB a_DD cost-saving_VVGJ or_CC cost-neutral_JJ adjunct_NN to_II percutaneous_JJ coronary_JJ intervention_NN ._.
P09550500A02
The_DD Scandinavian_NN Simvastatin_NN Survival_NN Study_NN (_( 4S_NN )_) ,_, the_DD West_NN of_II Scotland_NNP Coronary_JJ Prevention_NN Study_NN (_( WOSCOPS_NN )_) ,_, and_CC the_DD Cholesterol_NN and_CC Recurrent_JJ Events_NNS (_( CARE_NN )_) trial_NN ,_, as_CC+ well_CC+ as_CC numerous_JJ other_JJ investigations_NNS ,_, have_VHB established_VVN that_CST decreasing_VVGN elevated_VVNJ levels_NNS of_II low-density_NN lipoprotein_NN (_( LDL_NN )_) cholesterol_NN will_VM result_VVB in_II a_DD reduction_NN in_II CAD_NN risk_NN ._.
P09560079A08
Older_JJR age_NN was_VBD also_RR sometimes_NNS associated_VVN with_II decreased_VVNJ participation_NN in_II research_NN ._.
P09578541A02
Patients_NNS and_CC doctors_NNS seek_VVB evidence-based_VVNJ clinical_JJ information_NN ,_, regulatory_JJ agencies_NNS look_VVB for_II efficacy_NN and_CC safety_NN ,_, and_CC the_DD health-care_NN industry_NN demands_VVZ data_NNS on_II the_DD risk-benefit_NN ratio_NN attached_VVN to_II a_DD product_NN ._.
P09586593A16
Transurethral_JJ microwave_NN thermotherapy_NN of_II the_DD prostate_NN (_( TUMT_NN )_) and_CC radiofrequency_NN transurethral_JJ needle_NN ablation_NN (_( TUNA_NN )_) are_VBB minimally_RR invasive_JJ ,_, safe_JJ new_JJ therapies_NNS ._.
P09597223A04
The_DD published_VVNJ literature_NN was_VBD reviewed_VVN and_CC classified_VVN into_II one_MC of_II four_MC categories_NNS ,_, according_II+ to_II study_NN design_NN and_CC scientific_JJ value_NN ._.
P09606473A06
Cumulative_JJ outcomes_NNS were_VBD considered_VVN up_II+ to_II 6_MC months_NNS after_II initial_JJ PTCA_NN ._.
P09615298A03
With_II funding_VVGN from_II the_DD Office_NN of_II Alternative_JJ Medicine_NN ,_, National_JJ Institutes_NNS of_II Health_NN ,_, our_PNG goal_NN was_VBD to_TO identify_VVI the_DD type_NN and_CC prevalence_NN of_II complementary_JJ and_CC alternative_JJ treatments_NNS for_II asthma_NN in_II use_NN in_II the_DD United_VVNJ States_NNS in_II order_NN to_TO establish_VVI a_DD research_NN agenda_NN for_II the_DD study_NN of_II the_DD most_RRT promising_VVGJ therapies_NNS ._.
P09625664A03
DATA_NNS SOURCES_NNS :_: Published_VVNJ reports_NNS of_II clinical_JJ studies_NNS were_VBD found_VVN by_II searching_VVGN MEDLINE_NN and_CC selected_VVNJ bibliographies_NNS ._.
P09636826A08
DATA_NNS SYNTHESIS_NN :_: Specialized_VVNJ centres_NNS /_SYM clinicians_NNS fared_VVD better_RRR both_CC when_CS process_NN and_CC outcome_NN indicators_NNS were_VBD used_VVN ._.
P09644351A25
Provision_NN of_II quality_NN ,_, cost-effective_JJ care_NN for_II patients_NNS requiring_VVG prolonged_VVNJ ventilation_NN is_VBZ a_DD true_JJ clinical_JJ challenge_NN ._.
P09649257A02
It_PN is_VBZ associated_VVN with_II a_DD considerable_JJ burden_NN of_II suffering_VVGN ._.
P09663319A04
The_DD interventional_JJ therapies_NNS include_VVB permanent_JJ pacing_VVGN for_II bradyarrhythmias_NNS ,_, arrhythmia_NN surgery_NN for_II arrhythmias_NNS ,_, percutaneous_JJ catheter_NN ablation_NN and_CC implantable_JJ devices_NNS for_II tachyarrhythmias_NNS ._.
P09676168A16
STUDY_NN IMPLICATIONS_NNS :_: The_DD trial_NN will_VM demonstrate_VVB whether_CST the_DD use_NN of_II a_DD heparin-bonded_VVNJ stent_NN can_VM improve_VVB long_JJ term_NN patency_NN and_CC clinical_JJ outcome_NN in_II patients_NNS undergoing_VVG clinically_RR indicated_VVNJ PTCA_NN of_II totally_RR occluded_VVNJ coronary_JJ arteries_NNS ._.
P09684847A09
This_DD collective_JJ new_JJ knowledge_NN provides_VVZ the_DD basis_NN for_II a_DD shift_NN in_II the_DD management_NN of_II CAD_NN from_II an_DD invasive_JJ ,_, procedure-oriented_VVNJ viewpoint_NN currently_RR dominant_JJ in_II cardiology_NN toward_II a_DD noninvasive_JJ orientation_NN that_PNR views_VVZ the_DD problem_NN as_II a_DD graded_VVNJ ,_, continuous_JJ ,_, heterogeneously_RR diffuse_JJ disease_NN process_NN for_II which_PNR reversal_NN treatment_NN is_VBZ optimal_JJ ._.
P09705684A07
RESULTS_NNS :_: A_DD total_NN of_II 10,948_MC patients_NNS were_VBD enrolled_VVN between_II November_NN 1995_MC and_CC January_NN 1997_MC ._.
P09707957A04
Major_JJ hypertension_NN texts_NNS were_VBD also_RR reviewed_VVN for_II information_NN on_II combination_NN therapy_NN ._.
P09712593A15
Benefits_NNS were_VBD not_RR restricted_VVN to_II particular_JJ patient_NN groups_NNS ._.
P09727542A04
The_DD primary_JJ efficacy_NN end_NN point_NN was_VBD death_NN ,_, reinfarction_NN ,_, or_CC any_DD (_( urgent_JJ or_CC elective_JJ )_) target_NN vessel_NN revascularization_NN (_( TVR_NN )_) at_II 6_MC months_NNS by_II intention-to-treat_NN (_( ITT_NN )_) analysis_NN ._.
P09738589A07
Panel_NN members_NNS also_RR considered_VVD the_DD effect_NN of_II CID_NN on_II quality_NN of_II life_NN and_CC the_DD cost-effectiveness_NN and_CC efficacy_NN of_II different_JJ pharmacologic_JJ approaches_NNS ._.
P09743780A08
As_II a_DD first_JJ step_NN ,_, many_DD medical_JJ schools_NNS introduce_VVB students_NNS to_II on-line_NN databases_NNS ,_, most_RRT notably_RR MEDLINE_NN ._.
P09753529A08
Level_NN 1_MC :_: Evidence_NN from_II at_RR+ least_RR one_MC randomized_VVNJ ,_, controlled_VVNJ trial_NN ._.
P09759577A09
For_II patients_NNS with_II local-regional_JJ disease_NN (_( stage_NN III_MC ,_, satellites_NNS ,_, and_CC local_JJ recurrence_NN )_) ,_, a_DD selective_JJ approach_NN to_II imaging_VVGJ studies_NNS is_VBZ warranted_VVN ._.
P09765748A16
Most_PND of_II the_DD patients_NNS with_II local_JJ recurrence_NN in_II these_DD trials_NNS underwent_VVD mastectomy_NN ._.
P09765759A19
Therefore_RR ,_, if_CS the_DD outcome_NN of_II interest_NN is_VBZ a_DD reduction_NN in_II the_DD frequency_NN of_II local_JJ tumour_NN recurrence_NN ,_, radiotherapy_NN is_VBZ recommended_VVN ._.
P09765768A25
Patient_NN or_CC tumour_NN factors_NNS (_( number_NN of_II involved_VVNJ sites_NNS ,_, location_NN of_II involved_VVNJ sites_NNS or_CC level_NN of_II pain_NN control_NN )_) that_PNR are_VBB relative_JJ contraindications_NNS to_II the_DD use_NN of_II multiple_JJ single_JJ fields_NNS of_II radiation_NN as_II an_DD alternative_NN ._.
P09777140A08
Recent_JJ trials_NNS have_VHB been_VBN performed_VVN in_II patients_NNS with_II unstable_JJ angina_NN ,_, and_CC trials_NNS of_II adjunctive_JJ therapy_NN are_VBB currently_RR underway_VVB in_II patients_NNS receiving_VVG thrombolysis_NN for_II AMI_NN ,_, and_CC for_II secondary_JJ prevention_NN ._.
P09783489A08
Each_PND of_II the_DD guidelines_NNS acknowledged_VVD the_DD important_JJ effect_NN of_II associated_VVNJ cardiovascular_JJ disease_NN (_( CVD_NN )_) risk_NN factors_NNS on_II the_DD likely_JJ benefits_NNS of_II treatment_NN ,_, but_CC did_VDD not_RR expand_VVB on_II the_DD magnitude_NN of_II this_DD effect_NN ._.
P09793596A02
DATA_NNS SOURCES_NNS :_: A_DD MEDLINE_NN search_NN (_( January_NN 1960-April_NN 1998_MC )_) ,_, Current_JJ Contents_NNS search_NN ,_, additional_JJ references_NNS listed_VVN in_II articles_NNS ,_, and_CC unpublished_VVNJ data_NNS obtained_VVN from_II the_DD manufacturer_NN were_VBD used_VVN to_TO identify_VVI data_NNS from_II scientific_JJ literature_NN ._.
P09794095A02
The_DD radiologist_NN who_PNR performs_VVZ percutaneous_JJ breast_NN biopsies_NNS assumes_VVZ an_DD increased_VVNJ level_NN of_II responsibility_NN for_II the_DD patient_NN regarding_VVG patient_NN selection_NN ,_, lesion_NN selection_NN ,_, performance_NN of_II the_DD biopsy_NN procedure_NN ,_, interpretation_NN of_II results_NNS ,_, and_CC patient_NN follow-up_NN ._.
P09794982A06
The_DD goals_NNS of_II such_DD studies_NNS would_VM be_VBB to_TO understand_VVI better_RRR the_DD acute_JJ HHE_NN event_NN and_CC to_TO evaluate_VVI the_DD possibility_NN of_II long-term_NN sequelae_NNS ._.
P09806109A02
Primarily_RR ,_, the_DD drug_NN inhibits_VVZ platelet_NN aggregation_NN ,_, but_CC it_PN may_VM also_RR have_VHB anticoagulant_NN activity_NN and_CC other_JJ beneficial_JJ effects_NNS ,_, such_II+ as_II inhibiting_VVGN migration_NN and_CC promoting_VVGN apoptosis_NN of_II smooth_JJ muscle_NN cells_NNS ._.
P09809771A17
An_DD automatic_JJ implantable_JJ cardioverter-defibrillator_NN should_VM be_VBB used_VVN in_II persons_NNS who_PNR have_VHB a_DD history_NN of_II ventricular_JJ fibrillation_NN or_CC serious_JJ sustained_VVNJ ventricular_JJ tachycardia_NN or_CC who_PNR are_VBB at_II very_RR high_JJ risk_NN for_II developing_VVGN sudden_JJ cardiac_JJ death_NN ._.
P09819098A02
Abundant_JJ clinical_JJ trial_NN evidence_NN supports_VVZ the_DD importance_NN of_II LDL_NN cholesterol-lowering_VVGN in_II decreasing_VVGN CAD_NN risk_NN ,_, both_CC in_II angiographic_JJ trials_NNS ,_, which_PNR measure_VVB CAD_NN progression_NN ,_, and_CC in_II trials_NNS with_II morbidity_NN and_CC mortality_NN endpoints_NNS ._.
P09821012A05
However_RR ,_, the_DD extent_NN of_II LDL-C_NN reduction_NN achieved_VVN often_RR fell_VVB short_JJ of_II LDL-C_NN treatment_NN targets_NNS recommended_VVN in_II national_JJ and_CC international_JJ guidelines_NNS ._.
P09825877A13
Drug_NN interactions_NNS involving_VVG atorvastatin_NN can_VM be_VBB expected_VVN to_TO parallel_VVI those_PND of_II other_JJ statins_NNS metabolized_VVN via_II CYP3A4_NN ._.
P09832669A05
In_II addition_NN ,_, emerging_VVGJ evidence_NN suggests_VVZ a_DD future_JJ role_NN for_II GP_NN IIb_NN /_SYM IIIa_NN receptor_NN inhibitors_NNS as_II an_DD adjunct_NN to_II low-dose_NN fibrinolytic_JJ therapy_NN in_II patients_NNS with_II acute_JJ MI_NN ._.
P09852937A05
Multiple_JJ randomized_VVNJ and_CC nonrandomized_VVNJ trials_NNS indicate_VVB that_CST prehospital_JJ care_NN providers_NNS (_( including_VVG paramedics_NNS ,_, nurses_NNS and_CC doctors_NNS )_) are_VBB able_JJ to_TO acquire_VVI prehospital_JJ ECGs_NNS with_II negligible_JJ increases_NNS in_II on-scene_NN time_NN ,_, ranging_VVG from_II 30_MC s_NNS to_II 7_MC mins_NNS ._.
P09858958A03
Currently_RR ,_, pneumonia_NN patients_NNS are_VBB classified_VVN as_II having_VVGN either_CC community-acquired_VVNJ or_CC hospital-acquired_VVNJ infection_NN rather_II+ than_II typical_JJ versus_CC atypical_JJ ._.
P09861792A05
Review_NN of_II meta-analyses_NNS of_II clinical_JJ trials_NNS showed_VVD that_CST ERT_NN /_SYM HRT_NN ever-users_NNS (_( patients_NNS who_PNR have_VHB ever_RR used_VVN ERT_NN /_SYM HRT_NN )_) did_VDD not_RR have_VHB an_DD increased_VVNJ risk_NN of_II breast_NN cancer_NN ,_, but_CC current_JJ users_NNS did_VDD have_VHB an_DD increased_VVNJ risk_NN ,_, with_II some_DD studies_NNS reporting_VVGN increasing_VVGJ risk_NN with_II duration_NN of_II ERT_NN ._.
P09870124A01
OBJECTIVE_NN :_: To_TO review_VVI and_CC recognize_VVI how_CST presentation_NN ,_, investigation_NN ,_, risk_NN factor_NN modification_NN ,_, and_CC treatment_NN of_II coronary_JJ artery_NN disease_NN (_( CAD_NN )_) is_VBZ different_JJ for_II women_NNS than_CSN for_II men_NNS ._.
P09878986A07
There_EX was_VBD no_DD reduction_NN in_II the_DD rate_NN of_II death_NN at_II day_NN 30_MC or_CC nonfatal_JJ MI_NN in_II patients_NNS who_PNR received_VVD lamifiban_NN ;_: however_RR ,_, at_II 6_MC months_NNS a_DD significant_JJ treatment_NN effect_NN was_VBD seen_VVN in_II patients_NNS who_PNR received_VVD low_JJ dose_NN lamifiban_NN (_( 13.7_MC %_SYM ,_, p_NN =_SYM 0.02_MC )_) but_CC not_RR high_JJ dose_NN lamifiban_NN (_( 16.4_MC %_SYM ,_, p_NN =_SYM 0.38_MC )_) compared_VVN with_II those_PND who_PNR received_VVD heparin_NN alone_JJ (_( 18.1_MC %_SYM )_) ._.
P09891161A21
If_CS more_RR rigorous_JJ study_NN designs_NNS were_VBD required_VVN for_II publication_NN ,_, radiology_NN outcomes_NNS research_NN would_VM probably_RR improve_VVB drastically_RR ._.
P09915665A22
At_II the_DD same_JJ time_NN ,_, it_PN is_VBZ presently_RR unknown_VVN whether_CST improved_VVNJ glycemic_JJ control_NN decreases_VVZ coronary_JJ artery_NN disease_NN risk_NN in_II such_DD patients_NNS ._.
P09920227A05
DATA_NNS EXTRACTION_NN :_: Study_NN design_NN ,_, inclusion_NN and_CC exclusion_NN criteria_NNS ,_, setting_VVGN ,_, sample_NN size_NN ,_, response_NN rate_NN ,_, mean_NN age_NN ,_, method_NN of_II medication_NN verification_NN and_CC fall_NN assessment_NN ,_, fall_NN definition_NN ,_, and_CC the_DD number_NN of_II fallers_NNS and_CC non-fallers_NNS taking_VVG specific_JJ classes_NNS of_II psychotropic_JJ drugs_NNS ._.
P09924156A18
CONCLUSIONS_NNS :_: The_DD results_NNS of_II this_DD study_NN demonstrate_VVB that_CST GP_NN IIb_NN /_SYM IIIa_NN antagonists_NNS are_VBB able_JJ to_TO prevent_VVI vessel_NN occlusion_NN after_II PTCA_NN complicated_VVN by_II subsequent_JJ threatened_VVNJ or_CC abrupt_JJ vessel_NN closure_NN ._.
P09934917A14
Crystalloid_NN resuscitation_NN is_VBZ associated_VVN with_II a_DD lower_JJR mortality_NN in_II trauma_NN patients_NNS ._.
P09972388A08
CONCLUSIONS_NNS :_: In_II general_NN ,_, the_DD small_JJ amount_NN of_II published_VVNJ literature_NN supports_VVZ the_DD empirical_JJ use_NN of_II levodopa_NN /_SYM carbidopa_NN as_II a_DD safe_JJ and_CC effective_JJ therapy_NN to_TO manage_VVI the_DD distressing_VVGJ symptoms_NNS of_II RLS_NN in_II a_DD hemodialysis_NN population_NN ._.
P10026768A08
Men_NNS with_II high-grade_NN tumors_NNS (_( Gleason_NNP score_NN >_SYM or_CC =_SYM 7_MC )_) or_CC with_II seminal_JJ vesicle_NN or_CC lymph_NN node_NN involvement_NN in_II whom_PNR disease_NN recurs_VVZ within_II 2_MC years_NNS of_II radical_JJ prostatectomy_NN are_VBB most_RRT appropriately_RR observed_VVN or_CC treated_VVN with_II early_JJ hormonal_JJ therapy_NN ._.
P10047618A08
Sotalol_NN was_VBD 1_MC of_II 2_MC drugs_NNS selected_VVN for_II comparison_NN with_II implantable_JJ defibrillators_NNS in_II the_DD recent_JJ National_JJ Institutes_NNS of_II Health_NN Antiarrhythmics_NNS versus_CC Implantable_JJ Defibrillator_NN (_( AVID_NN )_) study_NN ._.
P10069357A02
The_DD traditional_JJ management_NN of_II type_NN 2_MC diabetes_NN has_VHZ been_VBN ineffective_JJ in_II altering_VVGN this_DD dismal_JJ prognosis_NN ._.
P10079780A01
OBJECTIVE_NN :_: To_TO estimate_VVI the_DD magnitude_NN of_II the_DD clinical_JJ benefits_NNS that_PNR may_VM result_VVB from_II use_NN of_II abciximab_NN at_II the_DD time_NN of_II angioplasty_NN and_CC the_DD cost_NN of_II achieving_VVGN them_PN ._.
P10082589A23
The_DD structured_VVNJ review_NN provides_VVZ a_DD concise_JJ analysis_NN of_II these_DD books_NNS to_TO allow_VVI readers_NNS to_TO determine_VVI application_NN of_II these_DD publications_NNS to_II their_PNG needs_NNS ._.
P10085198A03
In_II contrast_NN to_II other_JJ major_JJ chronic_JJ diseases_NNS such_II+ as_II heart_NN disease_NN and_CC cancer_NN ,_, medical_JJ treatments_NNS for_II COPD_NN have_VHB not_RR made_VVN decisive_JJ inroads_NNS into_II its_PNG morbidity_NN or_CC death_NN rates_NNS over_II the_DD last_JJ 20_MC years_NNS ,_, resulting_VVG in_II continuing_VVGJ efforts_NNS to_TO reduce_VVI disability_NN in_II patients_NNS with_II established_VVNJ disease_NN ._.
P10089844A12
Nevertheless_RR ,_, in_II comparison_NN with_II amiodarone_NN ,_, treatment_NN of_II MADIT_NN patients_NNS with_II ICDs_NNS seems_VVZ to_TO be_VBI cost-effective_JJ ,_, especially_RR if_CS ICDs_NNS are_VBB implanted_VVN transvenously_RR and_CC have_VHB the_DD improved_VVNJ battery_NN longevity_NN of_II the_DD current_JJ devices_NNS ._.
P10092711A02
The_DD most_RRT common_JJ pathology_NN of_II vascular_JJ diseases_NNS is_VBZ occlusion_NN ._.
P10094222A03
This_DD review_NN was_VBD undertaken_VVN to_TO evaluate_VVI the_DD relationship_NN of_II allergic_JJ rhinitis_NN to_II these_DD diseases_NNS and_CC to_TO provide_VVI support_NN for_II proposing_VVGN national_JJ guidelines_NNS for_II managing_VVGN rhinitis_NN ._.
P10103321A17
The_DD probability_NN of_II UTI_NN in_II each_PND of_II these_DD groups_NNS depends_VVZ not_RR only_RR on_II the_DD sensitivity_NN and_CC specificity_NN of_II the_DD test_NN ,_, but_CC also_RR on_II the_DD prior_JJ probability_NN of_II the_DD UTI_NN among_II the_DD children_NNS being_VBG tested_VVN ._.
P10140233A08
Rates_NNS of_II performance_NN of_II tasks_NNS of_II smoking_VVGJ cessation_NN by_II healthcare_NN professionals_NNS ,_, including_VVG offering_VVGN counselling_VVGN ,_, setting_VVGN dates_VVZ to_TO stop_VVI smoking_VVGN ,_, giving_VVGN follow_NN+ up_NN appointments_NNS ,_, distributing_VVGN self_PN help_NN materials_NNS ,_, and_CC recommending_VVGN nicotine_NN gum_NN ._.
P10147240A19
(_( ABSTRACT_NN TRUNCATED_VVD AT_II 400_MC WORDS_NNS )_)
P10160469A15
Although_CS limited_VVNJ formulary_NN choices_NNS have_VHB been_VBN used_VVN in_II the_DD hospital_NN setting_VVGN for_II years_NNS ,_, and_CC are_VBB now_RR becoming_VVG popular_JJ in_II managed_VVNJ care_NN ,_, there_EX is_VBZ no_DD proof_NN that_CST this_DD mechanism_NN saves_VVZ money_NN when_CS looking_VVG at_II the_DD overall_JJ picture_NN ._.
P10169000A05
If_CS current_JJ clinical_JJ information_NN is_VBZ unreliable_JJ ,_, then_RR healthcare_NN risk_NN management_NN strategies_NNS for_II LBP_NN must_VM be_VBB revised_VVN ._.
P10172669A12
In_II subgroup_NN analyses_NNS ,_, alteplase_NN was_VBD a_DD cost-effective_JJ treatment_NN option_NN for_II all_DD elderly_JJ patients_NNS (_( >_SYM 60_MC years_NNS of_II age_NN )_) and_CC all_DD patients_NNS >_SYM 40_MC years_NNS of_II age_NN with_II anterior_JJ infarction_NN ._.
P10182193A02
Some_DD preventive_JJ approaches_NNS are_VBB both_CC inexpensive_JJ and_CC effective_JJ ;_: others_NNS are_VBB expensive_JJ while_CS their_PNG effectiveness_NN is_VBZ slight_JJ or_CC unproven_VVN ._.
P10186462A18
These_DD benefits_NNS come_VVB at_II a_DD substantial_JJ economic_JJ cost_NN ,_, but_CC one_MC that_PNR is_VBZ in_II line_NN with_II accepted_VVNJ costs_NNS for_II other_JJ medical_JJ interventions_NNS ._.
P10190758A06
Of_II these_DD nine_MC ,_, four_MC controlled_VVNJ studies_NNS were_VBD chosen_VVN based_VVN upon_II their_PNG large_JJ patient_NN populations_NNS and_CC their_PNG consistency_NN in_II brand_NN and_CC dosage_NN of_II St._NN John_NN 's_GE wort_NN used_VVN ._.
P10196487A01
EXECUTIVE_NN SUMMARY_NN The_DD "_`` Guideline_NN for_II Prevention_NN of_II Surgical_JJ Site_NN Infection_NN ,_, 1999_MC "_'' presents_VVZ the_DD Centers_NNS for_II Disease_NN Control_NN and_CC Prevention_NN (_( CDC_NN )_) 's_GE recommendations_NNS for_II the_DD prevention_NN of_II surgical_JJ site_NN infections_NNS (_( SSIs_NNS )_) ,_, formerly_RR called_VVN surgical_JJ wound_NN infections_NNS ._.
P10203636A07
Participants_NNS reported_VVD using_VVGN EBM_NN in_II their_PNG clinical_JJ practice_NN always_RR (_( 33_MC ,_, 11_MC %_SYM )_) ,_, often_RR (_( 173_MC ,_, 59_MC %_SYM )_) ,_, sometimes_NNS (_( 80_MC ,_, 27_MC %_SYM )_) ,_, or_CC rarely_RR /_SYM never_RR (_( 8_MC ,_, 3_MC %_SYM )_) ._.
P10209667A20
Many_DD patients_NNS will_VM have_VHB primary_JJ refractory_JJ of_II relapsing_VVGJ disease_NN in_II whom_PNR survival_NN is_VBZ short_JJ despite_II all_DD current_JJ therapeutic_JJ modalities_NNS ._.
P10220238A03
A_DD good_JJ example_NN is_VBZ the_DD concern_NN about_II using_VVGN oral_JJ cobalamin_NN when_CS treating_VVG pernicious_JJ anemia_NN ._.
P10228456A11
CONSENSUS_NN PROCESS_NN :_: The_DD panel_NN ,_, answering_VVG predefined_VVNJ questions_NNS ,_, developed_VVD their_PNG conclusions_NNS based_VVN on_II the_DD scientific_JJ evidence_NN presented_VVN in_II open_JJ forum_NN and_CC the_DD scientific_JJ literature_NN ._.
P10321422A13
In_II adapting_VVGN the_DD findings_NNS on_II cholesterol-lowering_VVGJ efficacy_NN from_II this_DD analysis_NN to_II our_PNG lipid_NN clinic_NN ,_, we_PN concluded_VVD that_CST the_DD most_RRT cost-effective_JJ treatment_NN approach_NN is_VBZ to_TO individualize_VVI the_DD selection_NN of_II an_DD HMG-CoA_NN reductase_NN inhibitor_NN based_VVN on_II both_CC coronary_JJ risk_NN and_CC the_DD LDL-C_NN reduction_NN required_VVN to_TO achieve_VVI NCEP_NN ATP-II_NN goals_NNS ._.
P10332429A12
For_II prostate_NN cancer_NN strong_JJ evidence_NN exists_VVZ for_II a_DD preventive_JJ effect_NN of_II reduced_VVNJ fat_NN intake_NN ,_, vitamin_NN E_NN ,_, selenium_NN and_CC soy_NN proteins_NNS ._.
P10333848A16
(_( 2_MC )_) To_TO reduce_VVI blood_NN pressure_NN in_II the_DD population_NN at_JJ+ large_JJ ,_, it_PN is_VBZ recommended_VVN that_CST Canadians_NNS attain_VVB and_CC maintain_VVB a_DD healthy_JJ BMI_NN (_( 20-25_MC )_) ._.
P10333852A14
(_( 2_MC )_) For_II normotensive_JJ people_NNS obtaining_VVG on_II average_NN 60_MC mmol_NN of_II potassium_NN daily_RR through_II dietary_JJ intake_NN ,_, potassium_NN supplementation_NN is_VBZ not_RR recommended_VVN as_II a_DD means_NNS of_II preventing_VVGN an_DD increase_NN in_II blood_NN pressure_NN ._.
P10340840A14
Treatment_NN alone_JJ is_VBZ not_RR enough_PND ;_: treatment_NN to_II goal_NN blood_NN pressure_NN is_VBZ an_DD essential_JJ first_JJ step_NN towards_II optimal_JJ target-organ_NN protection_NN ._.
P10346425A02
US_NNP National_JJ Cholesterol_NN Education_NN Program_NN (_( NCEP_NN )_) guidelines_NNS recommend_VVB aggressive_JJ lipid-modifying_VVGJ therapy_NN for_II individuals_NNS at_II highest_JJT risk_NN for_II CHD_NN ._.
P10353983A05
The_DD therapeutic_JJ approaches_NNS considered_VVN included_VVD continuous_JJ anticonvulsant_JJ therapies_NNS ,_, intermittent_JJ therapy_NN ,_, or_CC no_DD anticonvulsant_JJ therapy_NN ._.
P10359204A09
RESULTS_NNS :_: As_II+ of_II March_NN 1_MC ,_, 1998_MC ,_, there_EX are_VBB 9,373_MC references_NNS ,_, excluding_VVG citations_NNS of_II letters_NNS or_CC comments_NNS ,_, contained_VVD in_II the_DD core_NN pediatric_JJ surgery_NN literature_NN ,_, as_CS provided_VVN through_II Medline_NN ._.
P10365602A08
In_II patients_NNS with_II symptomatic_JJ CHF_NN due_II+ to_II systolic_JJ dysfunction_NN the_DD addition_NN of_II diuretics_NNS and_CC digoxin_NN appears_VVZ to_II reducing_VVGN worsening_VVGJ CHF_NN without_II improving_VVGN survival_NN ._.
P10366798A05
RESULTS_NNS :_: In_II patients_NNS with_II symptoms_NNS or_CC signs_NNS suggestive_JJ of_II DVT_NN ,_, compression_NN ultrasound_NN (_( CUS_NN )_) appears_VVZ to_TO be_VBI the_DD diagnostic_JJ test_NN of_II first_JJ choice_NN ,_, since_CS it_PN is_VBZ a_DD noninvasive_JJ test_NN with_II high_JJ specificity_NN and_CC sensitivity_NN for_II proximal_JJ DVT_NN (_( about_RR 97_MC %_SYM )_) ._.
P10372678A04
With_II the_DD recognition_NN of_II that_DD reality_NN comes_VVZ a_DD variety_NN of_II challenges_NNS to_II clinicians_NNS and_CC investigators_NNS ._.
P10381989A12
When_CS these_DD data_NNS were_VBD combined_VVN using_VVG effect_NN size_NN as_II a_DD common_JJ measure_NN ,_, the_DD use_NN of_II ipratropium_NN was_VBD associated_VVN with_II a_DD summary_NN effect_NN size_NN of.38_MC (_( 95_MC %_SYM CI.27_MC to.48_MC )_) ._.
P10387403A01
BACKGROUND_NN :_: Although_CS the_DD randomised_VVNJ controlled_VVNJ trial_NN (_( RCT_NN )_) is_VBZ regarded_VVN as_II the_DD '_`` gold_NN standard_NN '_'' in_II terms_NNS of_II evaluating_VVGN the_DD effectiveness_NN of_II interventions_NNS ,_, it_PN is_VBZ susceptible_JJ to_II challenges_NNS to_II its_PNG external_JJ validity_NN if_CS those_PND participating_VVG are_VBB unrepresentative_JJ of_II the_DD reference_NN population_NN for_II whom_PNR the_DD intervention_NN in_II question_NN is_VBZ intended_VVN ._.
P10387985A21
The_DD methods_NNS used_VVN to_TO detect_VVI responses_NNS in_II solid_JJ tumours_NNS and_CC metastases_NNS are_VBB crude_JJ ,_, and_CC it_PN is_VBZ likely_JJ that_CST many_DD useful_JJ drugs_NNS are_VBB missed_VVN ._.
P10387991A14
He_PN first_RR came_VVD to_II the_DD NCI_NN as_II a_DD Clinical_JJ Associate_NN in_II 1967_MC ._.
P10388002A33
Further_RR ,_, the_DD list_NN above_JJ does_VDZ not_RR include_VVB his_PNG personal_JJ labortory_NN and_CC clinical_JJ accomplishments_NNS ,_, some_PND of_II which_PNR are_VBB :_: *_SYM Development_NN of_II the_DD principles_NNS of_II use_NN of_II important_JJ antimetabolites_NNS ,_, such_II+ as_II methotrexate_NN ._.
P10388010A16
The_DD survey_NN of_II 20_MC patients_NNS conducted_VVN by_II Dr._NN Quah_NN represents_VVZ a_DD substantial_JJ portion_NN of_II the_DD literature_NN on_II the_DD subject_NN of_II alternative_JJ therapy_NN use_NN for_II children_NNS with_II cancer_NN ._.
P10388013A07
As_II the_DD famed_VVNJ radiotherapist_NN and_CC Founding_VVGJ Editor_NN ,_, Eli_NNP Glatstein_NNP ,_, summarized_VVD ,_, "_`` The_DD Oncologist_NN emphasizes_VVZ the_DD interpretation_NN rather_II+ than_II the_DD data._NNS "_'' The_DD Oncologist_NN to_II date_NN has_VHZ published_VVN more_RR than_CSN forty_MC manuscripts_NNS from_II international_JJ authorities_NNS ._.
P10388030A26
In_II fact_NN ,_, the_DD growth_NN of_II radiosurgery_NN has_VHZ made_VVN radiation_NN oncologists_NNS re-think_VVB their_PNG own_JJ practice_NN of_II conventional_JJ radiation_NN therapy_NN ._.
P10388041A16
This_PND explains_VVZ the_DD difficulties_NNS one_PN encounters_VVZ in_II the_DD correct_JJ evaluation_NN of_II relevant_JJ data_NNS of_II one_MC specific_JJ patient_NN ._.
P10388095A19
The_DD preferred_VVNJ sequence_NN of_II treatment_NN has_VHZ been_VBN suggested_VVN to_TO be_VBI tamoxifen_NN followed_VVN by_II selective_JJ aromatase_NN inhibitor_NN and_CC then_RR a_DD progestin_NN ._.
P10388128A06
How_CST far_RR this_DD lymph_NN node_NN dissection_NN is_VBZ directly_RR therapeutic_JJ is_VBZ a_DD source_NN of_II controversy_NN ._.
P10391814A03
With_II appropriate_JJ multidisciplinary_JJ care_NN ,_, pain_NN can_VM be_VBB controlled_VVN in_II 90_MC %_SYM of_II patients_NNS who_PNR have_VHB advanced_VVNJ malignant_JJ conditions_NNS ,_, and_CC 90_MC %_SYM of_II ambulatory_JJ patients_NNS with_II spinal_JJ cord_NN compression_NN can_VM remain_VVB ambulatory_JJ ._.
P10404937A01
OBJECTIVE_NN :_: To_TO review_VVI the_DD prognosis_NN and_CC management_NN of_II ventricular_JJ arrhythmias_NNS (_( VA_NN )_) in_II persons_NNS with_II and_CC without_II heart_NN disease_NN ,_, with_II emphasis_NN on_II older_JJR adults_NNS ._.
P10410186A01
OBJECTIVE_NN :_: To_TO briefly_RR discuss_VVI the_DD pathophysiology_NN of_II acute_JJ coronary_JJ syndromes_NNS (_( ACS_NN )_) and_CC to_TO present_VVI the_DD clinical_JJ data_NNS currently_RR available_JJ regarding_VVG the_DD use_NN of_II platelet_NN glycoprotein_NN (_( GP_NN )_) IIb_NN /_SYM IIIa_NN inhibitors_NNS in_II the_DD management_NN of_II ACS_NN ._.
P10412759A09
RESULTS_NNS :_: Most_DD studies_NNS showed_VVD that_CST 3-hydroxy-3-methylglutaryl_NN coenzyme_NN A_NN (_( HMG-CoA_NN )_) reductase_NN inhibitors_NNS reduce_VVB cholesterol-rich_JJ apolipoprotein_NN (_( apo_NN )_) B-containing_VVGJ lipoproteins_NNS with_II no_DD effects_NNS on_II renal_JJ function_NN or_CC proteinuria_NN among_II patients_NNS with_II progressive_JJ renal_JJ disease_NN ._.
P10423049A14
Symptomatic_JJ measures_NNS in_II addition_NN to_II specific_JJ treatments_NNS for_II the_DD underlying_VVGJ cancer_NN and/or_CC other_JJ pulmonary_JJ and_CC cardiovascular_JJ diseases_NNS are_VBB indicated_VVN ._.
P10426859A15
It_PN is_VBZ hoped_VVN that_CST advances_NNS in_II molecular_JJ approach_NN to_II cardiovascular_JJ disease_NN ,_, molecular_JJ genetics_NNS and_CC transgenic_JJ techniques_NNS will_VM allow_VVB better_RRR understanding_VVGN and_CC more_RR effective_JJ therapeutic_JJ strategies_NNS to_TO prevent_VVI and_CC control_VVI IHD_NN ._.
P10433350A16
Combined_VVNJ therapy_NN with_II sulphonylureas_NNS may_VM be_VBB more_RR expensive_JJ and_CC clear_JJ clinical_JJ advantages_NNS have_VHB not_RR been_VBN consistently_RR demonstrated_VVN ._.
P10439825A01
To_TO help_VVI family_NN physicians_NNS manage_VVB patients_NNS with_II irritable_JJ bowel_NN syndrome_NN (_( IBS_NN )_) ,_, a_DD consensus_NN conference_NN was_VBD convened_VVN in_II June_NN 1997_MC at_II which_PNR 5_MC internationally_RR recognized_VVNJ experts_NNS in_II IBS_NN presented_VVD position_NN papers_NNS on_II selected_VVNJ topics_NNS previously_RR circulated_VVN to_II the_DD conference_NN participants_NNS ._.
P10448335A02
METHODS_NNS :_: Articles_NNS were_VBD selected_VVN from_II a_DD review_NN of_II Medline_NN ,_, accessed_VVN with_II the_DD OVID_NN search_NN engine_NN ._.
P10449891A06
Certain_JJ inotropic_JJ drugs_NNS may_VM reduce_VVB symptoms_NNS but_CC shorten_VVB life_NN expectancy_NN ._.
P10453829A22
The_DD data_NNS at_II present_NN are_VBB not_RR robust_JJ enough_RR to_TO address_VVI the_DD issue_NN of_II safety_NN ._.
P10467222A11
It_PN is_VBZ essential_JJ that_CST future_JJ intervention_NN strategies_NNS focus_VVB on_II improving_VVGN adoption_NN of_II new_JJ therapies_NNS into_II clinical_JJ practice_NN ._.
P10473016A03
In_II addition_NN ,_, morbidity_NN and_CC mortality_NN benefits_NNS have_VHB been_VBN suggested_VVN ,_, specifically_RR with_II the_DD non-selective_JJ vasodilating_VVGJ agent_NN ,_, carvedilol_NN ._.
P10474762A17
The_DD evidence_NN supports_VVZ the_DD use_NN dexrazoxane_NN to_TO provide_VVI protection_NN against_II the_DD cardiotoxicity_NN associated_VVN with_II conventional-dose_NN epirubicin_NN in_II patients_NNS with_II advanced_VVNJ but_CC anthracycline-sensitive_JJ cancer_NN ,_, in_II whom_PNR the_DD continued_VVNJ use_NN of_II anthracycline-containing_VVGJ chemotherapy_NN is_VBZ indicated_VVN in_II the_DD opinion_NN of_II the_DD treating_VVGJ physicians_NNS ._.
P10484239A04
According_II+ to_II estimates_NNS based_VVN on_II phase-2_NN NHANES_NN III_MC data_NNS (_( 1991-1994_MC )_) ,_, only_RR 1.4_MC million_MC (_( 6.6_MC %_SYM )_) of_II 21.1_MC million_MC American_JJ adults_NNS eligible_JJ for_II cholesterol-lowering_VVGJ drug_NN therapy_NN by_II NCEP_NN guidelines_NNS were_VBD receiving_VVG such_DD therapy_NN ,_, including_VVG 14_MC %_SYM of_II those_PND eligible_JJ in_II secondary_JJ prevention_NN and_CC 4_MC %_SYM of_II those_PND eligible_JJ in_II primary_JJ prevention_NN ._.
P10488367A02
The_DD target_NN group_NN for_II guideline_NN use_NN included_VVD general_JJ practitioners_NNS and_CC other_JJ primary_JJ health_NN care_NN providers_NNS in_II the_DD public_JJ and_CC private_JJ sectors_NNS ._.
P10494519A04
The_DD primary_JJ goal_NN of_II these_DD analyses_NNS is_VBZ to_TO maximize_VVI value_NN and_CC efficiency_NN ,_, not_RR necessarily_RR to_TO decrease_VVI spending_VVGN ._.
P10502233A06
Over_II the_DD past_JJ 2_MC years_NNS ,_, 4_MC major_JJ trials_NNS involving_VVG more_RR than_CSN 18,000_MC patients_NNS have_VHB evaluated_VVN the_DD therapeutic_JJ potential_NN of_II 3_MC small-molecule_NN ,_, intravenous_JJ GP_NN IIb-IIIa_NN inhibitors_NNS as_II a_DD component_NN of_II first-line_NN management_NN of_II unstable_JJ angina_NN or_CC non-ST-segment_NN elevation_NN myocardial_JJ infarction_NN ._.
P10505286A09
In_II this_DD registry_NN ,_, the_DD success_NN rate_NN of_II direct_JJ PTCA_NN was_VBD 87_MC %_SYM as_CS defined_VVN by_II a_DD final_JJ TIMI-grade_NN 3_MC perfusion_NN of_II the_DD infarct_NN vessel_NN which_PNR is_VBZ close_JJ to_II the_DD data_NNS of_II the_DD MITI-registry_NN and_CC the_DD GUSTO_NN IIb_NN study_NN ._.
P10507632A04
DATA_NNS SYNTHESIS_NN :_: In_II the_DD ICU_NN ,_, life_NN and_CC death_NN decisions_NNS are_VBB often_RR made_VVN in_II a_DD crisis_NN mode_NN or_CC in_II the_DD face_NN of_II uncertainty_NN ,_, and_CC may_VM necessitate_VVB the_DD withholding_VVGN and_CC withdrawal_NN of_II life-supporting_VVGJ technologies_NNS ._.
P10516909A07
In_II contrast_NN ,_, when_CS clinical_JJ improvement_NN has_VHZ not_RR occurred_VVN and_CC chest_NN radiographs_NNS are_VBB unchanged_VVN or_CC worse_JJ ,_, a_DD more_RR aggressive_JJ approach_NN is_VBZ warranted_VVN ._.
P10517720A07
DATA_NNS EXTRACTION_NN :_: The_DD sample_NN size_NN and_CC number_NN of_II subjects_NNS who_PNR developed_VVD preeclampsia_NN in_II the_DD calcium_NN supplementation_NN group_NN vs_CC a_DD control_NN group_NN were_VBD recorded_VVN and_CC analyzed_VVN on_II an_DD intent-to-treat_NN basis_NN ._.
P10526699A07
Beta_NN blockers_NNS can_VM also_RR improve_VVB the_DD intrinsic_JJ contractile_JJ function_NN of_II cardiomyocytes_NNS and_CC have_VHB also_RR been_VBN shown_VVN to_TO improve_VVI myocardial_JJ energetics_NNS in_II HF_NN ,_, possibly_RR through_II desirable_JJ changes_NNS in_II substrate_NN utilization_NN ._.
P10533351A07
Because_II+ of_II its_PNG short_JJ half-life_NN ,_, zaleplon_NN will_VM be_VBB useful_JJ in_II patients_NNS experiencing_VVG difficulty_NN in_II falling_VVGN asleep_JJ and_CC in_II those_PND who_PNR wake_VVB up_II at_II night_NN and_CC have_VHB trouble_JJ falling_VVGN back_II to_TO sleep_VVI ._.
P10534233A11
Pharmacological_JJ stress_NN testing_VVGN has_VHZ high_JJ clinical_JJ use_NN for_II risk_NN stratifying_VVGJ patients_NNS with_II known_VVNJ or_CC suspected_VVNJ CAD_NN ,_, in_II patients_NNS after_II myocardial_JJ infarction_NN ,_, and_CC in_II patients_NNS needing_VVG noncardiac_JJ surgery_NN ._.
P10538854A11
A_DD mini-pharmacoeconomic_JJ analysis_NN based_VVN on_II claims_NNS data_NNS over_II a_DD 6-month_NN period_NN from_II HMO_NN Colorado_NNP ,_, a_DD health_NN maintenance_NN organization_NN ,_, shows_VVZ that_CST switching_VVGN patients_NNS on_II dual_JJ therapy_NN with_II a_DD calcium_NN channel_NN blocker_NN and_CC an_DD ACE_NN inhibitor_NN to_II 1-pill_NN combination_NN therapy_NN with_II both_CC agents_NNS can_VM result_VVB in_II substantial_JJ cost_NN savings_NNS ._.
P10545862A18
There_RR have_VHB already_RR been_VBN several_JJ visits_NNS from_II senior_JJ NCI_NN personnel_NN to_II Ireland_NNP including_VVG Dr._NN Klausner_NN ,_, the_DD Director_NN of_II the_DD NCI_NN ,_, to_TO determine_VVI the_DD potential_JJ impact_NN of_II this_DD agreement_NN and_CC to_TO identify_VVI the_DD most_RRT productive_JJ areas_NNS of_II interaction_NN between_II the_DD NCI_NN and_CC the_DD Irish_NN Cancer_NN Community_NN ._.
P10550165A06
RESULTS_NNS :_: The_DD lack_NN of_II a_DD clearly_RR defined_VVNJ treatment_NN approach_NN to_II patients_NNS with_II locally_RR advanced_VVNJ prostate_NN cancer_NN stems_VVZ from_II multiple_JJ factors_NNS ,_, including_VVG ambiguities_NNS in_II clinical_JJ staging_VVGN ,_, inadequate_JJ knowledge_NN of_II the_DD natural_JJ history_NN of_II the_DD cancer_NN ,_, and_CC a_DD dearth_NN of_II comparative_JJ randomized_VVNJ trials_NNS evaluating_VVG efficacy_NN of_II different_JJ therapies_NNS ._.
P10551433A04
These_DD benefits_NNS are_VBB sustained_VVN at_II 6_MC months_NNS ._.
P10561236A04
EVIDENCE_NN :_: A_DD comprehensive_JJ ,_, formal_JJ literature_NN review_NN was_VBD conducted_VVN for_II tamoxifen_NN and_CC raloxifene_NN on_II the_DD following_VVGJ topics_NNS :_: breast_NN cancer_NN risk_NN reduction_NN ;_: tamoxifen_NN side_NN effects_NNS and_CC toxicity_NN ,_, including_VVG endometrial_JJ cancer_NN risk_NN ;_: tamoxifen_NN influences_NNS on_II nonmalignant_JJ diseases_NNS ,_, including_VVG coronary_JJ heart_NN disease_NN and_CC osteoporosis_NN ;_: and_CC decision_NN making_VVGN by_II women_NNS at_II risk_NN for_II breast_NN cancer_NN ._.
P10568677A14
Pharmacologic_JJ therapy_NN is_VBZ likely_RR to_TO be_VBI dominated_VVN by_II compounds_NNS that_PNR exert_VVB their_PNG predominant_JJ effect_NN by_II prolonging_VVGN atrial_JJ repolarization_NN ._.
P10577465A08
In_II addition_NN ,_, intramural_JJ delivery_NN of_II enoxaparin_NN to_TO achieve_VVI a_DD locally_RR high_JJ concentration_NN is_VBZ being_VBG investigated_VVN for_II the_DD prevention_NN of_II restenosis_NN after_II coronary_JJ stenting_VVGN ._.
P10583795A03
Various_JJ surveys_NNS have_VHB shown_VVN that_CST residents_NNS are_VBB under-trained_VVN in_II managed_VVNJ care_NN principles_NNS and_CC practice_NN ._.
P10588173A08
Other_JJ patient_NN characteristics_NNS that_PNR may_VM be_VBB useful_JJ in_II the_DD future_NN in_II deciding_VVGN suitability_NN for_II a_DD trial_NN ,_, or_CC predicting_VVGN response_NN ,_, include_VVB symptom_NN pattern_NN ,_, length_NN of_II symptom_NN history_NN ,_, whether_CST the_DD condition_NN was_VBD triggered_VVN by_II enteric_JJ infection_NN ,_, whether_CST a_DD patient_NN is_VBZ in_II primary_JJ ,_, secondary_JJ ,_, or_CC tertiary_JJ care_NN ,_, psychological_JJ characteristics_NNS ,_, a_DD history_NN of_II physical_JJ or_CC sexual_JJ abuse_NN ,_, and_CC possibly_RR visceral_JJ sensitivity_NN testing_VVGN or_CC autonomic_JJ dysfunction_NN ._.
P10591384A09
MAIN_JJ OUTCOME_NN MEASURES_NNS :_: Primary_JJ efficacy_NN was_VBD an_DD excellent_JJ neurologic_JJ recovery_NN at_II day_NN 90_MC (_( National_JJ Institutes_NNS of_II Health_NN Stroke_NN Scale_NN [_( NIHSS_NN ]_) score_NN of_II <_SYM or_CC =1_MC )_) ;_: secondary_JJ end_NN points_NNS included_VVD excellent_JJ recovery_NN on_II functional_JJ outcome_NN measures_NNS (_( Barthel_NNP index_NN ,_, modified_VVNJ Rankin_NNP scale_NN ,_, and_CC Glasgow_NNP Outcome_NN Scale_NN )_) at_II days_NNS 30_MC and_CC 90_MC ._.
P10595286A07
RESULTS_NNS :_: Twenty-two_MC trials_NNS ,_, including_VVG a_DD total_NN of_II 1042_MC patients_NNS (_( median_NN 36_MC ,_, range_NN 10-150_MC )_) ,_, met_VVD the_DD inclusion_NN criteria_NNS ._.
P10599376A25
It_PN was_VBD extremely_RR effective_JJ ,_, and_CC most_DD dermatologists_NNS who_PNR used_VVD it_PN have_VHB patients_NNS who_PNR consider_VVB it_PN the_DD most_RRT effective_JJ therapy_NN in_II the_DD last_JJ year_NN ._.
P10605194A03
Over_II the_DD last_JJ two_MC decades_NNS ,_, a_DD marked_VVNJ shift_NN in_II the_DD spectrum_NN of_II causative_JJ organisms_NNS towards_II a_DD gram-positive_JJ predominance_NN has_VHZ been_VBN the_DD main_JJ factor_NN influencing_VVG therapeutic_JJ approaches_NNS ._.
P10612273A05
Unfortunately_RR ,_, adverse_JJ effects_NNS may_VM limit_VVB compliance_NN in_II some_DD patients_NNS ._.
P10624417A04
The_DD choice_NN of_II a_DD specific_JJ antihypertensive_JJ drug_NN is_VBZ dependent_JJ upon_II the_DD severity_NN of_II the_DD hypertension_NN and_CC the_DD presence_NN of_II other_JJ cardiovascular_JJ risk_NN factors_NNS and_CC concurrent_JJ diseases_NNS ._.
P10630795A01
OBJECTIVE_NN :_: To_TO determine_VVI the_DD effect_NN of_II reamed_VVNJ versus_CC nonreamed_VVNJ intramedullary_JJ (_( IM_NN )_) nailing_VVGN of_II lower_JJR extremity_NN long_JJ bone_NN fractures_NNS on_II the_DD rates_NNS of_II nonunion_NN ,_, implant_NN failure_NN ,_, malunion_NN ,_, compartment_NN syndrome_NN ,_, pulmonary_JJ embolus_NN ,_, and_CC infection_NN ._.
P10632305A04
METHODS_NNS :_: We_PN conducted_VVD a_DD retrospective_JJ cohort_NN study_NN using_VVG the_DD SAGE_NN database_NN ,_, a_DD long-term_NN care_NN database_NN linking_VVG patient_NN information_NN with_II drug_NN utilization_NN data_NNS ._.
P10635046A21
The_DD explosive_JJ expansion_NN of_II information_NN now_RR available_JJ to_II ,_, and_CC frequently_RR quoted_VVN by_II ,_, HCV_NN patients_NNS seeking_VVG treatment_NN will_VM increasingly_RR make_VVB this_DD option_NN less_RR acceptable_JJ to_II a_DD great_JJ many_PND of_II this_DD group_NN ._.
P10646698A02
The_DD clinical_JJ goal_NN of_II peri-menopause_NN therapy_NN is_VBZ to_TO optimize_VVI the_DD woman_NN 's_GE health_NN during_II and_CC after_II this_DD transitional_JJ period_NN ._.
P10651602A03
This_DD paper_NN reviews_VVZ the_DD clinical_JJ characteristics_NNS of_II normal_JJ grief_NN and_CC clinical_JJ depression_NN and_CC explains_VVZ strategies_NNS for_II differential_JJ diagnosis_NN ._.
P10653213A12
The_DD methodologic_JJ quality_NN of_II all_DD trials_NNS was_VBD assessed_VVN ._.
P10665250A03
STUDY_NN SELECTION_NN :_: Clinical_JJ trials_NNS and_CC pertinent_JJ review_NN articles_NNS that_PNR discussed_VVD the_DD pharmacology_NN ,_, pharmacokinetics_NNS ,_, efficacy_NN ,_, and_CC safety_NN of_II PPIs_NNS in_II the_DD management_NN of_II acid-related_VVNJ disease_NN ._.
P10674059A08
Patient-reported_VVNJ outcomes_NNS were_VBD more_RR optimistic_JJ for_II sleep_NN latency_NN ;_: those_PND randomized_VVN to_II benzodiazepine_NN treatment_NN estimated_VVD a_DD sleep_NN latency_NN decrease_NN of_II 14.3_MC minutes_NNS (_( 95_MC %_SYM CI_NN 10.6_MC to_II 18.0_MC )_) ._.
P10678340A04
DATA_NNS COLLECTION_NN /_SYM ANALYSIS_NN :_: Abstracts_NNS of_II trials_NNS were_VBD reviewed_VVN independently_RR by_II 2_MC members_NNS of_II the_DD study_NN team_NN ._.
P10682170A01
Insulin_NN resistance_NN syndrome_NN (_( IRS_NN )_) ,_, also_RR termed_VVN syndrome_NN X_NN ,_, is_VBZ a_DD distinctive_JJ constellation_NN of_II risk_NN factors_NNS for_II the_DD development_NN of_II type_NN 2_MC diabetes_NN mellitus_NN and_CC cardiovascular_JJ disease_NN ._.
P10689260A04
Patients_NNS were_VBD randomly_RR assigned_VVN to_TO receive_VVI a_DD bolus_NN and_CC infusion_NN of_II either_CC eptifibatide_NN or_CC placebo_NN in_II addition_NN to_II standard_JJ therapy_NN ._.
P10695704A08
Inpatient_NN medical_JJ records_NNS from_II a_DD 254-bed_NN Brown_NNP University-affiliated_VVNJ teaching_VVGJ hospital_NN were_VBD also_RR evaluated_VVN for_II lipid_NN profile_NN ,_, achievement_NN of_II NCEP_NN II_MC goal_NN ,_, and_CC use_NN of_II lipid-lowering_VVGJ medication_NN on_II admission_NN and_CC discharge_NN ._.
P10699540A02
Controversy_NN also_RR exists_VVZ concerning_VVG its_PNG effectiveness_NN in_II the_DD chronically_RR ill_NN ._.
P10711239A12
Tamoxifen_NN also_RR reduced_VVD the_DD incidence_NN of_II contralateral_JJ breast_NN cancer_NN ,_, as_CC+ well_CC+ as_CC tumour_NN in_II the_DD ipsilateral_JJ breast_NN following_VVG lumpectomy_NN ._.
P10715310A06
The_DD panel_NN addressed_VVD which_DD patients_NNS to_TO treat_VVI and_CC when_PNR in_II their_PNG course_NN of_II disease_NN ,_, specific_JJ drug_NN delivery_NN issues_NNS ,_, duration_NN of_II therapy_NN ,_, management_NN of_II bony_JJ metastases_NNS with_II other_JJ therapies_NNS ,_, and_CC the_DD public_JJ policy_NN implications_NNS ._.
P10727363A05
RESULTS_NNS :_: a_DD total_NN of_II 34_MC articles_NNS were_VBD found_VVN ,_, but_CC only_RR 10_MC were_VBD reports_NNS of_II randomised_VVNJ controlled_VVNJ trials_NNS ._.
P10731376A14
It_PN should_VM be_VBB used_VVN early_RR after_II symptom_NN onset_NN and_CC in_II conjunction_NN with_II a_DD more_RR specific_JJ marker_NN of_II myocardial_JJ damage_NN ._.
P10733260A02
CHF_NN is_VBZ thought_VVN to_TO progress_VVI as_II a_DD result_NN of_II activation_NN of_II endogenous_JJ neurohormonal_JJ systems_NNS which_PNR are_VBB activated_VVN by_II the_DD initial_JJ myocardial_JJ injury_NN ._.
P10744594A07
DATA_NNS EXTRACTION_NN :_: Two_MC independent_JJ reviewers_NNS abstracted_VVD each_DD article_NN by_II following_VVGN a_DD prospectively_RR designed_VVNJ protocol_NN ._.
P10750936A03
Meta-analysis_NN of_II randomized_VVNJ ,_, placebo_NN controlled_VVNJ trials_NNS ._.
P10755326A12
While_CS waiting_VVG for_II a_DD donor_NN ,_, patients_NNS have_VHB been_VBN bridged_VVN with_II various_JJ intravenous_JJ agents_NNS ,_, most_RRT often_RR inotropes_NNS ,_, but_CC symptom_NN relief_NN is_VBZ associated_VVN with_II risk_NN of_II increased_VVNJ mortality_NN due_II+ to_II these_DD drugs_NNS ._.
P10767115A09
There_EX may_VM be_VBB a_DD role_NN for_II IV_NN IgG_NN and_CC steroids_NNS ,_, especially_RR for_II cases_NNS of_II thrombocytopenia_NN that_PNR are_VBB immune-mediated_VVN ;_: however_RR ,_, further_JJ investigations_NNS are_VBB necessary_JJ ._.
P10772302A07
DATA_NNS SYNTHESIS_NN :_: Six_MC randomized_VVNJ controlled_VVNJ trials_NNS were_VBD included_VVN in_II the_DD review_NN ,_, 4_MC of_II which_PNR used_VVD crossover_NN design_NN ._.
P10783421A08
A_DD recent_JJ meta-analysis_NN analyzed_VVD 10_MC prospective_JJ studies_NNS comparing_VVG primary_JJ angioplasty_NN with_II intravenous_JJ fibrinolytic_JJ therapy_NN and_CC found_VVD that_CST the_DD mortality_NN rate_NN for_II 30_MC days_NNS or_CC less_PND was_VBD 4.4_MC %_SYM for_II 1,290_MC patients_NNS treated_VVN with_II primary_JJ angioplasty_NN compared_VVN with_II 6.5_MC %_SYM for_II 1,316_MC patients_NNS treated_VVN with_II fibrinolytic_JJ agents_NNS (_( 95_MC %_SYM confidence_NN intervals_NNS 0.46_MC to_II 0.49_MC ,_, P_NN =.02_MC )_) ._.
P10789664A04
OBJECTIVE_NN :_: To_TO compare_VVI the_DD effect_NN of_II doxazosin_NN ,_, an_DD alpha-blocker_NN ,_, with_II chlorthalidone_NN ,_, a_DD diuretic_NN ,_, on_II incidence_NN of_II CVD_NN in_II patients_NNS with_II hypertension_NN as_II part_NN of_II a_DD study_NN of_II 4_MC types_NNS of_II antihypertensive_JJ drugs_NNS :_: chlorthalidone_NN ,_, doxazosin_NN ,_, amlodipine_NN ,_, and_CC lisinopril_NN ._.
P10792162A04
RESULTS_NNS :_: In_II all_PND ,_, 444_MC men_NNS were_VBD enrolled_VVN in_II two_MC placebo-controlled_VVNJ and_CC two_MC comparative_JJ trials_NNS lasting_VVG 12-24_MC weeks_NNS ._.
P10796129A07
Expert_NN informant_NN 's_GE search_NN in_II the_DD Japanese_JJ language_NN was_VBD made_VVN by_II Prof._NN Y_NN ._.
P10796197A13
Further_JJ research_NN should_VM evaluate_VVB the_DD practice_NN of_II supplementation_NN of_II human_NN milk_NN with_II fat_NN ._.
P10796208A12
Data_NNS were_VBD entered_VVN into_II the_DD Review_NN Manager_NN software_NN and_CC double_RR checked_VVN ._.
P10796252A17
There_EX is_VBZ a_DD compelling_VVGJ need_NN for_II the_DD long_JJ term_NN follow-up_NN and_CC reporting_VVGN of_II late_JJ outcomes_NNS ,_, especially_RR neurologic_JJ and_CC developmental_JJ outcomes_NNS ,_, among_II surviving_VVGJ infants_NNS who_PNR participated_VVD in_II all_DD randomized_VVNJ trials_NNS of_II early_JJ postnatal_JJ corticosteroid_NN treatment_NN ._.
P10796264A19
Chronic_JJ administration_NN of_II furosemide_NN improves_VVZ both_CC oxygenation_NN and_CC lung_NN compliance_NN ._.
P10796274A21
Large_JJ studies_NNS are_VBB needed_VVN to_TO assess_VVI (_( 1_MC )_) whether_CST chronic_JJ diuretic_NN administration_NN improves_VVZ mortality_NN ,_, duration_NN of_II oxygen_NN dependency_NN ,_, ventilator_NN dependency_NN ,_, length_NN of_II hospital_NN stay_NN and_CC long-term_NN outcome_NN in_II patients_NNS without_II long-term_NN toxicity_NN and_CC (_( 2_MC )_) whether_CST adding_VVGN spironolactone_NN to_II thiazides_NNS or_CC adding_VVGN metolazone_NN to_II furosemide_NN has_VHZ any_DD beneficial_JJ effect_NN ._.
P10796282A11
MAIN_JJ RESULTS_NNS :_: Five_MC randomised_VVNJ trials_NNS with_II data_NNS for_II 3954_MC participants_NNS were_VBD included_VVN ._.
P10796300A12
The_DD five_MC included_VVNJ trials_NNS involved_VVD 1068_MC patients_NNS ._.
P10796306A30
The_DD significance_NN of_II these_DD results_NNS is_VBZ therefore_RR questionable_JJ ._.
P10796329A14
Two_MC trials_NNS used_VVD intra-arterial_JJ administration_NN but_CC the_DD rest_NN used_VVD the_DD intravenous_JJ route_NN ._.
P10796337A10
The_DD drugs_NNS analyzed_VVN were_VBD :_: nimodipine_NN (_( eight_MC trials_NNS ,_, 1574_MC patients_NNS )_) ,_, nicardipine_NN (_( two_MC trials_NNS ,_, 954_MC patients_NNS )_) ,_, and_CC AT877_NN (_( one_MC trial_NN ,_, 276_MC patients_NNS )_) ._.
P10796343A06
SELECTION_NN CRITERIA_NNS :_: Unconfounded_VVNJ truly_RR or_CC quasi_RR randomised_VVNJ controlled_VVNJ trials_NNS in_II dysphagic_JJ patients_NNS with_II acute_JJ /_SYM subacute_JJ (_( within_II 3_MC months_NNS )_) stroke_NN ._.
P10796350A16
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: Data_NNS in_II this_DD review_NN are_VBB too_RR inconclusive_JJ to_TO guide_VVI those_PND wishing_VVG to_II uphold_VVI or_CC refute_VVI the_DD effect_NN of_II intercessory_JJ prayer_NN on_II health_NN care_NN outcomes_NNS ._.
P10796364A18
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: There_EX is_VBZ insufficient_JJ information_NN on_II the_DD use_NN of_II rescue_NN HFOV_NN to_TO make_VVI recommendations_NNS for_II practice_NN ._.
P10796390A01
BACKGROUND_NN :_: Although_CS medication_NN is_VBZ the_DD mainstay_NN of_II treatment_NN for_II schizophrenia_NN ,_, always_RR ,_, some_DD sort_NN of_II informal_JJ or_CC formal_JJ talking_VVGJ therapy_NN is_VBZ indicated_VVN ._.
P10796398A11
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: All_DD data_NNS were_VBD abstracted_VVN by_II two_MC independent_JJ and_CC trained_VVNJ reviewers_NNS (_( DF_NNP ,_, AT_NNP )_) ,_, and_CC verified_VVN by_II a_DD third_JJ reviewer_NN (_( JP_NNP )_) ._.
P10796404A01
BACKGROUND_NN :_: Hallux_NN valgus_NN is_VBZ classified_VVN as_II an_DD abnormal_JJ deviation_NN of_II the_DD great_JJ toe_NN (_( hallux_NN )_) towards_II the_DD midline_NN of_II the_DD foot_NN ._.
P10796407A03
Non-nutritive_JJ sucking_VVGN has_VHZ been_VBN considered_VVN to_TO be_VBI a_DD benign_JJ intervention_NN ,_, although_CS it_PN has_VHZ the_DD potential_JJ to_TO have_VHI a_DD negative_JJ effect_NN on_II breastfeeding_VVGN or_CC on_II the_DD incidence_NN of_II later_RR oral_JJ aversion_NN ._.
P10796414A11
For_II continuous_JJ data_NNS Weighted_VVNJ Mean_NN Differences_NNS (_( WMD_NN )_) were_VBD calculated_VVN ._.
P10796420A08
Specifically_RR ,_, we_PN required_VVD that_CST trials_NNS be_VBB randomized_VVN or_CC cross-over_NN and_CC report_VVB at_RR+ least_RR one_MC of_II the_DD following_VVGJ outcome_NN measures_NNS in_II a_DD quantitative_JJ manner_NN :_: joint_NN tenderness_NN ,_, joint_NN swelling_VVGN ,_, grip_NN strength_NN ,_, or_CC erythrocyte_NN sedimentation_NN rate_NN (_( ESR_NN )_) ._.
P10796428A05
Date_NN of_II the_DD most_RRT recent_JJ search_NN :_: April_NN 1999_MC ._.
P10796432A07
For_II practical_JJ reasons_NNS only_RR those_PND in_II English_NN were_VBD included_VVN ,_, but_CC all_DD languages_NNS will_VM be_VBB retrieved_VVN and_CC translated_VVN for_II future_JJ updates_NNS ._.
P10796439A06
All_PND randomized_VVNJ controlled_VVNJ trials_NNS which_PNR compared_VVD pain_NN response_NN to_II venepuncture_NN vs._CC heel_NN lance_NN were_VBD searched_VVN using_VVG MEDLINE_NN ,_, Embase_NN ,_, CINAHL_NN ,_, the_DD Cochrane_NNP Library_NN ,_, reference_NN lists_NNS of_II identified_VVNJ trials_NNS and_CC personal_JJ files_NNS ._.
P10796442A16
There_EX were_VBD no_DD clear_JJ differences_NNS between_II the_DD two_MC preparations_NNS ._.
P10796457A03
It_PN has_VHZ been_VBN shown_VVN that_CST bone_NN mineral_NN loss_NN at_II the_DD hip_NN averages_VVZ 14_MC %_SYM in_II the_DD first_JJ year_NN after_II starting_VVGN corticosteroid_NN therapy_NN ._.
P10796461A07
The_DD pooled_VVNJ analysis_NN was_VBD performed_VVN using_VVG standardized_VVNJ mean_NN differences_NNS (_( SMDs_NNS )_) for_II joint_NN counts_NNS ,_, pain_NN and_CC global_JJ assessments_NNS ._.
P10796480A03
OBJECTIVES_NNS :_: The_DD objective_NN of_II this_DD review_NN was_VBD to_TO assess_VVI the_DD effects_NNS of_II adding_VVGN inhaled_VVNJ anti-cholinergics_NNS to_II beta2-agonists_NNS in_II acute_JJ paediatric_JJ asthma_NN ._.
P10796491A09
Six_MC of_II seven_MC trials_NNS that_PNR measured_VVD health_NN professional_JJ practice_NN demonstrated_VVD some_DD improvement_NN for_II at_RR+ least_RR one_MC outcome_NN variable_NN ,_, and_CC in_II two_MC trials_NNS ,_, the_DD results_NNS were_VBD statistically_RR significant_JJ and_CC clinically_RR important_JJ ._.
P10796506A11
Methodological_JJ quality_NN was_VBD assessed_VVN independently_RR by_II two_MC reviewers_NNS ._.
P10796515A21
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: For_II acute_JJ maxillary_JJ sinusitis_NN confirmed_VVN radiographically_RR or_CC by_II aspiration_NN ,_, current_JJ evidence_NN is_VBZ limited_VVN but_CC supports_VVZ penicillin_NN or_CC amoxicillin_NN for_II 7_MC to_II 14_MC days_NNS ._.
P10796525A05
The_DD Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN and_CC the_DD Inflammatory_JJ Bowel_NN Disease_NN Review_NN Group_NN Trials_NNS Register_NN were_VBD also_RR searched_VVN ._.
P10796528A16
Outcomes_NNS analysed_VVN included_VVD improvement_NN in_II menstrual_JJ blood_NN loss_NN ,_, satisfaction_NN ,_, change_NN in_II quality_NN of_II life_NN ,_, duration_NN of_II surgery_NN and_CC hospital_NN stay_NN ,_, time_NN to_TO return_VVI to_II work_NN ,_, adverse_JJ events_NNS and_CC requirement_NN for_II repeat_NN surgery_NN because_II+ of_II failure_NN of_II the_DD initial_JJ surgical_JJ treatment_NN ._.
P10796534A12
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: Data_NNS were_VBD extracted_VVN independently_RR by_II the_DD reviewers_NNS ,_, pooled_VVN where_CS appropriate_JJ and_CC possible_JJ ,_, and_CC the_DD pooled_VVNJ odds_NNS ratios_NNS (_( 95_MC %_SYM CI_NN )_) or_CC the_DD average_JJ differences_NNS (_( 95_MC %_SYM CI_NN )_) were_VBD estimated_VVN ._.
P10796541A09
Other_JJ sources_NNS including_VVG personal_JJ communications_NNS ,_, ongoing_VVGJ trials_NNS ,_, conference_NN proceedings_NNS ,_, handsearching_VVGN and_CC reference_NN lists_NNS of_II published_VVNJ papers_NNS and_CC books_NNS were_VBD all_PND searched_VVN for_II relevant_JJ randomized_VVNJ controlled_VVNJ trials_NNS ._.
P10796544A21
The_DD individual_JJ patient_NN data_NNS review_NN will_VM yield_VVB further_JJ evidence_NN on_II the_DD effects_NNS of_II selegiline_NN compared_VVN to_II control_NN as_CS would_VM additional_JJ studies_NNS evaluating_VVG the_DD use_NN of_II selegiline_NN for_II the_DD endpoints_NNS of_II standardised_VVNJ cognitive_JJ scales_NNS ,_, clinician_NN impression_NN of_II global_JJ change_NN ,_, dependency_NN and_CC caregiver_NN quality_NN of_II life_NN ._.
P10796550A06
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: Two_MC reviewers_NNS independently_RR assessed_VVD trial_NN quality_NN and_CC extracted_VVD data_NNS ._.
P10796567A08
Specialist_NN advice_NN was_VBD sought_VVN to_TO categorise_VVI interventions_NNS ._.
P10796576A07
The_DD main_JJ outcome_NN was_VBD the_DD rate_NN of_II tracheal_JJ re-intubation_NN after_II extubation_NN ._.
P10796587A01
BACKGROUND_NN :_: Excessively_RR heavy_JJ menstrual_JJ bleeding_VVGN (_( HMB_NN )_) or_CC menorrhagia_NN is_VBZ an_DD important_JJ cause_NN of_II ill_JJ health_NN in_II women_NNS ._.
P10796594A27
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: Treatment_NN of_II patients_NNS with_II COPD_NN with_II long_RR acting_VVGJ beta2-agonists_NNS produces_VVZ only_RR small_JJ increases_NNS in_II FEV1_NN ._.
P10796603A10
The_DD objective_NN of_II the_DD review_NN is_VBZ to_TO assess_VVI the_DD effects_NNS of_II RT_NN for_II dementia_NN ._.
P10796607A18
For_II the_DD risk_NN of_II leaving_VVGN the_DD study_NN early_RR ,_, there_EX was_VBD also_RR a_DD trend_NN for_II benefit_NN to_II those_PND allocated_VVN to_II zuclopenthixol_NN decanoate_NN ._.
P10796617A02
Although_CS beneficial_JJ effects_NNS upon_II clinically_RR relevant_JJ outcomes_NNS have_VHB been_VBN demonstrated_VVN in_II randomised_VVNJ controlled_VVNJ trials_NNS ,_, there_RR remains_VVZ a_DD risk_NN of_II severe_JJ and_CC sometimes_NNS fatal_JJ anaphylaxis_NN ._.
P10796622A05
To_TO evaluate_VVI the_DD relative_JJ efficacy_NN of_II different_JJ types_NNS of_II fatty_JJ acid_NN supplementation_NN ._.
P10796639A16
Change_NN in_II cognitive_JJ outcome_NN was_VBD towards_II being_VVGN in_II favour_NN of_II treatment_NN ._.
P10796650A09
Studies_NNS were_VBD included_VVN if_CS patients_NNS presented_VVD with_II acute_JJ asthma_NN and_CC were_VBD treated_VVN with_II IV_NN magnesium_NN sulfate_NN vs_CC placebo_NN ._.
P10796661A05
We_PN hand_NN searched_VVD relevant_JJ journals_NNS and_CC conference_NN proceedings_NNS ,_, and_CC contacted_VVD Hoechst_NNP (_( the_DD manufacturer_NN of_II the_DD drug_NN )_) and_CC experts_NNS in_II the_DD field_NN ._.
P10796671A04
SEARCH_NN STRATEGY_NN :_: Electronic_JJ searches_NNS of_II Biological_JJ Abstracts_NNS (_( 1980-1999_MC )_) ,_, CINAHL_NN (_( 1982-1999_MC )_) ,_, The_DD Cochrane_NNP Library_NN (_( Issue_NN 1_MC ,_, 1999_MC )_) ,_, The_DD Cochrane_NNP Schizophrenia_NN Group_NN 's_GE Register_NN (_( January_NN 1999_MC )_) ,_, EMBASE_NN (_( 1980-1999_MC )_) ,_, Dialog_NN Corporation_NN Datastar_NN service_NN (_( 1999_MC )_) ,_, MEDLINE_NN (_( 1966-1999_MC )_) ,_, and_CC PsycLIT_NN (_( 1974-1999_MC )_) were_VBD undertaken_VVN ._.
P10796678A02
From_II its_PNG beginnings_NNS telemedicine_NN has_VHZ been_VBN used_VVN in_II a_DD variety_NN of_II health_NN care_NN fields_NNS ,_, although_CS widespread_JJ interest_NN among_II healthcare_NN providers_NNS has_VHZ only_RR now_RR become_VVB apparent_JJ with_II the_DD development_NN of_II more_RR sophisticated_VVNJ technology_NN ._.
P10796688A13
Cardiovascular_JJ mortality_NN was_VBD reduced_VVN from_II 69_MC to_II 50_MC deaths_NNS (_( 95_MC %_SYM CI_NN of_II the_DD difference_NN 9_MC to_II 31_MC )_) ._.
P10796704A14
Levodopa_NN dose_NN was_VBD reduced_VVN more_RR in_II those_PND receiving_VVG pergolide_NN (_( 235_MC mg_NN v_CC 51_MC mg_NN ;_: p_NN <_SYM 0._MC 001_MC )_) ._.
P10796711A20
Trial_NN design_NN characteristics_NNS ._.
P10796715A21
No_DD increase_NN in_II endometrial_JJ cancer_NN was_VBD seen_VVN in_II any_PND of_II the_DD treatment_NN groups_NNS during_II the_DD limited_VVNJ duration_NN (_( maximum_NN of_II 3_MC years_NNS )_) of_II these_DD trials_NNS ._.
P10796723A15
Subgroup_NN analysis_NN was_VBD performed_VVN according_II+ to_II type_NN of_II control_NN group_NN ,_, no_DD pre-treatment_NN or_CC placebo_NN ,_, and_CC for_II some_DD outcomes_NNS there_EX were_VBD additional_JJ subgroup_NN analyses_NNS according_II+ to_II size_NN of_II the_DD uterus_NN in_II gestational_JJ weeks_NNS ._.
P10796730A20
MAIN_JJ RESULTS_NNS :_: Outcomes_NNS were_VBD evaluated_VVN separately_RR for_II unopposed_VVNJ oestrogen_NN and_CC oestrogen_NN /_SYM progestogen_NN regimens_NNS ._.
P10796739A23
Additional_JJ randomized_VVNJ placebo_NN and_CC active-controlled_VVNJ trials_NNS are_VBB needed_VVN to_TO evaluate_VVI the_DD long-term_NN clinical_JJ effectiveness_NN and_CC safety_NN of_II Cernilton_NN ._.
P10796750A10
Studies_NNS where_PNR less_RR than_CSN 50_MC %_SYM of_II patients_NNS had_VHD a_DD spinal_JJ cord_NN injury_NN were_VBD excluded_VVN ._.
P10796754A20
In_II order_NN to_TO detect_VVI a_DD realistic_JJ treatment_NN advantage_NN ,_, larger_JJR trials_NNS will_VM have_VHB to_TO be_VBI conducted_VVN ._.
P10796760A02
In_II Australia_NNP ,_, the_DD United_VVNJ Kingdom_NN and_CC the_DD United_VVNJ States_NNS ,_, it_PN is_VBZ the_DD second_JJ commonest_JJT cancer_NN for_II women_NNS after_II breast_NN cancer_NN (_( age-standardised_VVNJ incidence_NN 22-33_MC per_II 100,000_MC )_) ,_, and_CC men_NNS after_II prostate_NN or_CC lung_NN cancer_NN (_( age-standardised_VVNJ incidence_NN 31-47_MC per_II 100,000_MC )_) (_( Jeffs_NNP et_CC al_NN ,_, 1996_MC ;_: Parkin_NNP et_CC al_NN ,_, 1992_MC )_) ._.
P10796766A17
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: The_DD results_NNS of_II non-randomised_VVNJ studies_NNS have_VHB concluded_VVN that_CST a_DD phenylalanine_NN restricted_VVNJ diet_NN is_VBZ effective_JJ in_II reducing_VVGN blood_NN phenylalanine_NN levels_NNS and_CC improving_VVGN intelligence_NN quotient_NN and_CC neuropsychological_JJ outcome_NN ._.
P10796777A09
SELECTION_NN CRITERIA_NNS :_: We_PN included_VVD randomized_VVNJ controlled_VVNJ trials_NNS using_VVG any_DD antibiotic_NN compared_VVN with_II a_DD placebo_NN ._.
P10796785A17
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: Gabapentin_NN has_VHZ efficacy_NN as_II an_DD add-on_NN treatment_NN in_II patients_NNS with_II drug-resistant_JJ partial_JJ epilepsy_NN ._.
P10796793A05
Additional_JJ studies_NNS were_VBD identified_VVN from_II the_DD reference_NN lists_NNS of_II retrieved_VVNJ reports_NNS ._.
P10796799A16
No_DD significant_JJ differences_NNS were_VBD found_VVN between_II any_PND of_II the_DD other_JJ outcomes_NNS measured_VVN ._.
P10796805A08
Information_NN was_VBD collected_VVN on_II death_NN ,_, disability_NN ,_, and_CC incidence_NN of_II infection_NN ._.
P10796814A05
SELECTION_NN CRITERIA_NNS :_: All_DD randomised_VVNJ and_CC pseudorandomised_VVNJ trials_NNS (_( published_VVN or_CC unpublished_VVN )_) comparing_VVG any_DD influenza_NN vaccine_NN with_II a_DD placebo_NN or_CC with_II another_DD type_NN of_II influenza_NN vaccine_NN ._.
P10796818A17
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: There_EX still_RR remains_VVZ considerable_JJ uncertainty_NN about_II which_PNR forms_NNS of_II psychosocial_JJ and_CC physical_JJ treatments_NNS of_II self-harm_NN patients_NNS are_VBB most_RRT effective_JJ ,_, inclusion_NN of_II insufficient_JJ numbers_NNS of_II patients_NNS in_II trials_NNS being_VBG the_DD main_JJ limiting_VVGJ factor_NN ._.
P10796830A20
However_RR ,_, there_EX are_VBB only_RR limited_VVNJ data_NNS examining_VVG a_DD more-important_JJ longer-term_NN effect_NN on_II the_DD prevention_NN of_II unplanned_VVNJ pregnancies_NNS ._.
P10796838A14
Differences_NNS were_VBD resolved_VVN by_II discussion_NN ._.
P10796845A04
OBJECTIVES_NNS :_: The_DD aim_NN of_II this_DD review_NN is_VBZ to_TO examine_VVI the_DD evidence_NN for_II the_DD safety_NN and_CC effectiveness_NN of_II photodynamic_JJ therapy_NN in_II the_DD treatment_NN of_II neovascular_JJ age-related_VVNJ macular_JJ degeneration_NN ._.
P10796856A05
As_CS most_DD acne_NN prescribing_VVGN is_VBZ undertaken_VVN by_II general_JJ practitioners_NNS ,_, it_PN is_VBZ important_JJ that_CST guidelines_NNS issued_VVN to_II them_PN are_VBB based_VVN on_II the_DD best_RRT available_JJ evidence_NN rather_II+ than_II personal_JJ judgements_NNS ._.
P10796860A04
SEARCH_NN STRATEGY_NN :_: The_DD following_VVGJ electronic_JJ databases_NNS were_VBD searched_VVN :_: MEDLINE_NN to_II June_NN 1997_MC ;_: AMED_NN ;_: ASSIA_NN ;_: BIDS_NN ;_: BIOSIS_NN Previews_NNS (_( 1985-1996_MC )_) ;_: CINAHL_NN ;_: DHSS_NN Data_NNS ;_: EMBASE_NN (_( 1974_MC to_II June_NN 1997_MC )_) ;_: PsycLIT_NN and_CC SIGLE_NN ._.
P10796862A31
Some_DD women_NNS treated_VVN with_II cones_NNS stop_VVB treatment_NN early_RR so_CS cones_NNS may_VM only_RR be_VBB useful_JJ for_II those_PND who_PNR find_VVB them_PN acceptable_JJ ._.
P10799082A02
While_CS the_DD need_NN for_II randomized_VVNJ trials_NNS is_VBZ evident_JJ ,_, conducting_VVGN these_DD trials_NNS is_VBZ becoming_VVG increasingly_RR difficult_JJ and_CC complex_NN ._.
P10804811A08
Traditional_JJ laboratories_NNS which_PNR are_VBB unwilling_VVN to_TO adapt_VVI themselves_PN to_II the_DD new_JJ environment_NN will_VM not_RR survive_VVB in_II this_DD country_NN ._.
P10815085A01
OBJECTIVE_NN :_: Assays_NNS for_II drug_NN resistance_NN testing_VVGN in_II human_NN immunodeficiency_NN virus_NN type_NN 1_MC (_( HIV-1_NN )_) infection_NN are_VBB now_RR available_JJ and_CC clinical_JJ studies_NNS suggest_VVB that_CST viral_JJ drug_NN resistance_NN is_VBZ correlated_VVN with_II poor_JJ virologic_JJ response_NN to_II new_JJ therapy_NN ._.
P10819705A06
No_DD studies_NNS of_II computerized_VVNJ screening_VVGN were_VBD included_VVN ._.
P10824405A14
An_DD "_`` Optimal_JJ Volume_NN Strategy_NN "_'' with_II HFOV_NN was_VBD utilized_VVN to_TO recruit_VVI alveoli_NNS and_CC optimize_VVI lung_NN volume_NN ._.
P10828751A02
Resistance_NN is_VBZ an_DD ongoing_VVGJ problem_NN with_II antimicrobial_JJ therapy_NN but_CC considerable_JJ progress_NN has_VHZ now_RR been_VBN made_VVN into_II understanding_VVGN the_DD underlying_VVGJ genetic_JJ mechanisms_NNS of_II this_DD process_NN ._.
P10849468A02
Despite_II this_PND ,_, asthma_NN morbidity_NN and_CC mortality_NN rates_NNS are_VBB rising_VVG ._.
P10853406A23
The_DD guideline_NN is_VBZ endorsed_VVN by_II the_DD South_NN African_JJ Medical_JJ Association_NN ._.
P10858490A01
Cardiovascular_JJ disease_NN mortality-rate_NN reductions_NNS have_VHB slowed_VVN in_II the_DD United_VVNJ States_NNS in_II the_DD last_JJ decade_NN ,_, suggesting_VVG that_CST additional_JJ strategies_NNS are_VBB needed_VVN to_TO reduce_VVI rates_NNS further_RR ._.
P10860137A09
Leflunomide_NN has_VHZ been_VBN shown_VVN to_TO be_VBI equal_JJ to_II or_CC less_RR efficacious_JJ than_CSN methotrexate_NN ,_, and_CC may_VM be_VBB beneficial_JJ as_II a_DD second-line_NN disease-modifying_VVGJ antirheumatic_JJ drug_NN (_( DMARD_NN )_) ._.
P10863884A19
CONCLUSIONS_NNS :_: There_EX is_VBZ evidence_NN to_TO support_VVI the_DD role_NN of_II citalopram_NN as_II a_DD well-tolerated_VVNJ and_CC effective_JJ SSRI_NN antidepressant_NN ._.
P10872016A11
Smaller_JJR estrogen_NN dosages_NNS were_VBD associated_VVN with_II lower_JJR risk_NN (_( P=.01_NN for_II trend_NN )_) ,_, but_CC risk_NN was_VBD significantly_RR elevated_VVN for_II all_DD dosages_NNS ._.
P10874909A17
CONCLUSIONS_NNS :_: Traumatic_JJ Brain_NN Injury_NN (_( TBI_NN )_) results_VVZ principally_RR from_II vehicular_JJ incidents_NNS ,_, falls_NNS ,_, acts_NNS of_II violence_NN ,_, and_CC sports_NNS injuries_NNS ,_, and_CC is_VBZ more_RR than_CSN twice_RR as_RR likely_JJ in_II males_NNS as_CS in_II females_NNS ._.
P10890271A05
The_DD evidence_NN that_CST diet_NN alone_JJ improves_VVZ survival_NN is_VBZ poor_JJ ,_, although_CS specifically_RR increasing_VVGN intake_NN of_II polyunsaturated_VVNJ fatty_JJ acid_NN (_( including_VVG n-3_NN fatty_JJ acids_NNS )_) relative_JJ to_II saturated_VVNJ fatty_JJ acid_NN intake_NN may_VM provide_VVB some_DD clinical_JJ benefit_NN in_II the_DD secondary_JJ prevention_NN of_II coronary_JJ heart_NN disease_NN ._.
P10901828A07
OUTCOMES_NNS :_: The_DD main_JJ potential_JJ outcomes_NNS considered_VVN were_VBD :_: to_TO reduce_VVI morbidity_NN and_CC mortality_NN by_II correct_JJ diagnosis_NN of_II asthma_NN ,_, to_TO achieve_VVI the_DD best_JJT quality_NN of_II life_NN for_II the_DD child_NN with_II asthma_NN ,_, to_II minimise_VVI side-effects_NNS from_II medication_NN and_CC to_TO prevent_VVI development_NN of_II permanently_RR abnormal_JJ lung_NN function_NN ._.
P10908464A08
These_PND include_VVB acute_JJ phase_NN reactants_NNS ,_, disability_NN ,_, pain_NN ,_, patient_NN global_JJ assessment_NN ,_, physician_NN global_JJ assessment_NN ,_, swollen_JJ joint_NN count_NN ,_, tender_NN joint_NN count_NN and_CC radiographic_JJ changes_NNS of_II joints_NNS in_II any_DD trial_NN of_II one_MC year_NN or_CC longer_JJR [_( Tugwell_NNP 1993_MC ]_) ,_, and_CC the_DD change_NN in_II pooled_VVNJ disease_NN index_NN (_( DI_NN )_) ._.
P10908475A02
Although_CS payment_NN systems_NNS may_VM be_VBB used_VVN to_TO achieve_VVI policy_NN objectives_NNS (_( e.g._II improving_VVGN quality_NN of_II care_NN ,_, cost_NN containment_NN and_CC recruitment_NN to_II under-served_VVNJ areas_NNS )_) ,_, little_PND is_VBZ known_VVN about_II the_DD effects_NNS of_II different_JJ payment_NN systems_NNS in_II achieving_VVGN these_DD objectives_NNS ._.
P10908485A02
The_DD condition_NN usually_RR results_VVZ in_II an_DD increase_NN in_II symptoms_NNS ,_, a_DD greater_JJR reliance_NN on_II corticosteroids_NNS to_TO control_VVI the_DD disease_NN process_NN and_CC may_VM lead_VVB to_II a_DD progressive_JJ decline_NN in_II lung_NN function_NN ._.
P10908489A16
One_MC large_JJ study_NN (_( 106_MC patients_NNS )_) showed_VVD an_DD improvement_NN in_II PEFR_NN and_CC reduction_NN in_II rescue_NN bronchodilator_NN use_NN ._.
P10908496A18
Dose-response_NN studies_NNS examining_VVG survival_NN for_II either_DD agent_NN could_VM not_RR be_VBB identified_VVN ._.
P10908505A01
BACKGROUND_NN :_: Stress_NN is_VBZ considered_VVN an_DD important_JJ precipitating_VVGJ factor_NN for_II seizures_NNS ._.
P10908512A12
Overall_RR the_DD methodological_JJ quality_NN of_II the_DD studies_NNS included_VVN in_II our_PNG review_NN was_VBD rather_RR low_JJ ._.
P10908517A33
Its_PNG adverse_JJ events_NNS profile_NN is_VBZ similar_JJ to_II that_PND of_II other_JJ drugs_NNS ,_, but_CC it_PN may_VM have_VHB a_DD lower_JJR level_NN of_II extrapyramidal_JJ problems_NNS ._.
P10908521A18
All_PND found_VVD withdrawal_NN to_TO be_VBI less_RR severe_JJ in_II the_DD buprenorphine_JJ treatment_NN group_NN ._.
P10908538A10
The_DD majority_NN of_II the_DD studies_NNS lacked_VVD sample_NN size_NN calculations_NNS and_CC randomization_NN procedure_NN remained_VVD unclear_JJ in_II three_MC trials_NNS ._.
P10908543A08
Interventions_NNS were_VBD continuous_JJ distending_VVGJ airway_NN pressure_NN including_VVG continuous_JJ positive_JJ airway_NN pressure_NN (_( CPAP_NN )_) by_II mask_NN ,_, nasal_JJ prong_NN ,_, nasopharnygeal_JJ tube_NN ,_, or_CC endotracheal_JJ tube_NN ,_, or_CC continuous_JJ negative_JJ pressure_NN (_( CNDP_NN )_) via_II a_DD chamber_NN enclosing_VVG the_DD thorax_NN and_CC lower_JJR body_NN ,_, compared_VVN with_II standard_JJ care_NN ._.
P10908549A17
The_DD odds_NNS ratio_NN for_II '_`` same_JJ or_CC worse_JJ '_'' vs_CC '_`` improved_VVNJ symptoms_NNS '_'' at_II the_DD end_NN of_II treatment_NN was_VBD 0.34_MC (_( 95_MC %_SYM CI_NN 0.10_MC ,_, 1.19_MC )_) ,_, thus_RR showing_VVG no_DD statistically_RR significant_JJ difference_NN between_II the_DD two_MC interventions_NNS ._.
P10908555A03
OBJECTIVES_NNS :_: The_DD aims_NNS of_II this_DD review_NN study_NN are_VBB to_TO compare_VVI the_DD safety_NN and_CC efficacy_NN of_II anti-leukotriene_NN agents_NNS with_II inhaled_VVNJ glucocorticoids_NNS and_CC to_TO determine_VVI the_DD dose-equivalence_NN of_II anti-leukotrienes_NNS in_II mcg_NN of_II inhaled_VVNJ corticosteroids_NNS in_II the_DD management_NN of_II chronic_JJ asthma_NN ._.
P10912869A20
Our_PNG results_NNS cast_VVB serious_JJ doubt_NN on_II the_DD existing_VVGJ policies_NNS on_II VT_NN prophylaxis_NN ,_, and_CC we_PN call_VVB for_II a_DD large_JJ ,_, high-quality_NN ,_, multicenter_NN trial_NN that_PNR can_VM provide_VVB definitive_JJ answers_NNS ._.
P10920183A07
Whether_CST cases_NNS existed_VVD in_II Japan_NNP before_RR that_DD time_NN is_VBZ currently_RR under_II study_NN ._.
P10928402A04
STUDY_NN SELECTION_NN :_: Prospective_JJ ,_, randomized_VVNJ ,_, controlled_VVNJ studies_NNS ;_: prospective_JJ ,_, nonrandomized_VVNJ ,_, controlled_VVNJ studies_NNS ;_: prospective_JJ ,_, nonrandomized_VVNJ ,_, uncontrolled_VVNJ studies_NNS ;_: retrospective_JJ studies_NNS ;_: clinical_JJ experience_NN reports_NNS ;_: case_NN reports_NNS ;_: in_JJ+ vitro_JJ studies_NNS ;_: and_CC letters_NNS were_VBD evaluated_VVN for_II relevant_JJ information_NN ._.
P10934310A01
OBJECTIVE_NN :_: To_TO review_VVI the_DD development_NN of_II intracoronary_JJ ultrasound_NN ,_, its_PNG current_JJ utility_NN and_CC the_DD impetus_NN for_II its_PNG continued_VVNJ development_NN as_II a_DD coronary_JJ imaging_VVGJ modality_NN ._.
P10939145A19
The_DD expert_NN group_NN identified_VVD 16_MC key_JJ topics_NNS for_II a_DD national_JJ hypertension_NN guideline_NN ._.
P10949779A16
Results_NNS of_II trials_NNS with_II CIN3_NN as_II an_DD endpoint_NN are_VBB arguably_RR more_RR persuasive_JJ than_CSN those_PND from_II intervention_NN studies_NNS with_II HPV_NN infection_NN endpoints_NNS ._.
P10966006A08
Later_JJR reports_NNS have_VHB not_RR noted_VVN increased_VVNJ bleeding_VVGN when_CS incorporating_VVGN these_DD modifications_NNS plus_II early_JJ platelet_NN transfusion_NN ,_, if_CS required_VVN ._.
P10977460A06
The_DD angiotensin_NN II_MC receptor_NN blockers_NNS (_( ARBs_NNS )_) share_VVB many_PND of_II the_DD organ-protective_JJ effects_NNS of_II ACE_NN inhibitors_NNS when_CS studied_VVN in_II animal_NN models_NNS ._.
P10982214A02
DATA_NNS SOURCES_NNS :_: All_DD English_JJ language_NN MEDLINE_NN articles_NNS that_PNR cross-referenced_VVD allergy_NN ,_, fungal_JJ ,_, and_CC sinusitis_NN from_II 1983-present_NN ._.
P11000650A04
DATA_NNS SOURCES_NNS :_: A_DD MEDLINE_NN search_NN was_VBD performed_VVN to_TO identify_VVI all_DD English-language_NN articles_NNS regarding_VVG use_NN of_II Gp_NN IIb_NN /_SYM IIIa_NN inhibitors_NNS in_II ACSs_NNS published_VVN between_II 1966_MC and_CC June_NN 2000_MC ._.
P11005773A09
All_DD economic_JJ evaluations_NNS comprised_VVD analytical_JJ studies_NNS containing_VVG a_DD decision_NN tree_NN ._.
P11016488A07
Some_DD patients_NNS ,_, however_RR ,_, have_VHB symptomatic_JJ and_CC hemodynamic_JJ rebound_NN to_II worsened_VVNJ heart_NN failure_NN states_NNS during_II or_CC shortly_RR after_II inotrope_NN weaning_VVGN ._.
P11025346A05
The_DD recent_JJ introduction_NN of_II direct_JJ thrombin_NN inhibitors_NNS ,_, platelet_NN fibrinogen_NN receptor_NN antagonists_NNS and_CC low-molecular-weight_NN heparins_NNS (_( LMWHs_NNS )_) has_VHZ offered_VVN an_DD opportunity_NN to_TO develop_VVI more_RR aggressive_JJ antithrombotic_JJ regimens_NNS ._.
P11030020A09
Clinical_JJ trial_NN results_NNS provide_VVB evidence_NN that_CST some_DD ACE_NN inhibitors_NNS have_VHB renoprotective_JJ and_CC vasculoprotective_JJ effects_NNS and_CC improve_VVB outcomes_NNS of_II patients_NNS with_II a_DD variety_NN of_II cardiovascular_JJ disorders_NNS ;_: differences_NNS among_II the_DD ACE_NN inhibitors_NNS should_VM be_VBB considered_VVN in_II formulary_JJ decision-making_VVGN ._.
P11034667A06
We_PN also_RR contacted_VVD investigators_NNS in_II the_DD field_NN ._.
P11034678A09
MAIN_JJ RESULTS_NNS :_: Nine_MC trials_NNS involving_VVG over_II 750_MC patients_NNS aged_VVN eight_MC to_II over_RR 65_MC and_CC including_VVG smokers_NNS and_CC non-smokers_NNS were_VBD included_VVN ._.
P11034682A16
There_EX is_VBZ some_DD evidence_NN that_CST discharge_NN planning_VVGN may_VM lead_VVB to_II reduced_VVNJ hospital_NN length_NN of_II stay_NN ,_, and_CC in_II some_DD cases_NNS reduced_VVNJ readmission_NN to_II hospital_NN ._.
P11034686A17
Progestogen_NN (_( Medroxyprogesterone_NN acetate_NN )_) was_VBD associated_VVN with_II a_DD reduction_NN of_II pain_NN during_II treatment_NN ._.
P11034695A04
SEARCH_NN STRATEGY_NN :_: The_DD Cochrane_NNP Dementia_NN and_CC Cognitive_JJ Impairment_NN Group_NN Register_NN of_II Clinical_JJ Trials_NNS has_VHZ been_VBN searched_VVN ,_, as_CS have_VHB the_DD electronic_JJ databases_NNS MEDLINE_NN ,_, EMBASE_NN ,_, Psychlit_NN ,_, ISI_NN and_CC Current_JJ Contents_NNS ._.
P11034699A06
Subsequently_RR ,_, guidelines_NNS for_II their_PNG use_NN can_VM be_VBB made_VVN on_II a_DD sound_JJ evidence_NN base_NN ._.
P11034705A04
Several_JJ other_JJ cholinesterase_NN inhibitors_NNS ,_, including_VVG rivastigmine_NN ,_, with_II superior_JJ properties_NNS in_II terms_NNS of_II specificity_NN of_II action_NN and_CC low_JJ risk_NN of_II adverse_JJ effects_NNS ,_, have_VHB now_RR been_VBN introduced_VVN ._.
P11034709A15
In_II cross-over_NN studies_NNS ,_, evening_NN peak_JJ flow_NN was_VBD better_JJR with_II regular_JJ treatment_NN ,_, weighted_VVNJ mean_NN difference_NN (_( WMD_NN )_) 13.1_MC l_NN /_SYM min_NN (_( 95_MC %_SYM confidence_NN interval_NN 24.3_MC ,_, 1.9_MC )_) ._.
P11034713A03
OBJECTIVES_NNS :_: The_DD object_NN of_II this_DD review_NN was_VBD to_TO determine_VVI the_DD efficacy_NN and_CC safety_NN of_II corticosteroids_NNS or_CC ACTH_NN in_II reducing_VVGN the_DD short_JJ and_CC long_JJ term_NN morbidity_NN from_II MS_NN ._.
P11034719A10
Toxicity_NN was_VBD evaluated_VVN with_II pooled_VVNJ odds_NNS ratios_NNS for_II withdrawals_NNS and_CC adverse_JJ reactions_NNS ._.
P11034725A03
OBJECTIVES_NNS :_: The_DD objective_NN of_II this_DD review_NN was_VBD to_TO determine_VVI the_DD efficacy_NN of_II any_DD form_NN of_II surface_NN ES_NN in_II the_DD prevention_NN and/or_CC treatment_NN of_II pain_NN around_II the_DD shoulder_NN at_II any_DD time_NN after_II stroke_NN ._.
P11034730A01
BACKGROUND_NN :_: Preterm_NN infants_NNS experience_VVB a_DD range_NN of_II morbidity_NN related_VVN to_II the_DD immaturity_NN of_II their_PNG organ_NN systems_NNS and_CC to_II concurrent_JJ disease_NN states_NNS ._.
P11034734A11
MAIN_JJ RESULTS_NNS :_: Four_MC randomized_VVNJ controlled_VVNJ trials_NNS met_VVD the_DD inclusion_NN criteria_NNS ._.
P11034739A05
OBJECTIVES_NNS :_: The_DD objective_NN of_II this_DD review_NN was_VBD to_TO evaluate_VVI the_DD efficacy_NN and_CC safety_NN of_II long-term_NN treatment_NN of_II symptomatic_JJ venous_JJ thromboembolism_NN with_II low-molecular-weight_NN heparins_NNS compared_VVN with_II vitamin_NN K_NN antagonists_NNS ._.
P11034748A13
A_DD dose_NN response_NN relationship_NN was_VBD not_RR seen_VVN with_II duodenal_JJ ulcers_NNS ._.
P11034753A16
The_DD doses_NNS of_II aminophylline_NN and_CC other_JJ medications_NNS and_CC the_DD severity_NN of_II asthma_NN varied_VVD between_II studies_NNS ._.
P11034757A18
There_EX needs_VVZ to_TO be_VBI a_DD greater_JJR standardisation_NN of_II management_NN so_CS+ that_CS comparisons_NNS between_II different_JJ series_NN can_VM be_VBB made_VVN ._.
P11034764A02
It_PN is_VBZ important_JJ to_TO quantify_VVI the_DD drop-out_NN rates_NNS of_II different_JJ antidepressant_NN drugs_NNS in_II order_NN to_TO have_VHI a_DD better_JJR understanding_VVGN of_II the_DD relative_JJ tolerability_NN of_II these_DD drugs_NNS ._.
P11034770A15
Patients_NNS reported_VVD that_CST they_PN preferred_VVD heat_NN therapy_NN to_II no_DD therapy_NN (_( 94_MC %_SYM like_VVB heat_NN therapy_NN better_JJR than_CSN no_DD therapy_NN )_) ._.
P11034777A07
Date_NN of_II last_JJ search_NN :_: June_NN 2000_MC ._.
P11041454A12
A_DD multicenter_NN international_JJ study_NN has_VHZ shown_VVN that_CST serum_NN Tg_NN measurements_NNS alone_JJ are_VBB not_RR as_RR sensitive_JJ in_II the_DD identification_NN of_II patients_NNS with_II persistent_JJ or_CC recurrent_JJ tumor_NN as_CSN are_VBB rhTSH-stimulated_VVNJ serum_NN Tg_NN determinations_NNS ._.
P11048901A13
The_DD target_NN hemoglobin_NN level_NN is_VBZ 12_MC g_NN /_SYM dL_NN for_II men_NNS and_CC 11_MC g_NN /_SYM dL_NN for_II women_NNS ._.
P11051137A17
The_DD nail_NN lacquer_NN is_VBZ a_DD cost_NN effective_JJ agent_NN compared_VVN with_II the_DD oral_JJ antifungal_JJ therapies_NNS ,_, terbinafine_NN ,_, itraconazole_NN ,_, fluconazole_NN ,_, and_CC griseofulvin_NN ._.
P11059357A16
The_DD best_NN would_VM be_VBB records_NNS of_II the_DD progression_NN of_II a_DD disease-state_NN in_II untreated_VVNJ patients_NNS ._.
P11060248A14
Moreover_RR ,_, the_DD notion_NN that_CST coronary_JJ artery_NN disease_NN can_VM be_VBB considered_VVN to_TO be_VBI an_DD inflammatory_JJ condition_NN in_II its_PNG own_JJ right_NN has_VHZ opened_VVN new_JJ and_CC challenging_VVGJ avenues_NNS for_II research_NN ._.
P11062301A10
Investigators_NNS should_VM also_RR be_VBB encouraged_VVN to_TO combine_VVI their_PNG individual_JJ patient_NN data_NNS in_II meta-analyses_NNS to_TO obtain_VVI a_DD more_RR robust_JJ assessment_NN of_II the_DD value_NN of_II DWI_NN and_CC PI_NN from_II larger_JJR sample_NN sizes_NNS ._.
P11073480A02
The_DD administration_NN of_II thrombolytic_JJ therapy_NN for_II acute_JJ myocardial_JJ infarction_NN is_VBZ a_DD particularly_RR high-risk_NN situation_NN for_II emergency_NN physicians_NNS ._.
P11074393A21
Manufacturers_NNS '_GE submissions_NNS to_II the_DD National_JJ Institute_NN for_II Clinical_JJ Excellence_NN were_VBD searched_VVN ._.
P11074396A17
(_( 4_MC )_) Caregiver_NN 's_GE and_CC child_NN 's_GE QoL_NN ._.
P11076126A11
Patients_NNS who_PNR were_VBD discharged_VVN on_II a_DD statin_NN showed_VVD a_DD 50_MC %_SYM reduction_NN in_II mortality_NN over_II those_PND who_PNR did_VDD not_RR receive_VVB statin_NN therapy_NN independent_JJ of_II lipid_NN level_NN ._.
P11083694A01
STUDY_NN OBJECTIVES_NNS :_: Tracheostomy_NN is_VBZ one_MC of_II the_DD most_RRT commonly_RR performed_VVNJ procedures_NNS in_II the_DD patient_NN receiving_VVG long-term_NN mechanical_JJ ventilation_NN ._.
P11086757A01
OBJECTIVE_NN :_: To_TO critically_RR review_VVI the_DD current_JJ data_NNS concerning_VVG the_DD efficacy_NN of_II preventive_JJ measures_NNS described_VVN in_II the_DD literature_NN ,_, on_II the_DD incidence_NN of_II lateral_JJ ankle_NN ligament_NN injuries_NNS ._.
P11095158A13
In_II the_DD early_JJ 21st_JJ century_NN ,_, the_DD patient_NN with_II type_NN 2_MC diabetes_NN will_VM need_VVB to_TO be_VBI the_DD specific_JJ focus_NN for_II use_NN of_II these_DD preventive_JJ treatment_NN modalities_NNS due_II+ to_II the_DD geometric_JJ risk_NN in_II the_DD international_JJ incidence_NN of_II this_DD disease_NN ._.
P11096522A15
This_PND has_VHZ significant_JJ clinical_JJ relevance_NN because_CS the_DD presence_NN of_II these_DD disorders_NNS guides_VVZ treatment_NN specific_JJ to_II the_DD disorder_NN (_( s_NN )_) ._.
P11098244A20
Meta-analysis_NN of_II the_DD limited_VVNJ data_NNS available_JJ shows_VVZ a_DD statistically_RR significant_JJ difference_NN in_II survival_NN at_II 5_MC years_NNS that_PNR favors_VVZ combined_VVNJ androgen_NN blockade_NN ._.
P11100995A02
In_II the_DD last_JJ two_MC decades_NNS ,_, the_DD rediscovery_NN of_II H._NN pylori_NN ,_, development_NN of_II potent_JJ ulcer-healing_VVGJ drugs_NNS and_CC specific_JJ Cox-II_NN inhibitors_NNS have_VHB opened_VVN new_JJ horizons_NNS in_II the_DD management_NN of_II NSAID_NN toxicity_NN ._.
P11105180A07
Mortality_NN and_CC morbidity_NN from_II CHD_NN were_VBD derived_VVN from_II published_VVNJ meta-analyses_NNS and_CC recent_JJ studies_NNS ._.
P11109039A06
Evidence_NN for_II risk_NN stratification_NN of_II patients_NNS with_II non-ST_NN segment_NN acute_JJ coronary_JJ syndromes_NNS and_CC the_DD results_NNS of_II clinical_JJ trials_NNS for_II the_DD individual_JJ antithrombotic_JJ and_CC antiplatelet_NN agents_NNS were_VBD reviewed_VVN ._.
P11115025A04
Seven_MC trials_NNS (_( 286_MC children_NNS in_II total_NN )_) compared_VVD cisapride_NN with_II placebo_NN ._.
P11122746A01
The_DD advent_NN of_II statin_NN therapy_NN has_VHZ revolutionized_VVN the_DD ability_NN of_II the_DD clinician_NN to_TO manage_VVI patients_NNS at_II risk_NN for_II the_DD development_NN of_II an_DD ischemic_JJ event_NN due_II+ to_II dyslipidemia_NN ._.
P11129126A04
Recent_JJ evidence_NN indicates_VVZ that_CST budesonide_NN inhalation_NN suspension_NN is_VBZ significantly_RR more_RR effective_JJ than_CSN nebulised_VVNJ sodium_NN cromoglycate_NN in_II improving_VVGN control_NN of_II asthma_NN in_II young_JJ children_NNS with_II persistent_JJ asthma_NN ._.
P11130523A01
BACKGROUND_NN :_: This_DD programme_NN of_II overviews_NNS of_II randomised_VVNJ trials_NNS was_VBD established_VVN to_TO investigate_VVI the_DD effects_NNS of_II angiotensin-converting-enzyme_NN (_( ACE_NN )_) inhibitors_NNS ,_, calcium_NN antagonists_NNS ,_, and_CC other_JJ blood-pressure-lowering_VVGJ drugs_NNS on_II mortality_NN and_CC major_JJ cardiovascular_JJ morbidity_NN in_II several_JJ populations_NNS of_II patients_NNS ._.
P11134919A10
OBJECTIVES_NNS :_: The_DD objectives_NNS of_II this_DD scoping_VVGJ review_NN are_VBB two-fold_NN ._.
P11138871A02
The_DD purpose_NN of_II this_DD study_NN was_VBD to_TO observe_VVI potential_JJ risk_NN factors_NNS and_CC diagnostic_JJ tests_NNS for_II VTE_NN ,_, and_CC prophylaxis_NN against_II VTE_NN in_II medical-surgical_JJ ICU_NN patients_NNS ._.
P11141646A03
There_EX is_VBZ large_JJ evidence_NN from_II observational_JJ studies_NNS that_CST HRT_NN reduces_VVZ the_DD risk_NN of_II cardiovascular_JJ mortality_NN and_CC morbidity_NN in_II postmenopausal_JJ women_NNS ._.
P11145762A06
These_DD studies_NNS ,_, however_RR ,_, were_VBD either_CC uncontrolled_VVN or_CC poorly_RR controlled_VVN ,_, unblinded_VVN or_CC only_RR single-blinded_VVN ,_, and_CC enrolled_VVD small_JJ numbers_NNS of_II patients_NNS ._.
P11152019A04
After_II 50_MC weeks_NNS '_GE treatment_NN ,_, plasma_NN HIV_NN RNA_NN levels_NNS were_VBD below_II the_DD limit_NN of_II detection_NN (_( LOD_NN ;_: <_SYM 50_MC copies_NNS /_SYM ml_NN )_) for_II 40_MC %_SYM of_II patients_NNS receiving_VVG triple_JJ therapy_NN but_CC for_II only_RR 6_MC %_SYM of_II those_PND receiving_VVG dual_JJ NRTI_NN therapy_NN ._.
P11153637A07
SETTING_VVGN :_: A_DD ten-bed_NN surgical_JJ ICU_NN in_II an_DD academic-affiliated_VVNJ community_NN hospital_NN ._.
P11159653A07
There_EX were_VBD five_MC randomised_VVNJ controlled_VVNJ trials_NNS published_VVN between_II 1989-99_MC ._.
P11174359A01
BACKGROUND_NN :_: In_II the_DD context_NN of_II a_DD comprehensive_JJ population_NN strategy_NN to_TO reduce_VVI tobacco_NN use_NN ,_, encourage_VVI healthy_JJ food_NN choices_NNS ,_, and_CC increase_VVI physical_JJ activity_NN for_II the_DD whole_JJ population_NN ,_, the_DD medical_JJ priority_NN is_VBZ to_TO focus_VVI on_II those_PND who_PNR have_VHB developed_VVN symptoms_NNS of_II coronary_JJ heart_NN disease_NN (_( CHD_NN )_) or_CC other_JJ major_JJ atherosclerotic_JJ disease_NN ,_, and_CC those_PND who_PNR are_VBB at_II high_JJ risk_NN of_II developing_VVGN such_DD diseases_NNS in_II the_DD future_NN ._.
P11179262A07
The_DD risk_NN of_II major_JJ bleeding_VVGN balanced_VVD the_DD reduction_NN in_II cardiovascular_JJ events_NNS when_CS cardiovascular_JJ event_NN risk_NN was_VBD 0.22_MC %_SYM /_SYM year_NN ._.
P11190039A05
Methods_NNS of_II epithelial_JJ cauterization_NN and_CC curettage_NN were_VBD grouped_VVN as_II relatively_RR equivalent_JJ physicochemical_JJ therapy_NN ,_, and_CC solution_NN and_CC ointment_NN formulations_NNS of_II a_DD given_VVNJ topical_JJ antiviral_JJ agent_NN were_VBD combined_VVN ._.
P11192359A05
This_DD was_VBD so_RR prevalent_JJ as_RR to_TO allow_VVI the_DD conduct_NN of_II a_DD substantial_JJ study_NN ,_, the_DD ATLAS_NN trial_NN ,_, to_TO compare_VVI high_JJ and_CC low_JJ dose_NN ACE_NN inhibition_NN ._.
P11195408A01
These_DD guidelines_NNS propose_VVB a_DD treatment_NN algorithm_NN in_II which_PNR patients_NNS are_VBB evaluated_VVN regularly_RR for_II fatigue_NN ,_, using_VVG a_DD brief_JJ screening_VVGJ instrument_NN ,_, and_CC are_VBB treated_VVN as_CS indicated_VVN by_II their_PNG fatigue_NN level_NN ._.
P11199101A10
In_II patients_NNS with_II severe_JJ disease_NN ,_, reduction_NN in_II operating_VVGJ lung_NN volumes_NNS is_VBZ more_RR important_JJ than_CSN '_`` bronchodilitation_NN '_'' and_CC is_VBZ better_JJR sustained_VVN by_II long_JJ acting_VVGJ beta_NN agonists_NNS and_CC anticholinergics_NNS ._.
P11206593A01
BACKGROUND_NN :_: This_DD review_NN summarizes_VVZ and_CC evaluates_VVZ clinical_JJ experience_NN with_II citalopram_NN ,_, the_DD latest_JJT selective_JJ serotonin_NN reuptake_NN inhibitor_NN (_( SSRI_NN )_) to_TO be_VBI approved_VVN for_II the_DD treatment_NN of_II depression_NN in_II the_DD United_VVNJ States_NNS ._.
P11220287A09
Other_JJ novel_JJ antidiabetic_JJ agents_NNS are_VBB currently_RR under_II development_NN ,_, including_VVG pramlintide_NN (_( an_DD amylin_NN analogue_NN )_) and_CC glucagon-like_JJ peptide_NN ._.
P11224885A01
STUDY_NN DESIGN_NN :_: A_DD systematic_JJ review_NN of_II randomized_VVNJ and_CC nonrandomized_VVNJ controlled_VVNJ trials_NNS ._.
P11230834A10
The_DD use_NN of_II eptifibatide_NN independently_RR predicted_VVD a_DD lower_JJR risk_NN of_II events_NNS (_( adjusted_VVNJ RR_NN 0.31_MC ,_, 95_MC %_SYM CI_NN 0.10_MC to_II 0.93_MC ,_, p_NN =_SYM 0.04_MC )_) ._.
P11232362A29
Only_RR in_II this_DD way_NN can_VM the_DD challenges_NNS of_II the_DD present_NN and_CC the_DD future_NN be_VBB met_VVN ._.
P11236168A11
Likewise_RR ,_, TEE_NN also_RR may_VM prove_VVB to_TO be_VBI useful_JJ in_II identifying_VVGN patients_NNS with_II a_DD low-clinical_JJ risk_NN profile_NN who_PNR may_VM be_VBB treated_VVN with_II aspirin_NN alone_JJ and_CC patients_NNS in_II whom_PNR warfarin_NN may_VM be_VBB superior_JJ ._.
P11242429A03
OBJECTIVE_NN :_: To_TO explore_VVI disagreement_NN for_II serious_JJ adverse_JJ safety_NN (_( intracranial_JJ hemorrhage_NN [_( ICH_NN ]_) )_) and_CC efficacy_NN outcomes_NNS between_II meta-analysis_NN of_II phase_NN 2_MC (_( small_JJ )_) vs_CC meta-analysis_NN of_II phase_NN 3_MC (_( large_JJ )_) randomized_VVNJ controlled_VVNJ trials_NNS comparing_VVG the_DD efficacy_NN of_II bolus_NN thrombolytic_JJ therapy_NN with_II infusion_NN for_II acute_JJ myocardial_JJ infarction_NN (_( AMI_NN )_) ._.
P11249510A12
Fewer_JJR studies_NNS have_VHB investigated_VVN statins_NNS '_GE effects_NNS on_II the_DD quality_NN of_II lipoprotein_NN particles_NNS ,_, the_DD activities_NNS of_II cholesteryl_NN ester_NN transfer_NN protein_NN and_CC lecithin_NN :_: cholesterol_NN acyltransferase_NN as_CC+ well_CC+ as_CC their_PNG possible_JJ synergistic_JJ effects_NNS with_II n-3_NN fatty_JJ acids_NNS ,_, anti-oxidants_NNS and_CC aspirin_NN in_II reducing_VVGN cardiovascular_JJ events_NNS ._.
P11255426A03
DATA_NNS SOURCES_NNS :_: Studies_NNS with_II English-language_NN abstracts_NNS identified_VVN in_II MEDLINE_NN (_( 1966-August_NN 2000_MC )_) ,_, HealthSTAR_NN (_( 1975-August_NN 2000_MC ,_, PsychINFO_NN (_( 1984-August_NN 2000_MC )_) ;_: Cochrane_NNP Library_NN databases_NNS ;_: and_CC articles_NNS listed_VVN in_II reference_NN lists_NNS of_II key_JJ articles_NNS ._.
P11255880A19
For_II this_DD reason_NN ,_, guidelines_NNS for_II such_DD patients_NNS are_VBB aimed_VVN at_II keeping_VVGN the_DD other_JJ risk_NN factors_NNS under_II strict_JJ control_NN in_II order_NN to_II significantly_RR reduce_VVI their_PNG effect_NN ._.
P11261530A05
STUDY_NN SELECTION_NN AND_CC DATA_NNS EXTRACTION_NN :_: Prospective_JJ ,_, randomized_VVNJ ,_, double-blind_JJ ,_, placebo-controlled_VVNJ ,_, human_NN trials_NNS were_VBD selected_VVN for_II review_NN and_CC discussion_NN ._.
P11262422A02
Policy_NN documents_NNS have_VHB advocated_VVN the_DD importance_NN of_II public_JJ views_NNS as_II one_MC such_DD criterion_NN ._.
P11270126A05
The_DD anticoagulation_NN target_NN for_II AF_NN is_VBZ INR_NN 2_MC to_II 3_MC with_II INR_NN 2.5_MC as_II the_DD specific_JJ goal_NN ._.
P11276294A08
A_DD total_NN of_II 18_MC trials_NNS involving_VVG 2939_MC men_NNS were_VBD reviewed_VVN ._.
P11279681A08
Additional_JJ information_NN was_VBD sought_VVN from_II all_DD trialists_NNS ._.
P11279687A04
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD the_DD The_DD Cochrane_NNP Library_NN ,_, Issue_NN 32000_MC ;_: MEDLINE_NN ,_, EMBASE_NN ,_, LILACS_NN ,_, Current_JJ Contents_NNS ,_, Dissertation_NN Abstracts_NNS ,_, and_CC Index_NN to_II UK_NNP Theses_NNS to_II August_NN 2000_MC ._.
P11279691A04
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD the_DD Cochrane_NNP Musculoskeletal_JJ Injuries_NNS Group_NN trials_NNS register_NN ,_, MEDLINE_NN ,_, PubMed_NN ,_, the_DD Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN ,_, CINAHL_NN ,_, the_DD National_JJ Research_NN Register_NN and_CC bibliographies_NNS of_II trial_NN reports_NNS ._.
P11279699A02
When_CS it_PN affects_VVZ one_MC side_NN of_II the_DD mouth_NN the_DD lower_JJR jaw_NN may_VM have_VHB to_TO move_VVI to_II one_MC side_NN to_TO allow_VVI the_DD back_II teeth_NN to_TO meet_VVI together_RR ._.
P11279702A14
The_DD effect_NN remained_VVD statistically_RR significant_JJ when_CS the_DD results_NNS from_II studies_NNS with_II less_RR rigorous_JJ methodology_NN were_VBD excluded_VVN in_II a_DD sensitivity_NN analysis_NN ._.
P11279713A01
BACKGROUND_NN :_: Asthma_NN is_VBZ one_MC of_II the_DD most_RRT common_JJ reasons_NNS for_II paediatric_JJ admissions_NNS to_II hospital_NN ,_, with_II substantial_JJ cost_NN to_II the_DD community_NN ._.
P11279716A25
PFMT_NN may_VM be_VBB more_RR effective_JJ than_CSN some_DD types_NNS of_II electrical_JJ stimulation_NN but_CC there_EX were_VBD problems_NNS in_II combining_VVGN the_DD data_NNS from_II these_DD trials_NNS ._.
P11279720A01
BACKGROUND_NN :_: Long_JJ term_NN levodopa_NN therapy_NN in_II Parkinson_NN 's_GE disease_NN is_VBZ associated_VVN with_II the_DD development_NN of_II motor_NN complications_NNS including_VVG abnormal_JJ involuntary_JJ movements_NNS and_CC a_DD shortening_VVGJ response_NN to_II each_DD dose_NN (_( wearing_VVG off_II phenomenon_NN )_) ._.
P11279723A14
The_DD clinical_JJ trial_NN registers_NNS of_II the_DD National_JJ Cancer_NN Institute_NN and_CC the_DD Radiation_NN Therapy_NN Oncology_NN Group_NN were_VBD consulted_VVN for_II ongoing_VVGJ trials_NNS ._.
P11279726A23
Low_JJ dose_NN corticosteroids_NNS (_( <_SYM or_CC =_SYM 80_MC mg_NN /_SYM day_NN of_II methylprednisolone_NN or_CC <_SYM or_CC =_SYM 400_MC mg_NN /_SYM day_NN of_II hydrocortisone_NN )_) appear_VVB to_TO be_VBI adequate_JJ in_II the_DD initial_JJ management_NN of_II these_DD adult_NN patients_NNS ._.
P11279735A01
BACKGROUND_NN :_: Concerns_NNS regarding_VVG the_DD safety_NN of_II transfused_VVNJ blood_NN have_VHB prompted_VVN re-consideration_NN of_II the_DD use_NN of_II allogeneic_JJ (_( blood_NN from_II an_DD unrelated_VVNJ donor_NN )_) blood_NN transfusion_NN ._.
P11279739A08
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: No_DD controlled_VVNJ trials_NNS of_II suitable_JJ quality_NN were_VBD identified_VVN for_II inclusion_NN in_II the_DD review_NN ._.
P11279745A18
These_DD results_NNS should_VM be_VBB interpreted_VVN with_II caution_NN ._.
P11279752A01
BACKGROUND_NN :_: Coronary_JJ artery_NN bypass_NN surgery_NN (_( CABG_NN )_) may_VM be_VBB life_NN saving_VVGN ,_, but_CC known_VVNJ side_NN effects_NNS include_VVB neurological_JJ damage_NN and_CC cognitive_JJ impairment_NN ._.
P11279758A01
BACKGROUND_NN :_: Prevalence_NN studies_NNS show_VVB that_CST behaviour_NN problems_NNS in_II children_NNS are_VBB quite_RR common_JJ (_( 10-15_MC %_SYM in_II preschoolers_NNS )_) ._.
P11279762A08
Data_NNS were_VBD excluded_VVN where_CS more_RR than_CSN 50_MC %_SYM of_II participants_NNS in_II any_DD group_NN were_VBD lost_VVN to_II follow_NN+ up_NN ._.
P11279766A16
Suitable_JJ outcome_NN measures_NNS should_VM be_VBB chosen_VVN so_CS+ that_CS the_DD efficacy_NN and_CC effectiveness_NN of_II non-pharmacological_JJ swallowing_VVGJ therapy_NN can_VM be_VBB assessed_VVN and_CC an_DD economic_JJ analysis_NN performed_VVN ._.
P11279772A04
OBJECTIVES_NNS :_: To_TO assess_VVI whether_CST computer_NN support_NN for_II drug_NN dosage_NN benefits_VVZ patients_NNS and_CC hence_RR whether_CST it_PN should_VM be_VBB more_RR widely_RR available_JJ ._.
P11279781A19
Further_JJ reviews_NNS comparing_VVG the_DD effective_JJ interventions_NNS and_CC studies_NNS that_PNR include_VVB cost-effectiveness_NN ,_, women_NNS 's_GE satisfaction_NN and_CC equity_NN issues_NNS are_VBB needed_VVN ._.
P11279789A16
More_DD research_NN is_VBZ needed_VVN to_TO investigate_VVI the_DD effects_NNS of_II these_DD and_CC other_JJ related_VVNJ interventions_NNS ._.
P11281087A04
Risk_NN is_VBZ highest_JJT in_II smokers_NNS with_II chronic_JJ obstructive_JJ pulmonary_JJ disease_NN ._.
P11286095A05
Our_PNG current_JJ quality_NN improvement_NN initiative_NN ,_, developed_VVN through_II the_DD Occupational_JJ Health_NN Services_NNS Project_NN ,_, synthesizes_VVZ what_PND was_VBD learned_VVN from_II the_DD MCP_NN and_CC other_JJ pilot_NN studies_NNS to_TO make_VVI delivery_NN system_NN improvements_NNS ._.
P11288383A16
The_DD guideline_NN was_VBD developed_VVN by_II the_DD Executive_NN Committee_NN of_II the_DD Southern_JJ African_JJ Hypertension_NN Society_NN with_II consensus_NN meeting_VVGJ endorsement_NN ,_, and_CC is_VBZ endorsed_VVN by_II the_DD South_NN African_JJ Medical_JJ Association_NN Guideline_NN Commitee_NN ._.
P11293649A02
Nocturnal_JJ and_CC early_JJ morning_NN symptoms_NNS are_VBB quite_RR common_JJ among_II patients_NNS with_II asthma_NN ._.
P11296189A01
STUDY_NN OBJECTIVES_NNS :_: To_TO critically_RR review_VVI the_DD available_JJ data_NNS on_II the_DD diagnostic_JJ evaluation_NN ,_, risk_NN stratification_NN ,_, and_CC therapeutic_JJ management_NN of_II patients_NNS with_II acute_JJ exacerbations_NNS of_II COPD_NN ._.
P11302109A09
Mainly_RR because_II+ of_II the_DD on-course_NN modification_NN of_II the_DD study_NN protocol_NN ,_, 402_MC /_SYM 2133_MC (_( 18.8_MC %_SYM )_) patients_NNS in_II the_DD control_NN group_NN started_VVD a_DD cholesterol-lowering_VVGJ treatment_NN during_II follow-up_NN ._.
P11303413A02
The_DD total_JJ economic_JJ cost_NN of_II COPD_NN in_II the_DD US_NNP in_II 1993_MC was_VBD estimated_VVN to_TO be_VBI over_RR $_SYM US15.5_NN billion_MC ,_, with_II $_SYM US6.1_NN billion_MC for_II hospitalisation_NN ,_, $_SYM US4.4_NN billion_MC for_II physician_NN and_CC other_JJ fees_NNS ,_, $_SYM US2.5_NN billion_MC for_II drugs_NNS ,_, $_SYM US1.5_NN billion_MC for_II nursing_VVGJ home_NN care_NN and_CC $_SYM US1.0_NN billion_MC for_II home_NN care_NN ._.
P11306234A15
Four_MC high-risk_NN studies_NNS reported_VVD results_NNS for_II preterm_NN delivery_NN less_RR than_CSN 34_MC weeks_NNS ._.
P11308231A14
There_EX was_VBD no_DD difference_NN in_II studies_NNS that_PNR provided_VVD lipids_NNS as_II a_DD component_NN of_II TPN_NN when_CS compared_VVN with_II studies_NNS that_PNR did_VDD not_RR ._.
P11315826A04
This_DD study_NN will_VM help_VVB clarify_VVI the_DD treatment_NN of_II HTN_NN in_II the_DD setting_VVGN of_II diabetes_NN ._.
P11318073A04
OBJECTIVE_NN :_: This_DD article_NN reviews_VVZ the_DD pharmacologic_JJ properties_NNS and_CC clinical_JJ usefulness_NN of_II linezolid_NN ._.
P11319991A09
METHODS_NNS -_: DATA_NNS EXTRACTION_NN (_( NON-HEALTH_NN TECHNOLOGY_NN ASSESSMENT_NN LITERATURE_NN SEARCH_NN )_) :_: The_DD new_JJ statistical_JJ techniques_NNS identified_VVN were_VBD categorised_VVN into_II four_MC subgroups_NNS of_II increasing_VVGJ complexity_NN :_: exploratory_JJ data_NNS analysis_NN ;_: simple_JJ series_NN data_NNS analysis_NN ;_: complex_JJ data_NNS structure_NN analysis_NN ,_, generic_JJ techniques_NNS ._.
P11331734A30
Continued_VVNJ scientific_JJ efforts_NNS need_VVB to_TO be_VBI directed_VVN to_II the_DD identification_NN of_II the_DD causes_NNS of_II ASD_NN ._.
P11346064A05
STUDY_NN SELECTION_NN :_: Clinical_JJ efficacy_NN data_NNS were_VBD extracted_VVN from_II clinical_JJ trials_NNS ,_, case_NN reports_NNS ,_, and_CC abstracts_NNS that_PNR mentioned_VVD linezolid_NN ._.
P11349622A03
Moreover_RR ,_, the_DD mechanisms_NNS leading_VVG to_II the_DD instability_NN of_II an_DD atherosclerotic_JJ plaque_NN are_VBB complex_JJ themselves_PN ._.
P11359552A12
Actual_JJ patient_NN harm_NN from_II serious_JJ errors_NNS was_VBD rarely_RR recorded_VVN ._.
P11373981A04
The_DD total_JJ CK_NN level_NN is_VBZ far_RR too_RR insensitive_JJ and_CC nonspecific_JJ a_DD test_NN to_TO be_VBI used_VVN to_TO diagnose_VVI AMI_NN ._.
P11376301A09
CONCLUSIONS_NNS :_: The_DD potential_JJ clinical_JJ impact_NN of_II the_DD PRINCE_NN trial_NN is_VBZ substantial_JJ because_CS nearly_RR 50_MC %_SYM of_II myocardial_JJ infarctions_NNS in_II the_DD United_VVNJ States_NNS occur_VVB in_II persons_NNS with_II normal_JJ cholesterol_NN levels_NNS ,_, and_CC inflammatory_JJ markers_NNS such_II+ as_II hs-CRP_NN may_VM provide_VVB a_DD means_NNS to_TO detect_VVI such_DD individuals_NNS at_II high_JJ risk_NN who_PNR do_VDB not_RR currently_RR qualify_VVB for_II statin_NN therapy_NN ._.
P11381277A07
Reference_NN lists_NNS were_VBD scanned_VVN ,_, experts_NNS were_VBD polled_VVN ,_, and_CC the_DD personal_JJ files_NNS of_II the_DD subgroup_NN members_NNS and_CC authors_NNS were_VBD used_VVN to_TO identify_VVI other_JJ studies_NNS ._.
P11394560A08
However_RR ,_, the_DD discriminating_VVGJ power_NN of_II specific_JJ variables_NNS from_II the_DD medical_JJ history_NN and_CC exercise_NN test_NN remains_VVZ unclear_JJ because_II+ of_II inadequate_JJ study_NN design_NN and_CC differences_NNS in_II study_NN populations_NNS ._.
P11399237A21
Quality_NN assessment_NN was_VBD conducted_VVN independently_RR by_II two_MC reviewers_NNS ._.
P11401736A02
STUDY_NN DESIGN_NN :_: A_DD systematic_JJ review_NN was_VBD performed_VVN with_II meta-analysis_NN where_CS appropriate_JJ ._.
P11405951A11
The_DD meta-analysis_NN shows_VVZ that_CST the_DD use_NN of_II natural_JJ surfactant_NN rather_II+ than_II synthetic_JJ surfactant_NN results_VVZ in_II a_DD significant_JJ reduction_NN in_II the_DD risk_NN of_II pneumothorax_NN (_( typical_JJ relative_JJ risk_NN 0.63_MC ,_, 95_MC %_SYM CI_NN 0.53_MC ,_, 0.75_MC ;_: typical_JJ risk_NN difference_NN -0.04_MC ,_, 95_MC %_SYM CI_NN -0.06_MC ,_, -0.03_MC )_) and_CC the_DD risk_NN of_II mortality_NN (_( typical_JJ relative_JJ risk_NN 0.87_MC ,_, 95_MC %_SYM CI_NN 0.76_MC ,_, 0.98_MC ;_: typical_JJ risk_NN difference_NN -0.02_MC ,_, 95_MC %_SYM CI_NN -0.05_MC ,_, 0.00_MC )_) ._.
P11405961A13
Where_CS possible_JJ ,_, intention-to-treat_NN data_NNS were_VBD used_VVN ._.
P11405964A11
To_TO avoid_VVI duplication_NN of_II data_NNS in_II the_DD reviews_NNS ,_, the_DD labour_NN induction_NN methods_NNS have_VHB been_VBN listed_VVN in_II a_DD specific_JJ order_NN ,_, from_II one_MC to_II 25_MC ._.
P11405971A01
OBJECTIVES_NNS :_: To_TO determine_VVI the_DD clinical_JJ efficacy_NN of_II piracetam_NN for_II the_DD features_NNS of_II dementia_NN or_CC cognitive_JJ impairment_NN ,_, classified_VVN according_II+ to_II the_DD major_JJ subtypes_NNS of_II dementia_NN :_: vascular_JJ ,_, Alzheimer_NNP 's_GE disease_NN or_CC mixed_VVNJ vascular_JJ and_CC Alzheimer_NNP 's_GE disease_NN ,_, or_CC unclassified_VVNJ dementia_NN ,_, or_CC cognitive_JJ impairment_NN not_RR fulfilling_VVG the_DD criteria_NNS for_II dementia_NN ._.
P11405980A21
Frequency_NN of_II STIs_NNS :_: In_II both_CC Mwanza_NNP and_CC Rakai_NNP ,_, there_EX was_VBD no_DD significant_JJ reduction_NN in_II gonorrhoea_NN ,_, chlamydia_NN ,_, urethritis_NN ,_, or_CC reported_VVNJ STI_NN symptoms_NNS among_II intervention_NN communities_NNS ._.
P11405986A05
OBJECTIVES_NNS :_: To_TO assess_VVI the_DD effectiveness_NN of_II prophylactic_JJ antibiotic_JJ administration_NN before_II IUD_NN insertion_NN in_II reducing_VVGN IUD-related_VVNJ complications_NNS and_CC discontinuations_NNS within_II three_MC months_NNS of_II insertion_NN ._.
P11405990A23
For_II this_DD outcome_NN there_EX was_VBD statistically_RR significant_JJ between_II study_NN heterogeneity_NN (_( for_II RR_NN ,_, p=0.02_NN ;_: for_II RD_NN ,_, p=0.0001_NN )_) ._.
P11405998A15
Any_DD disagreement_NN was_VBD resolved_VVN by_II discussion_NN ._.
P11406004A03
OBJECTIVES_NNS :_: To_TO review_VVI evidence_NN for_II the_DD efficacy_NN of_II speleotherapy_NN in_II the_DD treatment_NN of_II asthma_NN ._.
P11406016A11
In_II DDAVP-treated_VVNJ patients_NNS the_DD relative_JJ risk_NN of_II requiring_VVGN re-operation_NN due_II+ to_II bleeding_VVGN was_VBD 0.56_MC (_( 95_MC %_SYM CI_NN :_: 0.18_MC to_II 1.73_MC )_) ._.
P11406027A01
BACKGROUND_NN :_: Reduced_VVNJ perfusion_NN of_II organs_NNS such_II+ as_II the_DD brain_NN ,_, heart_NN ,_, kidneys_NNS and_CC the_DD gastrointestinal_JJ tract_NN may_VM lead_VVB to_II acute_JJ dysfunction_NN and_CC be_VBB associated_VVN with_II permanent_JJ injury_NN ._.
P11406033A10
SELECTION_NN CRITERIA_NNS :_: Randomized_VVNJ controlled_VVNJ trials_NNS in_II patients_NNS with_II localized_VVNJ esophageal_JJ cancer_NN ,_, with_II one_MC arm_NN employing_VVGN radiotherapy_NN alone_JJ ,_, and_CC one_MC arm_NN employing_VVGN combination_NN radiotherapy_NN chemotherapy_NN were_VBD included_VVN ._.
P11406037A17
MAIN_JJ RESULTS_NNS :_: In_II general_NN ,_, media-based_VVNJ therapies_NNS for_II behavioural_JJ disorders_NNS in_II children_NNS had_VHD a_DD moderate_JJ effect_NN when_CS compared_VVN with_II both_CC no-treatment_NN controls_NNS and_CC with_II standard_JJ care_NN ._.
P11406045A11
These_DD methodological_JJ problems_NNS could_VM potentially_RR lead_VVN to_II bias_NN from_II a_DD number_NN of_II sources_NNS ._.
P11406055A16
The_DD trials_NNS included_VVD 584_MC patients_NNS ._.
P11406061A14
Authors_NNS ,_, other_JJ experts_NNS in_II the_DD field_NN and_CC pharmaceutical_JJ companies_NNS were_VBD contacted_VVN for_II knowledge_NN of_II suitable_JJ trials_NNS ,_, published_VVN or_CC unpublished_VVN ._.
P11406065A10
SELECTION_NN CRITERIA_NNS :_: Randomised_VVNJ or_CC quasi-randomised_VVNJ controlled_VVNJ clinical_JJ trials_NNS involving_VVG preterm_NN infants_NNS ._.
P11406071A15
An_DD adequately_RR powered_VVNJ randomised_VVNJ controlled_VVNJ trial_NN would_VM be_VBB useful_JJ to_TO determine_VVI if_CST the_DD use_NN of_II extra-amniotic_JJ prostaglandins_NNS would_VM lower_VVB the_DD rate_NN of_II caesarean_NN section_NN ._.
P11419424A09
These_DD data_NNS support_VVB a_DD policy_NN involving_VVG broader_JJR use_NN of_II the_DD early_JJ inhibition_NN of_II glycoprotein_NN IIb_NN /_SYM IIIa_NN in_II combination_NN with_II an_DD early_JJ invasive_JJ strategy_NN in_II such_DD patients_NNS ._.
P11427188A08
It_PN reports_VVZ a_DD series_NN of_II case_NN studies_NNS ,_, each_PND describing_VVG the_DD development_NN of_II a_DD clinical_JJ guideline_NN ;_: each_DD case_NN study_NN illustrates_VVZ different_JJ issues_NNS in_II incorporating_VVGN these_DD different_JJ types_NNS of_II evidence_NN ._.
P11434828A06
INTERVENTIONS_NNS :_: Participants_NNS in_II the_DD double-blind_JJ primary_JJ prevention_NN trial_NN were_VBD randomly_RR assigned_VVN to_TO receive_VVI 40_MC mg_NN /_SYM d_NN of_II pravastatin_NN (_( n_NN =_SYM 865_MC )_) or_CC placebo_NN (_( n_NN =_SYM 837_MC )_) for_II 24_MC weeks_NNS ._.
P11441927A13
These_PND constitute_VVB about_II 75_MC %_SYM ,_, of_II all_DD haematological_JJ malignancies_NNS ._.
P11441935A03
This_DD synthesis_NN of_II the_DD literature_NN on_II chemotherapy_NN in_II patients_NNS with_II acute_JJ myeloid_NN leukaemia_NN (_( AML_NN )_) is_VBZ based_VVN on_II 129_MC scientific_JJ articles_NNS :_: one_MC meta-analysis_NN ,_, 51_MC randomised_VVNJ trials_NNS ,_, 39_MC prospective_JJ and_CC 18_MC retrospective_JJ studies_NNS ,_, and_CC 20_MC other_JJ articles_NNS ._.
P11441937A21
High-dose_NN infusional_JJ regimens_NNS with_II modulated_VVNJ fluorouracil_NN may_VM turn_VVB out_II to_TO be_VBI superior_JJ to_II conventional_JJ bolus_NN regimens_NNS ,_, since_CS they_PN result_VVB in_II more_DD tumour_NN regressions_NNS ,_, longer_JJR times_NNS to_II disease_NN progression_NN and_CC possibly_RR longer_JJR survival_NN ._.
P11441940A22
Thus_RR ,_, there_EX are_VBB preliminary_JJ data_NNS supporting_VVG the_DD substitution_NN of_II cisplatin_NN with_II carboplatin_NN ._.
P11445744A10
These_DD studies_NNS reported_VVD variable_JJ hospital_NN and_CC intensive_JJ care_NN unit_NN (_( ICU_NN )_) occurrence_NN rates_NNS ,_, ranging_VVG from_II 2_MC %_SYM to_II 11_MC %_SYM of_II all_DD hospital_NN or_CC ICU_NN admissions_NNS ._.
P11449817A12
Although_CS many_PND of_II these_DD studies_NNS can_VM be_VBB cited_VVN for_II various_JJ methodologic_JJ flaws_NNS ,_, the_DD most_RRT consistent_JJ problem_NN is_VBZ that_CST sample_NN sizes_NNS are_VBB too_RR small_JJ to_TO detect_VVI difference_NN between_II two_MC or_CC more_DD active_JJ treatments_NNS ._.
P11455747A08
Incidence_NN is_VBZ 5_MC %_SYM to_II 40_MC %_SYM in_II high-risk_NN surgical_JJ patients_NNS ._.
P11464448A13
However_RR ,_, recent_JJ retrospective_JJ real-life_NN clinical_JJ studies_NNS show_VVB that_CST only_RR 38_MC %_SYM of_II patients_NNS receiving_VVG some_DD form_NN of_II lipid-lowering_VVGJ therapy_NN achieved_VVD NCEP-defined_VVNJ LDL-C_NN target_NN levels_NNS ,_, demonstrating_VVG the_DD need_NN for_II the_DD use_NN of_II more_RR aggressive_JJ treatment_NN ._.
P11469927A01
The_DD continued_VVNJ widespread_JJ prevalence_NN of_II breast_NN cancer_NN supports_VVZ placing_VVGN a_DD high_JJ priority_NN on_II research_NN aimed_VVN at_II its_PNG primary_JJ prevention_NN ,_, particularly_RR among_II women_NNS who_PNR are_VBB at_II increased_VVNJ risk_NN for_II developing_VVGN this_DD disease_NN ._.
P11478189A12
4._MC Work_VVB at_II building_VVGN a_DD reputation_NN for_II general_JJ objectivity_NN ,_, reliance_NN on_II multiple_JJ data_NNS sources_NNS ,_, reaching_VVGN opinions_NNS only_RR after_II reviewing_VVGN complete_JJ information_NN from_II both_CC sides_NNS ,_, and_CC completing_VVGN the_DD evaluation_NN ._.
P11483848A16
The_DD presumed_VVNJ efficacy_NN is_VBZ based_VVN on_II a_DD collection_NN of_II animal_NN and_CC human_NN data_NNS concerning_VVG occupational_JJ ,_, perinatal_JJ ,_, and_CC nonoccupational_JJ exposures_NNS to_II HIV_NN ._.
P11495374A06
Mammograms_NNS miss_VVB approximately_RR 12_MC %_SYM to_II 37_MC %_SYM of_II cancers_NNS ,_, generate_VVB false-positive_JJ results_NNS ,_, and_CC cause_VVB anxiety_NN while_CS abnormal_JJ results_NNS are_VBB evaluated_VVN ._.
P11501601A06
Subgroup_NN analyses_NNS have_VHB demonstrated_VVN that_CST the_DD efficacy_NN of_II statins_NNS extends_VVZ to_II specific_JJ subgroups_NNS of_II patients_NNS ,_, including_VVG women_NNS ,_, people_NNS with_II diabetes_NN ,_, and_CC older_JJR individuals_NNS ._.
P11509058A04
DESIGN_NN AND_CC SETTING_VVGN :_: Cost-effectiveness_NN analysis_NN using_VVG the_DD Coronary_JJ Heart_NN Disease_NN Policy_NN Model_NN ,_, a_DD validated_VVNJ ,_, state-transition_NN model_NN of_II CHD_NN events_NNS in_II adults_NNS aged_VVN 35_MC through_CC 84_MC years_NNS ._.
P11512506A07
The_DD panel_NN composed_VVD a_DD draft_JJ statement_NN that_PNR was_VBD read_VVN in_II its_PNG entirety_NN and_CC circulated_VVN to_II the_DD experts_NNS and_CC the_DD audience_NN for_II comment_NN ._.
P11520256A09
There_EX are_VBB no_DD clearcut_NN advantages_NNS to_TO distinguish_VVI these_DD antihistamines_NNS ,_, although_CS for_II children_NNS under_II 5_MC years_NNS of_II age_NN ,_, only_RR cetirizine_NN and_CC loratadine_NN are_VBB approved_VVN ._.
P11524642A04
Antiplatelet_NN ,_, antithrombin_NN ,_, and_CC fibrinolytic_JJ agents_NNS unknown_VVN in_II clinical_JJ practice_NN as_RR recently_RR as_CSN 5_MC years_NNS ago_RR have_VHB secured_VVN places_NNS in_II the_DD emergency_NN physician_NN 's_GE armamentarium_NN for_II treating_VVGN acute_JJ coronary_JJ syndrome_NN ._.
P11529246A05
This_DD pathology_NN results_VVZ in_II focal_JJ changes_NNS in_II the_DD function_NN of_II several_JJ deep_JJ brain_NN nuclei_NNS ,_, which_PNR have_VHB been_VBN well-characterized_VVN in_II humans_NNS and_CC animal_NN models_NNS and_CC which_PNR account_VVB for_II many_PND of_II the_DD motor_NN symptoms_NNS of_II PD_NN ._.
P11530420A04
Whether_CST or_CC not_RR individuals_NNS with_II TS_NN have_VHB significant_JJ discrepancies_NNS between_II their_PNG verbal_JJ and_CC nonverbal_JJ abilities_NNS remains_VVZ unclear_JJ ._.
P11532236A23
This_PND was_VBD not_RR a_DD cohesive_JJ group_NN ,_, however_RR ._.
P11532238A38
METHODS_NNS -_: DATA_NNS SYNTHESIS_NN :_: For_II all_DD comparisons_NNS ,_, the_DD primary_JJ outcome_NN was_VBD the_DD number_NN of_II clients_NNS who_PNR were_VBD in_II competitive_JJ employment_NN at_II various_JJ time_NN points_NNS ._.
P11532240A03
In_II addition_NN ,_, the_DD research_NN :_: (_( 1_MC )_) explored_VVD the_DD '_`` diagnostic_JJ accuracy_NN '_'' of_II initial_JJ clinical_JJ investigation_NN of_II the_DD knee_NN by_II an_DD orthopaedic_JJ trainee_NN ,_, consultant_NN knee_NN specialist_NN and_CC consultant_NN radiologist_NN ;_: (_( 2_MC )_) considered_VVD the_DD variability_NN and_CC diagnostic_JJ accuracy_NN of_II interpretations_NNS of_II knee_NN MRI_NN investigations_NNS between_II radiologists_NNS ;_: (_( 3_MC )_) measured_VVD the_DD strength_NN of_II preference_NN for_II the_DD potential_JJ diagnostic_JJ /_SYM therapeutic_JJ impact_NN of_II knee_NN MRI_NN (_( i.e._II the_DD avoidance_NN of_II surgery_NN )_) ._.
P11533360A28
Policy-level_NN changes_NNS at_II the_DD state_NN and_CC community_NN led_VVD to_II lasting_VVGJ changes_NNS in_II the_DD organization_NN and_CC financing_VVGN of_II care_NN ,_, which_PNR enabled_VVD changes_NNS in_II clinical_JJ services_NNS to_TO take_VVI place_NN ._.
P11535983A08
The_DD results_NNS of_II ICON3_NN ,_, in_II accordance_NN with_II GOG132_NN study_NN ,_, appear_VVB to_TO contradict_VVI the_DD earlier_JJR positive_JJ results_NNS seen_VVN for_II PTX_NN and_CC CP_NN in_II the_DD GOG-111_NN and_CC OV10_NN trials_NNS and_CC suggested_VVD that_CST single_JJ agent_NN carboplatin_NN ,_, CY-adriamycin-CP_NN are_VBB safe_JJ and_CC effective_JJ first-line_NN treatments_NNS for_II women_NNS requiring_VVG chemotherapy_NN for_II ovarian_JJ cancer_NN ._.
P11550833A02
The_DD objective_NN of_II this_DD review_NN was_VBD to_TO assess_VVI the_DD effectiveness_NN of_II the_DD various_JJ methods_NNS of_II immobilisation_NN for_II acute_JJ ankle_NN sprain_NN ._.
P11557249A01
Patients_NNS admitted_VVN with_II suspicion_NN of_II an_DD acute_JJ coronary_JJ syndrome_NN (_( ACS_NN )_) still_RR constitute_VVB a_DD diagnostic_JJ ,_, prognostic_JJ and_CC therapeutic_JJ challenge_NN for_II the_DD treating_VVGJ physician_NN ._.
P11561607A05
Specialized_VVNJ centers_NNS have_VHB reported_VVN improved_VVNJ hospital_NN morbidity_NN ,_, mortality_NN and_CC survival_NN after_II pancreaticoduodenectomy_NN ;_: however_RR ,_, disease-specific_JJ survival_NN after_II surgical_JJ resection_NN remains_VVZ dismal_JJ ._.
P11567728A09
The_DD continuing_VVGJ elucidation_NN of_II pathophysiological_JJ pathways_NNS relevant_JJ in_II rheumatoid_JJ arthritis_NN ,_, coupled_VVN with_II continuing_VVGJ advances_NNS in_II biotechnology_NN and_CC rational_JJ drug_NN design_NN ,_, offer_VVB substantial_JJ hope_NN for_II the_DD continued_VVNJ development_NN of_II increasingly_RR potent_JJ and_CC specific_JJ pharmacotherapy_NN for_II treatment_NN of_II rheumatoid_JJ arthritis_NN ._.
P11570305A01
OBJECTIVE_NN :_: To_TO help_VVI family_NN physicians_NNS who_PNR care_VVB for_II patients_NNS with_II acute_JJ stroke_NN or_CC who_PNR are_VBB involved_VVN in_II planning_VVGN service_NN delivery_NN or_CC resource_NN allocation_NN to_TO understand_VVI recent_JJ developments_NNS in_II acute_JJ stroke_NN care_NN ._.
P11575024A05
Scientific_JJ evidence_NN was_VBD given_VVN precedence_NN over_II clinical_JJ anecdotal_JJ experience_NN ._.
P11581453A18
Ethically_RR sound_JJ ,_, specific_JJ policies_NNS for_II storage_NN ,_, ownership_NN ,_, and_CC use_NN in_II future_JJ studies_NNS of_II archived_VVNJ samples_NNS remaining_VVG from_II PKU_NN testing_VVGN should_VM be_VBB established_VVN ._.
P11587008A09
CONCLUSIONS_NNS :_: Consensus_NN recommendations_NNS were_VBD used_VVN to_TO create_VVI an_DD algorithm_NN for_II evaluating_VVGN women_NNS with_II postmenopausal_JJ bleeding_VVGN ._.
P11589256A11
Finally_RR ,_, risedronate_NN has_VHZ been_VBN associated_VVN with_II a_DD lower_JJR incidence_NN of_II gastric_JJ ulcers_NNS than_CSN alendronate_NN ._.
P11595196A06
The_DD Beyond_II Endorsed_VVNJ Lipid_NN Lowering_VVGN with_II EBCT_NN Scanning_VVGN (_( BELLES_NN )_) trial_NN will_VM use_VVB EBCT_NN to_TO compare_VVI the_DD effects_NNS of_II 12_MC months_NNS of_II treatment_NN with_II aggressive_JJ or_CC moderate_JJ statin_NN therapy_NN on_II the_DD progression_NN of_II coronary_JJ atherosclerosis_NN ._.
P11669360A03
Prior_JJ evidence_NN has_VHZ been_VBN limited_VVN regarding_VVG effective_JJ diagnostic_JJ strategies_NNS for_II the_DD assessment_NN of_II symptomatic_JJ women_NNS ._.
P11680099A07
reports_NNS and_CC opinion_NN of_II expert_NN committees_NNS and_CC working_VVGJ teams_NNS ._.
P11685852A02
Routine_JJ ultrasound_NN in_II late_JJ pregnancy_NN (_( after_II 24_MC weeks_NNS gestation_NN )_) (_( Cochrane_NNP Review_NN )_) ._.
P11686052A60
The_DD proposed_VVNJ treatments_NNS for_II the_DD other_JJ disorders_NNS are_VBB conventional_JJ :_: haloperidol_NN and_CC lithium_NN for_II bipolar_JJ disorders_NNS ,_, fluvoxamine_NN for_II obsessive_JJ compulsive_JJ disorders_NNS and_CC neuroleptics_NNS for_II psychotic_JJ disorders_NNS ._.
P11686949A17
No_DD completed_VVNJ studies_NNS of_II interventions_NNS to_TO raise_VVI blood_NN pressure_NN were_VBD identified_VVN ._.
P11686953A16
Higher_JJR doses_NNS of_II nicotine_NN patch_NN may_VM produce_VVB small_JJ increases_NNS in_II quit_NN rates_NNS ._.
P11686957A20
~bullet~Home_NN hazard_NN modification_NN in_II association_NN with_II advice_NN on_II optimising_VVGN medication_NN (_( 1_MC trial_NN ,_, 658_MC participants_NNS )_) ,_, or_CC in_II association_NN with_II an_DD education_NN package_NN on_II exercise_NN and_CC reducing_VVGN fall_NN risk_NN (_( 1_MC trial_NN ,_, 3182_MC participants_NNS )_) ._.
P11686965A09
SELECTION_NN CRITERIA_NNS :_: Two_MC reviewers_NNS independently_RR assessed_VVD citations_NNS or_CC papers_NNS and_CC selected_VVD all_DD randomised_VVNJ trials_NNS that_PNR included_VVD people_NNS with_II serious_JJ mental_JJ illnesses_NNS and_CC compared_VVD zuclopenthixol_NN acetate_NN with_II other_JJ drug_NN regimes_NNS ._.
P11686970A06
OBJECTIVES_NNS :_: To_TO determine_VVI the_DD effects_NNS of_II vaginal_JJ misoprostol_NN for_II third_JJ trimester_NN cervical_JJ ripening_VVGN or_CC induction_NN of_II labour_NN ._.
P11686975A11
Measured_VVD clinically_RR relevant_JJ outcomes_NNS ._.
P11686981A15
Further_JJ trials_NNS -_: one_MC of_II them_PN very_RR large_JJ -_: are_VBB currently_RR in_II progress_NN ._.
P11686989A13
Method_NN to_TO ascertain_VVI cases_NNS was_VBD similar_JJ in_II one_MC study_NN and_CC not_RR similar_JJ in_II the_DD other_JJ ._.
P11686996A23
Two_MC women_NNS in_II the_DD Goretex_NN group_NN had_VHD late_JJ sling_NN erosion_NN of_II the_DD urethra_NN requiring_VVG removal_NN of_II the_DD Goretex_NN ,_, although_CS their_PNG incontinence_NN remained_VVD cured_VVN ._.
P11687000A13
MAIN_JJ RESULTS_NNS :_: Seven_MC eligible_JJ controlled_VVNJ trials_NNS were_VBD included_VVN in_II the_DD analysis_NN representing_VVG 924_MC randomized_VVNJ pediatric_JJ patients_NNS ._.
P11687004A09
PPIs_NNS were_VBD significantly_RR more_RR effective_JJ than_CSN both_CC H2RA_NN s_NNS and_CC antacids_NNS ._.
P11687013A33
JAPANESE_JJ HERBAL_JJ COMBINATION_NN :_: One_MC small_JJ trial_NN showed_VVD the_DD herbal_JJ combination_NN to_TO be_VBI more_RR effective_JJ for_II pain_NN relief_NN than_CSN placebo_NN ,_, and_CC less_DD additional_JJ pain_NN medication_NN was_VBD taken_VVN by_II the_DD treatment_NN group_NN ._.
P11687024A14
The_DD two_MC in-hospital_NN studies_NNS were_VBD very_RR different_JJ in_II quality_NN (_( A_NN and_CC C_NN )_) and_CC size_NN (_( 773_MC and_CC 53_MC patients_NNS )_) ._.
P11687028A02
The_DD role_NN of_II the_DD occupational_JJ therapist_NN is_VBZ to_TO support_VVI the_DD patient_NN and_CC help_VVB them_PN maintain_VVI their_PNG usual_JJ level_NN of_II self-care_NN ,_, work_NN and_CC leisure_NN activities_NNS for_II as_RR long_RR as_CSN possible_JJ ._.
P11687033A13
The_DD conclusions_NNS are_VBB also_RR limited_VVN by_II some_PND of_II the_DD methodological_JJ deficiencies_NNS of_II the_DD included_VVNJ studies_NNS ._.
P11687038A06
SELECTION_NN CRITERIA_NNS :_: All_DD randomized_VVNJ controlled_VVNJ trials_NNS (_( RCTs_NNS )_) and_CC controlled_VVNJ clinical_JJ trials_NNS (_( CCTs_NNS )_) comparing_VVG therapeutic_JJ ultrasound_NN against_II placebo_NN or_CC another_DD active_JJ intervention_NN in_II patients_NNS with_II OA_NN were_VBD selected_VVN ._.
P11687043A01
BACKGROUND_NN :_: :_: Two_MC recent_JJ clinical_JJ reports_NNS describe_VVB an_DD association_NN between_II statin_NN therapy_NN and_CC a_DD reduction_NN in_II the_DD occurrence_NN of_II Alzheimer_NNP 's_GE disease_NN by_II as_RR much_PND as_CSN 70_MC %_SYM ._.
P11687048A19
Because_CS alternative_JJ antidepressants_NNS exist_VVB which_PNR have_VHB been_VBN proven_VVN to_TO be_VBI effective_JJ and_CC safe_JJ the_DD clinical_JJ usefulness_NN of_II 5-HTP_NN and_CC tryptophan_NN is_VBZ limited_VVN at_II present_NN ._.
P11687053A20
MAIN_JJ RESULTS_NNS :_: One_MC eligible_JJ study_NN was_VBD found_VVN dealing_VVG with_II prevention_NN of_II CLD_NN ;_: this_DD study_NN used_VVD salbutamol_NN and_CC enrolled_VVD 173_MC infants_NNS ._.
P11687058A09
SELECTION_NN CRITERIA_NNS :_: All_DD randomised_VVNJ or_CC quasi-randomised_VVNJ clinical_JJ trials_NNS comparing_VVG different_JJ haemodialysis_NN membrane_NN material_NN in_II patients_NNS with_II ESRD_NN ._.
P11687061A18
Amniotomy_NN and_CC intravenous_JJ oxytocin_NN resulted_VVD in_II more_DD postpartum_NN haemorrhage_NN than_CSN vaginal_JJ prostaglandins_NNS (_( RR_NN 5.5_MC ,_, CI_NN 1.26-24.07_MC )_) ._.
P11687078A12
95_MC %_SYM confidence_NN intervals_NNS were_VBD used_VVN ._.
P11687084A23
There_EX is_VBZ a_DD possible_JJ reduction_NN in_II the_DD severity_NN of_II chronic_JJ lung_NN disease_NN (_( shortened_VVNJ duration_NN of_II assisted_VVNJ ventilation_NN )_) ._.
P11687092A17
van_NNP Wassenaer_NNP 1997_MC found_VVD no_DD significant_JJ differences_NNS in_II the_DD Bayley_NNP MDI_NN and_CC PDI_NN at_II 24_MC months_NNS ,_, incidence_NN of_II cerebral_JJ palsy_NN (_( RR_NN 0.72_MC ,_, 95_MC %_SYM CI_NN 0.28_MC ,_, 1.84_MC )_) ,_, death_NN and_CC cerebral_JJ palsy_NN (_( RR_NN 0.70_MC ,_, 95_MC %_SYM CI_NN 0.43_MC ,_, 1.14_MC )_) or_CC the_DD RAKIT_NN IQ_NN score_NN (_( WMD_NN -2.10_MC ,_, 95_MC %_SYM CI_NN -7.91_MC ,_, 3.71_MC )_) at_II 5.7_MC years_NNS of_II age_NN ._.
P11687098A08
Trial_NN quality_NN was_VBD scored_VVN by_II the_DD Cochrane_NNP assessment_NN of_II allocation_NN concealment_NN &_CC the_DD Jadad_NNP scale_NN of_II methodological_JJ quality_NN ._.
P11687106A17
Manual_JJ muscle_NN testing_VVGN was_VBD assessed_VVN in_II three_MC studies_NNS (_( 54_MC patients_NNS )_) ,_, with_II 29_MC patients_NNS (_( 54_MC %_SYM )_) improving_VVGN in_II at_RR+ least_RR one_MC muscular_JJ district_NN during_II study_NN treatment_NN versus_CC four_MC patients_NNS (_( 7_MC %_SYM )_) during_II placebo_NN (_( odds_NNS ratio_NN [_( OR_CC ]_) 14.5_MC ,_, 95_MC %_SYM confidence_NN interval_NN [_( CI_NN ]_) 4.7-43.7_MC )_) ._.
P11687114A05
SELECTION_NN CRITERIA_NNS :_: Prospective_JJ randomised_VVNJ controlled_VVNJ trials_NNS (_( RCTs_NNS )_) which_PNR evaluated_VVD educational_JJ programmes_NNS for_II the_DD prevention_NN of_II foot_NN ulcers_NNS in_II people_NNS with_II diabetes_NN mellitus_NN ._.
P11687118A03
The_DD present_JJ reviews_NNS addresses_VVZ to_II the_DD use_NN of_II hot_JJ ,_, humid_NN air_NN in_II common_JJ cold_NN ._.
P11687120A24
The_DD GnRH_NN antagonist_NN flexible_JJ regimen_NN should_VM be_VBB the_DD area_NN of_II research_NN in_II the_DD near_JJ future_NN ._.
P11687130A08
MAIN_JJ RESULTS_NNS :_: Three_MC trials_NNS were_VBD included_VVN ,_, two_MC based_VVN in_II general_JJ practice_NN and_CC one_MC in_II a_DD neurology_NN centre_NN ._.
P11687134A08
MAIN_JJ RESULTS_NNS :_: We_PN found_VVD three_MC small_JJ trials_NNS (_( 50_MC patients_NNS )_) of_II relaxation_NN therapy_NN ._.
P11687139A02
Treatment_NN is_VBZ readily_RR available_JJ and_CC puts_VVZ a_DD large_JJ demand_NN on_II healthcare_NN budgets_NNS ._.
P11687142A13
Of_II these_DD nine_MC trials_NNS ,_, four_MC were_VBD excluded_VVN ,_, two_MC at_II further_JJ investigation_NN revealed_VVD a_DD lack_NN of_II randomisation_NN and_CC two_MC included_VVD combined_VVNJ oral_JJ contraceptives_NNS that_PNR are_VBB now_RR discontinued_VVN due_II+ to_II very_RR high_JJ oestrogen_NN content_NN ._.
P11687152A20
Details_NNS of_II late_JJ morbidity_NN were_VBD sparse_JJ ._.
P11687159A18
The_DD results_NNS should_VM be_VBB viewed_VVN with_II caution_NN as_CS patient_NN numbers_NNS are_VBB small_JJ ._.
P11687164A18
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: There_EX is_VBZ a_DD need_NN for_II evaluations_NNS of_II interventions_NNS combining_VVG provider_NN training_VVGN and_CC patient_NN education_NN ,_, and_CC for_II evaluations_NNS conducted_VVN in_II developing_VVGJ countries_NNS ._.
P11687168A14
Positive_JJ urine_NN sample_NN for_II cocaine_NN metabolites_NNS was_VBD the_DD main_JJ efficacy_NN outcome_NN ,_, with_II no_DD significant_JJ results_NNS obtained_VVN regardless_RR the_DD type_NN of_II antidepressant_NN ._.
P11687174A02
In_II RA_NN this_PND resulted_VVD in_II the_DD development_NN of_II the_DD Outcome_NN Measures_NNS in_II Arthritis_NN Clinical_JJ Trials_NNS (_( OMERACT_NN )_) ,_, and_CC in_II juvenile_JJ arthritis_NN the_DD Pediatric_JJ Rheumatology_NN International_JJ Trials_NNS Organization_NN (_( PRINTO_NN )_) core_NN set_NN ._.
P11687176A13
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: :_: There_EX is_VBZ no_DD good_JJ evidence_NN to_TO recommend_VVI statins_NNS for_II reducing_VVGN the_DD risk_NN of_II Alzheimer_NNP 's_GE disease_NN ._.
P11687180A29
Thus_RR there_EX is_VBZ insufficient_JJ evidence_NN on_II the_DD total_JJ costs_NNS and_CC benefits_NNS of_II treating_VVGN pre-dialysis_NN patients_NNS with_II rHu_NN EPO_NN ._.
P11687187A12
MAIN_JJ RESULTS_NNS :_: Four_MC studies_NNS were_VBD included_VVN ._.
P11687193A20
There_EX were_VBD no_DD significant_JJ differences_NNS in_II trials_NNS where_PNR participants_NNS had_VHD primary_JJ cocaine_NN dependence_NN or_CC had_VHD additional_JJ diagnosis_NN of_II opioid_NN dependence_NN and/or_CC were_VBD in_II methadone_NN maintenance_NN treatment_NN ._.
P11687198A12
The_DD pooled_VVNJ RR_NN for_II remission_NN of_II binge_NN episodes_NNS was_VBD 0.88_MC (_( 95_MC %_SYM CI_NN 0.83-0.93_MC ;_: p_NN <_SYM 0,001_MC )_) favoring_VVG drugs_NNS ._.
P11695246A01
The_DD cyclooxygenase_NN (_( COX_NN )_) -2_MC selective_JJ inhibitors_NNS celecoxib_NN and_CC rofecoxib_NN have_VHB been_VBN found_VVN to_TO be_VBI more_RR effective_JJ than_CSN placebo_NN and_CC comparably_RR effective_JJ to_II nonselective_JJ nonsteroidal_JJ anti-inflammatory_JJ drugs_NNS (_( NSAIDs_NNS )_) in_II the_DD treatment_NN of_II patients_NNS with_II osteoarthritis_NN and_CC rheumatoid_JJ arthritis_NN ._.
P11699634A27
None_MC of_II these_DD anticipated_VVNJ advances_NNS will_VM be_VBB achieved_VVN ,_, however_RR ,_, in_II the_DD absence_NN of_II a_DD progressive_JJ ,_, third-party_NN payment_NN system_NN that_PNR acknowledges_VVZ its_PNG responsibility_NN to_TO compensate_VVI providers_NNS adequately_RR to_TO ensure_VVI that_CST the_DD next_JJ generation_NN of_II conservative_JJ therapy_NN can_VM be_VBB enjoyed_VVN by_II the_DD American_JJ people_NNS ._.
P11701099A48
Trials_NNS should_VM be_VBB undertaken_VVN in_II community_NN settings_NNS to_TO ensure_VVI the_DD generalisability_NN of_II results_NNS ._.
P11701102A23
However_RR ,_, power_NN was_VBD considerably_RR reduced_VVN for_II smaller_JJR interactions_NNS ,_, which_PNR are_VBB much_RR more_RR likely_JJ in_II practice_NN ._.
P11701786A05
Computer_NN database_NN searches_NNS were_VBD performed_VVN independently_RR by_II two_MC investigators_NNS to_TO identify_VVI all_DD potentially_RR relevant_JJ study_NN titles_NNS ._.
P11702861A16
Methods_NNS used_VVN to_TO determine_VVI the_DD extent_NN of_II resection_NN were_VBD subjective_JJ and_CC qualitative_JJ in_II almost_RR all_DD studies_NNS ._.
P11708038A04
METHODOLOGY_NN :_: The_DD MEDLINE_NN ,_, EMBASE_NN ,_, Best_JJT Evidence_NN ,_, and_CC Cochrane_NNP Systematic_JJ Review_NN databases_NNS and_CC Internet_NN Web_NN sites_NNS were_VBD searched_VVN for_II articles_NNS and_CC guidelines_NNS published_VVN between_II January_NN 1980_MC and_CC May_NN 2001_MC to_TO identify_VVI quality_NN indicators_NNS for_II CAP_NN and_CC relevant_JJ evidence_NN ._.
P11711010A09
CONCLUSIONS_NNS :_: There_EX is_VBZ no_DD evidence_NN to_TO support_VVI using_VVGN beta2-agonists_NNS in_II children_NNS with_II acute_JJ cough_NN and_CC no_DD evidence_NN of_II airflow_NN obstruction_NN ._.
P11713849A02
Blood_NN pressure_NN management_NN remains_VVZ one_MC of_II the_DD most_RRT cost-effective_JJ methods_NNS of_II cardiovascular_JJ risk_NN factor_NN reduction_NN ._.
P11715181A21
The_DD current_JJ multicenter_NN prospective_JJ trials_NNS will_VM provide_VVB much_DD needed_VVNJ guidance_NN on_II this_DD subject_NN ._.
P11720920A15
More_DD research_NN is_VBZ needed_VVN to_TO establish_VVI more_DD evidence_NN regarding_VVG situations_NNS in_II which_PNR teleadvice_NN is_VBZ beneficial_JJ and_CC efficient_JJ ._.
P11724098A06
Treatment_NN of_II these_DD underlying_VVGJ etiologies_NNS should_VM be_VBB considered_VVN ._.
P11727406A09
The_DD patients_NNS for_II whom_PNR combination_NN therapy_NN is_VBZ most_RRT commonly_RR successful_JJ are_VBB those_PND who_PNR do_VDB not_RR achieve_VVB adequate_JJ glycemic_JJ control_NN using_VVG daytime_NN oral_JJ agents_NNS but_CC who_PNR still_RR show_VVB some_DD evidence_NN of_II responsiveness_NN to_II the_DD medications_NNS ._.
P11728541A05
We_PN calculated_VVD summary_NN estimates_NNS across_II studies_NNS for_II important_JJ efficacy_NN and_CC tolerability_NN parameters_NNS ,_, and_CC separately_RR summarised_VVD direct_JJ comparator_NN trials_NNS ._.
P11735631A11
Wide_JJ variability_NN in_II ACE_NN inhibitor_NN use_NN is_VBZ noted_VVN ,_, with_II higher_JJR rates_NNS consistently_RR reported_VVN among_II patients_NNS having_VHG systolic_JJ dysfunction_NN confirmed_VVN by_II an_DD objective_JJ assessment_NN --_: an_DD apparent_JJ minority_NN of_II the_DD those_PND having_VHG CHF_NN ._.
P11735713A10
For_II diagnostic_JJ accuracy_NN ,_, sensitivity_NN was_VBD 0.81_MC to_II 1.00_MC for_II dermatologists_NNS and_CC 0.42_MC to_II 1.00_MC for_II PCPs_NNS ._.
P11747684A05
Medications_NNS analyzed_VVN include_VVB alendronate_NN ,_, either_CC 5_MC mg_NN /_SYM day_NN or_CC 5_MC mg_NN /_SYM day_NN ,_, followed_VVN by_II 10_MC mg_NN /_SYM day_NN ;_: raloxifene_NN ,_, 60_MC or_CC 120_MC mg_NN /_SYM day_NN ;_: and_CC combination_NN hormone_NN replacement_NN therapy_NN (_( HRT_NN )_) of_II four_MC different_JJ regimen_NN types_NNS ._.
P11756209A02
Thus_RR diabetes_NN not_RR only_RR increases_VVZ the_DD risk_NN of_II coronary_JJ heart_NN disease_NN but_CC also_RR increases_VVZ the_DD case_NN fatality_NN rate_NN ,_, ensuring_VVG that_CST the_DD majority_NN of_II patients_NNS die_VVB of_II cardiovascular_JJ causes_NNS ,_, often_RR before_II the_DD age_NN of_II 50_MC years_NNS ._.
P11761209A07
All_DD randomised_VVNJ controlled_VVNJ trials_NNS (_( RCTs_NNS )_) descrbiing_VVG individuals_NNS with_II diagnosed_VVNJ lateral_JJ epicondylitis_NN and_CC assessing_VVG the_DD use_NN of_II an_DD orthotic_JJ device_NN as_II a_DD treatment_NN strategy_NN were_VBD evaluatedfor_VVN inclusion_NN ._.
P11768834A10
Full_JJ reports_NNS were_VBD available_JJ for_II only_RR 6_MC of_II the_DD 11_MC studies_NNS ._.
P11772158A17
CONCLUSIONS_NNS :_: Paclitaxel_NN used_VVN in_II combination_NN with_II cisplatin_NN offers_VVZ survival_NN and_CC utility_NN gains_NNS versus_CC cyclophosphamide_NN plus_CC cisplatin_NN ,_, when_CS used_VVN as_II first-line_NN treatment_NN in_II patients_NNS with_II stage_NN III_MC or_CC IV_MC ovarian_JJ cancer_NN ._.
P11773571A24
Comparison_NN of_II final_JJ videotape_NN interpretation_NN to_II initial_JJ telemedicine_NN diagnosis_NN resulted_VVD in_II 1_MC minor_JJ diagnostic_JJ change_NN (_( membranous_JJ versus_CC inlet_RR ventricular_JJ septal_JJ defect_NN )_) ._.
P11780589A03
In_II the_DD United_VVNJ States_NNS alone_JJ ,_, the_DD uncontrolled_VVNJ epilepsy_NN represents_VVZ more_RR than_CSN 500,000_MC people_NNS ._.
P11784221A05
Patients_NNS with_II 2_MC or_CC more_DD cardiac_JJ risk_NN factors_NNS or_CC with_II documented_VVNJ coronary_JJ artery_NN disease_NN were_VBD classified_VVN as_II high_JJ risk_NN and_CC were_VBD considered_VVN eligible_JJ for_II treatment_NN with_II a_DD beta-blocker_NN if_CS they_PN had_VHD no_DD obvious_JJ contraindications_NNS to_II its_PNG use_NN ._.
P11789467A04
The_DD Dietary_JJ Supplement_NN and_CC Health_NN Education_NN Act_NN signed_VVN into_II law_NN in_II October_NN 1994_MC ,_, requires_VVZ no_DD proof_NN of_II efficacy_NN ,_, no_DD demonstration_NN of_II safety_NN ,_, and_CC sets_VVZ no_DD standards_NNS for_II quality_NN control_NN for_II the_DD products_NNS labeled_VVN as_II "_`` supplements_NNS "_'' thereby_RR increasing_VVG the_DD risk_NN of_II adverse_JJ effects_NNS of_II these_DD herbs_NNS ._.
P11791816A03
To_TO investigate_VVI the_DD effects_NNS of_II exercise_NN training_VVGN upon_II CHF_NN patients_NNS ,_, a_DD systematic_JJ literature_NN review_NN was_VBD carried_VVN out_II of_II trials_NNS (_( from_II 1966_MC to_II December_NN 2000_MC )_) which_PNR used_VVD as_II their_PNG main_JJ outcome_NN measures_NNS the_DD effects_NNS of_II exercise_NN training_VVGN upon_II :_: (_( a_NN )_) physical_JJ performance_NN ;_: or_CC (_( b_NN )_) quality_NN of_II life_NN ;_: or_CC (_( c_NN )_) morbidity_NN /_SYM mortality_NN ._.
P11793629A03
STUDY_NN SELECTION_NN AND_CC DATA_NNS EXTRACTION_NN :_: All_PND of_II the_DD articles_NNS identified_VVN from_II the_DD data_NNS sources_NNS were_VBD evaluated_VVN ._.
P11802753A13
Continued_VVNJ efforts_NNS should_VM be_VBB made_VVN in_II all_DD settings_NNS to_TO optimize_VVI the_DD use_NN of_II antithrombotic_JJ therapy_NN among_II persons_NNS at_II an_DD elevated_VVNJ risk_NN of_II atherothrombotic_JJ events_NNS ._.
P11809427A06
Total_JJ cholesterol_NN and_CC apolipoprotein_NN B_NN reductions_NNS and_CC apolipoprotein_NN A-I_NN increases_NNS were_VBD also_RR greater_JJR with_II rosuvastatin_NN ;_: triglyceride_NN reductions_NNS were_VBD similar_JJ ._.
P11813503A28
Despite_II a_DD poor_JJ virologic_JJ response_NN for_II some_PND of_II them_PN ,_, a_DD rise_NN in_II CD4_NN cell_NN count_NN was_VBD observed_VVN for_II all_DD patients_NNS during_II the_DD study_NN period_NN ._.
P11817979A04
In_II general_NN ,_, quinapril_NN provided_VVD similar_JJ blood_NN pressure_NN control_NN to_II other_JJ standard_JJ antihypertensive_JJ therapies_NNS including_VVG other_JJ ACE_NN inhibitors_NNS ,_, calcium_NN antagonists_NNS and_CC beta-adrenoceptor_NN antagonists_NNS in_II comparative_JJ clinical_JJ trials_NNS ._.
P11820489A06
First_RR ,_, the_DD topic_NN should_VM be_VBB of_II common_JJ interest_NN and_CC relevance_NN to_II family_NN practice_NN ._.
P11827558A06
Quinupristin_NN /_SYM dalfopristin_NN is_VBZ a_DD streptogramin_NN ,_, which_PNR impairs_VVZ bacterial_JJ protein_NN synthesis_NN at_II both_CC early_JJ peptide_NN chain_NN elongation_NN and_CC late_JJ peptide_NN chain_NN extrusion_NN steps_NNS ._.
P11832671A11
A_DD hybrid_NN strategy_NN using_VVG greater-than-or-equal15_NN %_SYM risk_NN ,_, or_CC 10_MC %_SYM to_II 14_MC %_SYM risk_NN with_II a_DD parental_JJ history_NN of_II premature_JJ coronary_JJ heart_NN disease_NN or_CC treated_VVNJ ,_, controlled_VVNJ hypertension_NN ,_, identified_VVD 20_MC %_SYM for_II treatment_NN :_: n=2646_NN ;_: events_NNS expected_VVN to_TO be_VBI prevented=97_NN ;_: number_NN needed_VVN to_II treat=27_NN ;_: sensitivity=0.44_NN (_( 0.40-0.47_MC )_) ;_: sensitivity_NN when_CS LDL-C_NN was_VBD greater-than-or-equal130_NN mg_NN /_SYM dL=0.66_NN ._.
P11837527A01
BACKGROUND_NN :_: Dysarthria_NN is_VBZ a_DD common_JJ sequel_NN of_II nonprogressive_JJ brain_NN damage_NN (_( typically_RR stroke_NN and_CC traumatic_JJ brain_NN damage_NN )_) ._.
P11840109A03
SUMMARY_NN OF_II BACKGROUND_NN DATA_NNS :_: Whiplash_NN constitutes_VVZ a_DD considerable_JJ problem_NN in_II health_NN care_NN ._.
P11845635A02
They_PN are_VBB not_RR absolute_JJ care_NN directives_NNS ,_, but_CC are_VBB intended_VVN to_TO facilitate_VVI individualized_VVNJ decision_NN making_VVGN related_VVN to_II patient_NN care_NN situations_NNS ._.
P11850611A14
For_II chronic_JJ treatment_NN of_II VTE_NN ,_, warfarin_NN is_VBZ the_DD treatment_NN of_II choice_NN (_( INR_NN 2.0-3.0_MC )_) ,_, also_RR in_II the_DD elderly_NN ._.
P11858225A03
High_JJ incidence_NN of_II alcohol-impaired_VVNJ driving_VVGN ._.
P11862245A14
Future_JJ trials_NNS comparing_VVG efficacy_NN of_II agents_NNS in_II high_JJ risk_NN patients_NNS and_CC rigorously_RR evaluating_VVG thromboembolic_JJ events_NNS will_VM allow_VVB unconditional_JJ recommendations_NNS ._.
P11865567A58
DISCUSSION_NN :_: The_DD diversity_NN of_II psychiatric_JJ morbidity_NN in_II SLE_NN and_CC SS_NN may_VM be_VBB due_II+ to_II differences_NNS in_II patient_NN selection_NN and_CC a_DD lack_NN of_II uniform_JJ clinical_JJ criteria_NNS ._.
P11869563A24
Given_VVN the_DD lower_JJR complication_NN rate_NN of_II the_DD SHS_NN in_II comparison_NN with_II intramedullary_JJ nails_NNS ,_, it_PN appears_VVZ that_CST for_II trochanteric_NN fractures_NNS the_DD SHS_NN is_VBZ superior_JJ ._.
P11869578A04
It_PN is_VBZ also_RR recommended_VVN for_II neonates_NNS with_II post-extubation_NN tracheal_JJ obstruction_NN and_CC stridor_NN in_II neonatal_JJ and_CC respiratory_JJ textbooks_NNS and_CC reviews_NNS ._.
P11869583A13
Continuous_JJ measures_NNS of_II outcome_NN were_VBD combined_VVN using_VVG standardised_VVNJ mean_NN differences_NNS ._.
P11869591A05
SELECTION_NN CRITERIA_NNS :_: Randomised_VVNJ trials_NNS comparing_VVG intravenous_JJ immunoglobulin_NN (_( monoclonal_JJ or_CC polyclonal_JJ )_) with_II placebo_NN or_CC no_DD intervention_NN ,_, in_II patients_NNS with_II bacterial_JJ sepsis_NN or_CC septic_JJ shock_NN ._.
P11869600A08
Eligible_JJ studies_NNS needed_VVD to_TO assess_VVI at_RR+ least_RR one_MC of_II the_DD outcome_NN variables_NNS defined_VVN a_RR+ priori_RR for_II this_DD systematic_JJ review_NN ._.
P11869609A01
BACKGROUND_NN :_: Lateral_JJ epicondylitis_NN (_( tennis_NN elbow_NN )_) is_VBZ a_DD frequently_RR reported_VVNJ condition_NN ._.
P11869615A16
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: There_EX is_VBZ weak_JJ and_CC unreliable_JJ evidence_NN that_CST the_DD absorbed_VVNJ drug_NN ,_, ketoconazole_NN ,_, may_VM eradicate_VVB oral_JJ candidiasis_NN and_CC that_CST a_DD higher_JJR dose_NN of_II the_DD partially_RR absorbed_VVNJ drug_NN ,_, clotrimazole_NN ,_, may_VM give_VVB greater_JJR benefit_NN than_CSN a_DD lower_JJR 10mg_NN dose_NN ,_, however_RR ,_, researchers_NNS may_VM wish_VVB to_TO prevent_VVI rather_CC+ than_CC treat_VVI oral_JJ candidiasis_NN ._.
P11869624A15
In_II most_DD cases_NNS ,_, the_DD first_PN or_CC corresponding_VVGJ author_NN of_II each_DD included_VVNJ trial_NN was_VBD contacted_VVN for_II additional_JJ information_NN ._.
P11869629A17
Large_JJ clinical_JJ trials_NNS underway_VVB or_CC about_RR to_TO commence_VVI are_VBB likely_RR to_TO contribute_VVI valuable_JJ further_JJ information_NN to_TO clarify_VVI these_DD areas_NNS of_II clinical_JJ uncertainty_NN ._.
P11869636A05
SELECTION_NN CRITERIA_NNS :_: Randomised_VVNJ trials_NNS in_II children_NNS and_CC adults_NNS comparing_VVG Fluticasone_NN to_II either_CC Beclomethasone_NN or_CC Budesonide_NN in_II the_DD treatment_NN of_II chronic_JJ asthma_NN ._.
P11869641A07
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: Two_MC reviewers_NNS independently_RR selected_VVD trials_NNS for_II inclusion_NN and_CC extracted_VVD data_NNS ._.
P11869648A11
MAIN_JJ RESULTS_NNS :_: The_DD initial_JJ search_NN retrieved_VVD 95_MC studies_NNS ._.
P11869655A16
~bullet~There_EX is_VBZ no_DD good_JJ evidence_NN comparing_VVG the_DD Epley_NNP manoeuvre_NN with_II other_JJ physical_JJ ,_, medical_JJ or_CC surgical_JJ therapy_NN for_II posterior_JJ canal_NN BPPV_NN ._.
P11869662A04
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD the_DD Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN ,_, issue_NN 1_MC ,_, 2001_MC ,_, MEDLINE_NN 1966_MC to_II 2001_MC ,_, EMBASE_NN 1980_MC to_II 2001_MC ,_, CANCERCD_NN 1980_MC to_II 2001_MC ,_, Science_NN Citation_NN Index_NN 1991_MC to_II 2001_MC ,_, CINAHL_NN 1982_MC to_II 2001_MC ,_, as_CC+ well_CC+ as_CC sources_NNS of_II grey_JJ literature_NN ._.
P11869665A15
The_DD percent_NN overall_JJ survival_NN at_II 1_MC ,_, 2_MC ,_, 5_MC ,_, and_CC 10_MC years_NNS for_II the_DD early_JJ treatment_NN group_NN was_VBD 88_MC %_SYM ,_, 73_MC %_SYM ,_, 44_MC %_SYM ,_, and_CC 18_MC %_SYM ._.
P11869669A02
Lateral_JJ elbow_NN pain_NN ,_, or_CC tennis_NN elbow_NN ,_, is_VBZ a_DD common_JJ condition_NN causing_VVG pain_NN in_II the_DD elbow_NN and_CC forearm_NN and_CC lack_NN of_II strength_NN and_CC function_NN of_II the_DD elbow_NN and_CC wrist_NN ._.
P11869676A03
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD the_DD Cochrane_NNP Airways_NNS Group_NN trials_NNS register_NN ,_, electronic_JJ reference_NN databases_NNS ,_, UK_NNP National_JJ Research_NN Register_NN ,_, bibliographies_NNS of_II included_VVNJ studies_NNS ,_, and_CC contacted_VVD pharmaceutical_JJ companies_NNS ._.
P11872916A02
The_DD realization_NN that_CST atherosclerosis_NN is_VBZ an_DD inflammatory_JJ disease_NN has_VHZ led_VVN to_II a_DD search_NN for_II new_JJ stroke_NN and_CC cardiovascular_JJ disease_NN risk_NN factors_NNS and_CC treatments_NNS ._.
P11884907A10
A_DD fixed_VVNJ effects_NNS model_NN was_VBD used_VVN throughout_RR for_II continuous_JJ variables_NNS ,_, except_CS where_CS heterogeneity_NN existed_VVD ,_, in_II which_DD case_NN ,_, a_DD random_JJ effects_NNS model_NN was_VBD used_VVN ._.
P11888339A06
Various_JJ migraine_NN surveys_NNS have_VHB indicated_VVN that_CST a_DD rapid_JJ onset_NN of_II therapeutic_JJ effect_NN is_VBZ a_DD highly_RR desirable_JJ attribute_NN of_II an_DD antimigraine_JJ drug_NN ._.
P11899566A04
Owing_II+ to_II their_PNG age_NN ,_, the_DD elderly_NN are_VBB more_RR afflicted_VVN with_II chronic_JJ diseases_NNS ,_, including_VVG coronary_JJ artery_NN disease_NN ._.
P11907914A04
DATA_NNS EXTRACTION_NN :_: Data_NNS extraction_NN and_CC quality_NN assessment_NN were_VBD performed_VVN in_II duplicate_NN ,_, with_II assistance_NN of_II a_DD manual_NN ._.
P11918516A04
Abstracts_NNS presented_VVN at_II infectious_JJ diseases_NNS and_CC critical_JJ care_NN meetings_NNS were_VBD also_RR reviewed_VVN ._.
P11923602A03
The_DD past_JJ decade_NN has_VHZ witnessed_VVN the_DD development_NN of_II a_DD variety_NN of_II locoregional_JJ therapies_NNS for_II HCC_NN ._.
P11925374A14
However_RR ,_, this_DD study_NN failed_VVD to_TO recruit_VVI the_DD planned_VVNJ number_NN of_II participants_NNS and_CC was_VBD consequently_RR underpowered_VVN ._.
P11929334A05
Among_II patients_NNS with_II acute_JJ ST_NN elevation_NN MI_NN ,_, randomised_VVNJ trials_NNS have_VHB demonstrated_VVN bivalirudin_NN to_TO be_VBI significantly_RR more_RR effective_JJ than_CSN heparin_NN in_II improving_VVGN early_JJ patency_NN in_II patients_NNS receiving_VVG thrombolytic_JJ therapy_NN with_II streptokinase_NN ._.
P11939601A04
IVIG_NN is_VBZ U.S_NN ._.
P11959890A08
Nevertheless_RR ,_, by_II exploring_VVGN the_DD relative_JJ effectiveness_NN of_II the_DD different_JJ intervention_NN strategies_NNS for_II each_DD outcome_NN and_CC follow-up_NN period_NN ,_, we_PN suggest_VVB the_DD specific_JJ therapies_NNS that_PNR should_VM be_VBB considered_VVN for_II further_JJ investigation_NN ._.
P11967397A06
RESULTS_NNS :_: Major_JJ deficiencies_NNS in_II treatment_NN that_PNR were_VBD identified_VVN include_VVB inappropriate_JJ dosing_VVGN with_II antipsychotic_JJ agents_NNS ,_, underutilization_NN of_II adjunctive_JJ antidepressant_NN therapy_NN ,_, very_RR low_JJ rates_NNS of_II prescription_NN of_II psychosocial_JJ interventions_NNS and_CC lack_NN of_II continuity_NN between_II inpatient_NN and_CC outpatient_JJ settings_NNS ._.
P11967417A01
BACKGROUND_NN :_: "_`` Systematic_JJ reviews_NNS "_'' have_VHB come_VVB to_TO be_VBI recognized_VVN as_II the_DD most_RRT rigorous_JJ method_NN of_II summarizing_VVGN confusing_VVGJ and_CC often_RR contradictory_JJ primary_JJ research_NN in_II a_DD transparent_JJ and_CC reproducible_JJ manner_NN ._.
P11967432A03
AIMS_NNS OF_II THE_DD STUDY_NN :_: The_DD scope_NN of_II this_DD review_NN was_VBD to_TO examine_VVI studies_NNS published_VVN in_II the_DD international_JJ literature_NN to_TO describe_VVI and_CC compare_VVI the_DD social_JJ costs_NNS of_II depression_NN in_II various_JJ countries_NNS ._.
P11967455A22
IMPLICATIONS_NNS FOR_II FURTHER_JJ RESEARCH_NN :_: Further_RR research_NN that_PNR improves_VVZ our_PNG understanding_VVGN of_II how_CST decisions_NNS regarding_VVG provider_NN choice_NN ,_, concurrent_JJ psychotherapy_NN ,_, and_CC drug_NN choice_NN are_VBB made_VVN will_VM improve_VVB our_PNG understanding_VVGN of_II the_DD effects_NNS treatment_NN choices_NNS on_II the_DD cost-effectiveness_NN of_II depression_NN care_NN ._.
P11978164A06
Clinical_JJ investigations_NNS were_VBD evaluated_VVN for_II design_NN ,_, sample_NN size_NN ,_, diagnosis_NN ,_, duration_NN ,_, and_CC outcome_NN ._.
P11982721A25
The_DD response_NN is_VBZ durable_JJ in_II approximately_RR 80_MC %_SYM of_II responders_NNS ._.
P11991548A01
OBJECTIVE_NN :_: This_DD article_NN reviews_VVZ the_DD recommendations_NNS by_II the_DD World_NN Health_NN Organization_NN 's_GE new_JJ guidelines_NNS ,_, "_`` Allergic_JJ Rhinitis_NN and_CC Its_PNG Impact_NN on_II Asthma_NN "_'' (_( ARIA_NN )_) ,_, and_CC the_DD paradigm_NN for_II treating_VVGN allergic_JJ rhinitis_NN based_VVN on_II disease_NN classification_NN ._.
P11993293A32
Few_JJ schools_NNS screen_VVB for_II processing_VVGJ problems_NNS ,_, including_VVG auditory_JJ and_CC visual_JJ motor_NN processing_VVGJ problems_NNS ,_, processing_VVGJ speed_NN ,_, comprehension_NN ,_, and_CC short-term_NN and_CC long-term_NN memory_NN problems_NNS ._.
P12004249A04
DATA_NNS SUMMARY_NN :_: Taken_VVN en_RR+ toto_RR ,_, the_DD data_NNS suggest_VVB that_CST NE_NN could_VM contribute_VVB to_II ALI_NN and_CC endothelial_JJ cell_NN injury_NN that_PNR is_VBZ relevant_JJ to_II ALI_NN ._.
P12011590A01
Although_CS the_DD manifestations_NNS of_II sickle_JJ cell_NN disease_NN (_( SCD_NN )_) do_VDB not_RR typically_RR necessitate_VVB critical_JJ care_NN management_NN ,_, several_JJ life-threatening_VVGJ complications_NNS may_VM require_VVB admission_NN to_II the_DD pediatric_JJ intensive_JJ care_NN unit_NN ._.
P12017503A04
DATA_NNS EXTRACTION_NN :_: All_DD titles_NNS (_( 4397_MC )_) ,_, articles_NNS ,_, and/or_CC abstracts_NNS (_( 1362_MC )_) were_VBD evaluated_VVN by_II 2_MC independent_JJ reviewers_NNS who_PNR extracted_VVD data_NNS on_II study_NN design_NN and_CC quality_NN ,_, sample_NN size_NN ,_, type_NN of_II intervention_NN ,_, and_CC outcomes_NNS ._.
P12020339A01
CONTEXT_NN :_: Complications_NNS of_II atherosclerosis_NN cause_VVB most_DD morbidity_NN and_CC mortality_NN in_II patients_NNS with_II diabetes_NN mellitus_NN ._.
P12022907A12
Bivalirudin_NN has_VHZ also_RR induced_VVN early_JJ patency_NN in_II patients_NNS with_II myocardial_JJ infarction_NN in_II combination_NN with_II streptokinase_NN ,_, but_CC its_PNG use_NN with_II newer_JJR thrombolytics_NNS needs_VVZ to_TO be_VBI studied_VVN ._.
P12027776A16
Treatment_NN should_VM be_VBB individualised_VVN for_II each_DD patient_NN ._.
P12034414A04
Two_MC reviewers_NNS independently_RR extracted_VVD data_NNS from_II the_DD studies_NNS ._.
P12040543A09
CONCLUSIONS_NNS :_: Further_JJ work_NN is_VBZ needed_VVN to_TO create_VVI operational_JJ definitions_NNS and_CC to_TO pilot_NN test_VVI the_DD selected_VVNJ measures_NNS ._.
P12045080A02
METHODS_NNS :_: The_DD review_NN followed_VVD the_DD methodology_NN of_II systematic_JJ reviews_NNS and_CC was_VBD facilitated_VVN through_II the_DD use_NN of_II a_DD structured_VVNJ template_NN ,_, a_DD companion_NN explanatory_JJ piece_NN ,_, and_CC a_DD grading_VVGJ and_CC methodological_JJ scoring_VVGJ system_NN based_VVN on_II published_VVNJ criteria_NNS for_II critical_JJ appraisal_NN ._.
P12049028A32
NATIONAL_JJ IMPLEMENTATION_NN OF_II THE_DD PRIMARY_JJ CARE_NN RESEARCH_NN TEAM_NN ASSESSMENT_NN :_: The_DD pilot_NN project_NN has_VHZ been_VBN very_RR successful_JJ and_CC recommendations_NNS have_VHB been_VBN made_VVN to_TO progress_VVI to_II a_DD UK_NNP scheme_NN ._.
P12053714A05
The_DD motion_NN studies_NNS afforded_VVN by_II cineangiography_NN also_RR permitted_VVD dynamic_JJ visualization_NN of_II the_DD contracting_VVGJ ventricle_NN which_PNR led_VVD to_II the_DD concept_NN of_II regional_JJ wall_NN motion_NN abnormalities_NNS being_VVGN characteristic_JJ of_II CAD_NN and_CC provided_VVD some_PND of_II our_PNG earliest_JJT understanding_VVGN of_II left_VVNJ ventricular_JJ dysfunction_NN ._.
P12057986A04
At_II the_DD time_NN of_II enrollment_NN ,_, patients_NNS were_VBD stratified_VVN according_II+ to_II diabetes_NN status_NN ._.
P12064194A14
The_DD findings_NNS of_II both_CC the_DD SPEED_NN and_CC TIMI_NN 14_MC trials_NNS were_VBD incorporated_VVN into_II the_DD design_NN of_II the_DD large_JJ (_( approximately_RR 17,000_MC patients_NNS )_) GUSTO_NN V_MC mortality_NN trial_NN ,_, which_PNR compared_VVD standard_JJ reteplase_NN therapy_NN with_II abciximab_NN plus_CC low-dose_NN reteplase_NN ._.
P12065798A03
Data_NNS from_II recently_RR completed_VVNJ phase_NN III_MC adjuvant_NN trials_NNS and_CC worldwide_JJ consensus_NN conferences_NNS document_VVB the_DD benefits_NNS of_II adjuvant_NN therapy_NN in_II improving_VVGN disease-free_JJ survival_NN and_CC overall_JJ survival_NN for_II patients_NNS diagnosed_VVN with_II invasive_JJ breast_NN cancer_NN >_SYM 1.0_MC cm_NN in_II size_NN ._.
P12072654A14
SUMMARY_NN :_: Among_II the_DD multitude_NN of_II oral_JJ ,_, intravesical_JJ ,_, interventional_JJ and_CC complementary_JJ treatments_NNS suggested_VVN few_JJ studies_NNS have_VHB high_JJ levels_NNS of_II evidence_NN ._.
P12075559A04
We_PN assess_VVB the_DD evidence_NN for_II the_DD use_NN of_II apheresis_NN ,_, the_DD optimal_JJ schedules_NNS for_II apheresis_NN ,_, and_CC the_DD replacement_NN solutions_NNS used_VVN ,_, based_VVN on_II randomized_VVNJ controlled_VVNJ trials_NNS ._.
P12076380A01
BACKGROUND_NN :_: Electroconvulsive_NN therapy_NN (_( ECT_NN )_) involves_VVZ the_DD induction_NN of_II a_DD seizure_NN (_( fit_NN )_) for_II therapeutic_JJ purposes_NNS by_II the_DD administration_NN of_II a_DD variable_JJ frequency_NN electrical_JJ stimulus_NN shock_NN via_II electrodes_NNS applied_VVN to_II the_DD scalp_NN ._.
P12076389A07
Due_II+ to_II the_DD variable_JJ methods_NNS of_II collecting_VVGN and_CC presenting_VVGN outcome_NN data_NNS ,_, no_DD statistical_JJ summary_NN measure_NN was_VBD calculated_VVN ._.
P12076395A06
This_PND included_VVD searches_NNS of_II the_DD Oxford_NNP Database_NN of_II Perinatal_JJ trials_NNS ,_, Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN (_( Cochrane_NNP Library_NN ,_, Issue_NN 4_MC ,_, 2001_MC )_) ,_, MEDLINE_NN (_( 1966-January_NN 2002_MC )_) ,_, EMBASE_NN ,_, CINAHL_NN (_( 1982-January_NN 2002_MC )_) ,_, previous_JJ reviews_NNS including_VVG cross_NN references_NNS ,_, abstracts_NNS ,_, conferences_NNS and_CC symposia_NN proceedings_NNS ,_, expert_NN informants_NNS ,_, journal_NN hand_NN searching_VVGN mainly_RR in_II the_DD English_JJ language_NN ._.
P12076403A06
(_( 2_MC )_) Women_NNS defined_VVN as_II high_JJ risk_NN of_II hypertensive_JJ disorders_NNS of_II pregnancy_NN ._.
P12076407A08
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: All_DD trials_NNS ,_, judged_VVN as_II fitting_VVGN the_DD selection_NN criteria_NNS by_II two_MC reviewers_NNS ,_, were_VBD independently_RR assessed_VVN by_II two_MC reviewers_NNS for_II methodological_JJ quality_NN by_II use_NN of_II an_DD 11_MC item_NN checklist_NN ._.
P12076411A11
We_PN performed_VVD meta-analyses_NNS with_II Review_NN Manager_NN 4.1_MC software_NN using_VVG a_DD fixed_VVNJ effects_NNS model_NN ._.
P12076414A27
The_DD pharmacology_NN and_CC toxicology_NN of_II melatonin_NN needs_VVZ systematic_JJ study_NN ,_, and_CC routine_JJ pharmaceutical_JJ quality_NN control_NN of_II melatonin_NN products_NNS must_VM be_VBB established_VVN ._.
P12076418A22
There_EX is_VBZ also_RR insufficient_JJ evidence_NN to_TO determine_VVI the_DD effects_NNS of_II early_JJ weight_NN bearing_VVGN after_II the_DD internal_JJ fixation_NN of_II an_DD intracapsular_JJ proximal_JJ femoral_JJ fracture_NN ._.
P12076423A22
Also_RR ,_, no_DD difference_NN in_II mean_NN improvement_NN on_II the_DD disability_NN scale_NN was_VBD found_VVN at_II two_MC weeks_NNS (_( effect_NN size_NN -0.12_MC ,_, 95_MC %_SYM confidence_NN interval_NN -0.68_MC to_II 0.45_MC )_) or_CC six_MC weeks_NNS (_( effect_NN size_NN -0.07_MC ,_, 95_MC %_SYM confidence_NN interval_NN -0.63_MC to_II 0.50_MC )_) between_II prednisolone_NN and_CC intravenous_JJ immunoglobulin_NN ._.
P12076426A05
SEARCH_NN STRATEGY_NN :_: The_DD following_VVGJ databases_NNS were_VBD searched_VVN :_: MEDLINE_NN ,_, Psyclit_NN ,_, EMBASE_NN ,_, Science_NN Citation_NN Index_NN ,_, Social_JJ Science_NN Citation_NN Index_NN ,_, CINAHL_NN ,_, Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN (_( CCTR_NN )_) and_CC the_DD Cochrane_NNP Heart_NN Group_NN 's_GE specialised_VVNJ register_NN from_II 1985_MC to_II July_NN 2001_MC ._.
P12076431A07
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: One_MC reviewer_NN assessed_VVD potentially_RR relevant_JJ studies_NNS for_II inclusion_NN and_CC undertook_VVD data_NNS extraction_NN ._.
P12076435A10
Endolaryngeal_JJ resection_NN of_II early_JJ glottic_JJ tumours_NNS is_VBZ becoming_VVG more_RR common_JJ and_CC a_DD well_RR designed_VVNJ multicentre_NN RCT_NN is_VBZ warranted_VVN ._.
P12076440A14
In_II the_DD two_MC trials_NNS with_II adequate_JJ allocation_NN concealment_NN ,_, death_NN was_VBD more_RR common_JJ in_II the_DD anticonvulsant_JJ group_NN (_( Relative_JJ Risk_NN 2.0_MC ;_: 95_MC %_SYM confidence_NN interval_NN 1.20_MC to_II 3.33_MC ;_: fixed_VVNJ effect_NN model_NN )_) ._.
P12076445A03
The_DD major_JJ difficulty_NN with_II IPPV_NN is_VBZ that_CST it_PN is_VBZ invasive_JJ ,_, resulting_VVG in_II airway_NN and_CC lung_NN injury_NN and_CC contributing_VVG to_II the_DD development_NN of_II chronic_JJ lung_NN disease_NN ._.
P12076453A05
The_DD hallmark_NN of_II this_DD condition_NN ,_, is_VBZ a_DD massive_JJ shift_NN of_II fluid_NN from_II the_DD intra-vascular_JJ compartment_NN to_II the_DD third_JJ space_NN resulting_VVG in_II profound_JJ intra-vascular_JJ depletion_NN and_CC hemoconcentration_NN ._.
P12076456A13
Analysis_NN included_VVD haloperidol_NN treated_VVNJ patients_NNS ,_, compared_VVN with_II placebo_NN MAIN_JJ RESULTS_NNS :_: The_DD five_MC included_VVNJ trials_NNS led_VVD to_II the_DD following_VVGJ results_NNS :_: 1_MC ._.
P12076461A03
Metformin_NN ,_, however_RR ,_, is_VBZ thought_VVN to_TO increase_VVI the_DD risk_NN of_II lactic_JJ acidosis_NN ,_, and_CC is_VBZ considered_VVN to_TO be_VBI contraindicated_VVN in_II many_DD chronic_JJ hypoxemic_JJ conditions_NNS that_PNR may_VM be_VBB associated_VVN with_II lactic_JJ acidosis_NN ,_, such_II+ as_II cardiovascular_JJ ,_, renal_JJ ,_, hepatic_JJ and_CC pulmonary_JJ disease_NN ,_, and_CC advancing_VVGJ age_NN ._.
P12076468A04
Evidence_NN is_VBZ required_VVN as_II+ to_II the_DD safest_JJT and_CC most_RRT effective_JJ means_NNS of_II preventing_VVGN chest_NN tube_NN blockage_NN and_CC preventing_VVGN cardiac_JJ tamponade_NN ._.
P12076475A11
Initial_JJ treatment_NN was_VBD conservative_JJ ,_, involving_VVG plaster_NN cast_NN immobilisation_NN ,_, in_II all_PND but_CC 20_MC patients_NNS whose_PNR fractures_NNS were_VBD fixed_VVN surgically_RR ._.
P12076479A14
Regarding_VVG the_DD studies_NNS that_PNR compare_VVB methadone_NN with_II other_JJ opioid_NN agonists_NNS ,_, in_II Sorensen_NNP 1982_MC methadyl_NN acetate_NN performed_VVD similarly_RR to_II methadone_NN on_II most_DD process_NN and_CC outcome_NN measures_NNS ,_, while_CS in_II Tennant_NNP 1975_MC ,_, methadone_NN reduced_VVD severity_NN of_II withdrawal_NN and_CC had_VHD fewer_JJR drop-outs_NNS than_CSN did_VDD a_DD propoxyphene_NN group_NN ._.
P12076484A14
However_RR ,_, the_DD effectiveness_NN of_II the_DD '_`` long-short_JJ '_'' course_NN (_( from_II 28_MC weeks_NNS in_II pregnancy_NN for_II the_DD mother_NN and_CC for_II the_DD baby_NN until_II 3_MC days_NNS old_NN )_) and_CC the_DD '_`` short-long_JJ '_'' course_NN (_( from_II 35_MC weeks_NNS in_II pregnancy_NN for_II the_DD mother_NN and_CC for_II the_DD baby_NN until_II 6_MC weeks_NNS old_NN )_) did_VDD not_RR differ_VVB from_II that_PND of_II the_DD '_`` long-long_JJ '_'' course_NN ._.
P12076491A01
BACKGROUND_NN :_: Public_JJ concerns_NNS regarding_VVG the_DD safety_NN of_II transfused_VVNJ blood_NN have_VHB prompted_VVN re-consideration_NN of_II the_DD indications_NNS for_II the_DD transfusion_NN of_II allogeneic_JJ red_JJ cells_NNS (_( blood_NN from_II an_DD unrelated_VVNJ donor_NN )_) ,_, and_CC a_DD range_NN of_II techniques_NNS designed_VVN to_TO minimise_VVI transfusion_NN requirements_NNS ._.
P12076498A03
Hence_RR ,_, there_EX may_VM be_VBB a_DD role_NN for_II some_PND of_II these_DD drugs_NNS in_II the_DD treatment_NN of_II Alzheimer_NNP 's_GE disease_NN ._.
P12076503A04
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD the_DD Musculoskeletal_JJ Review_NN Group_NN 's_GE trials_NNS register_NN database_NN ,_, the_DD Cochrane_NNP Clinical_JJ Trials_NNS Register_NN (_( Cochrane_NNP Library_NN issue_NN 2_MC ,_, 2001_MC )_) ,_, MEDLINE_NN ,_, CINAHL_NN ,_, EMBASE_NN and_CC SCISEARCH_NN up_II+ to_II June_NN 2001_MC ._.
P12082187A02
A_DD number_NN of_II procedural_JJ and_CC patient_NN factors_NNS have_VHB been_VBN shown_VVN to_TO predict_VVI the_DD occurrence_NN of_II SAT_NN ,_, including_VVG longer_JJR stent_NN length_NN ,_, smaller_JJR minimum_NN luminal_JJ diameter_NN ,_, persistent_JJ dissection_NN ,_, multivessel_NN intervention_NN ,_, and_CC possibly_RR acute_JJ coronary_JJ syndrome_NN (_( ACS_NN )_) presentation_NN ._.
P12086276A16
While_CS 15_MC %_SYM were_VBD current_JJ smokers_NNS ,_, 56_MC %_SYM were_VBD ex-smokers_NNS ._.
P12086558A02
DATA_NNS SOURCES_NNS :_: Literature_NN search_NN strategy_NN involved_VVN using_VVGN MEDLINE_NN (_( 1966-July_NN 2001_MC )_) and_CC AIDSLINE_NN (_( MEDSCAPE_NN )_) databases_NNS (_( up_II+ to_II July_NN 2001_MC )_) ._.
P12092641A08
Information_NN was_VBD then_RR organized_VVN and_CC correlated_VVN in_II order_NN to_TO provide_VVI a_DD detailed_VVNJ description_NN of_II the_DD key_JJ conditions_NNS and_CC their_PNG interrelatedness_NN ._.
P12093715A11
Limited_VVNJ data_NNS exist_VVB for_II ED-based_VVNJ practice_NN ,_, but_CC ,_, based_VVN on_II the_DD burden_NN of_II disease_NN ,_, relative_JJ ease_NN of_II intervention_NN ,_, and_CC likely_JJ efficacy_NN ,_, routine_JJ screening_VVGN of_II all_DD patients_NNS for_II tobacco_NN use_NN and_CC referral_NN of_II smokers_NNS to_II primary_JJ care_NN and_CC cessation_NN programs_NNS are_VBB recommended_VVN ._.
P12096151A09
No_DD meta-analyses_NNS were_VBD performed_VVN ,_, as_CS no_DD data_NNS were_VBD available_JJ from_II randomized_VVNJ comparisons_NNS ._.
P12105077A09
Recognition_NN of_II the_DD seizure_NN state_NN remains_VVZ the_DD foremost_RRT challenge_NN to_TO overcome_VVI ._.
P12108581A22
Strategies_NNS to_TO protect_VVI the_DD safety_NN of_II both_CC the_DD patient_NN and_CC the_DD public_JJ safety_NN worker_NN must_VM be_VBB devised_VVN and_CC tested_VVN ._.
P12114036A15
INTERPRETATION_NN :_: Adding_VVGN simvastatin_NN to_II existing_VVGJ treatments_NNS safely_RR produces_VVZ substantial_JJ additional_JJ benefits_NNS for_II a_DD wide_JJ range_NN of_II high-risk_NN patients_NNS ,_, irrespective_JJ of_II their_PNG initial_JJ cholesterol_NN concentrations_NNS ._.
P12114165A20
Quiz_NN scores_NNS confirmed_VVD that_CST the_DD residents_NNS achieved_VVD the_DD desired_VVNJ learning_VVGJ objectives_NNS ._.
P12116690A17
Two_MC novel_JJ serotonin_NN agonists_NNS are_VBB currently_RR under_II development_NN for_II constipated_VVNJ IBS_NN patients_NNS ,_, tegaserod_NN and_CC prucalopride_NN ._.
P12117354A07
These_DD criteria_NNS were_VBD applied_VVN in_II a_DD blinded_VVNJ fashion_NN by_II 2_MC independent_JJ investigators_NNS ._.
P12120485A12
Training_VVGN and_CC preparation_NN for_II contingencies_NNS experienced_VVN in_II an_DD attack_NN have_VHB the_DD potential_JJ to_TO enhance_VVI delivery_NN of_II care_NN ._.
P12130935A04
Resolution_NN of_II nosocomial_JJ pneumonia_NN ,_, in_II terms_NNS of_II improvement_NN of_II clinical_JJ parameters_NNS such_II+ as_II oxygenation_NN ,_, fever_NN ,_, leukocytosis_NN and_CC bacterial_JJ eradication_NN ,_, has_VHZ been_VBN reported_VVN ,_, and_CC these_DD data_NNS can_VM lead_VVB to_II a_DD better_JJR understanding_VVGN of_II the_DD natural_JJ course_NN of_II the_DD disease_NN ._.
P12133028A07
Bradykinin_NN ,_, a_DD potent_JJ vasodilator_NN ,_, acts_VVZ by_II stimulating_VVGN formation_NN of_II vasodilatory_JJ prostaglandins_NNS such_II+ as_II prostacyclin_NN ,_, whereas_CS aspirin_NN or_CC acetyl_NN salicylic_JJ acid_NN inhibits_VVZ the_DD enzyme_NN cyclooxygenase_NN ,_, which_PNR in_II turn_NN decreases_VVZ the_DD production_NN of_II the_DD prostaglandins_NNS ._.
P12137445A06
Reasons_NNS for_II the_DD underuse_NN may_VM include_VVB physicians_NNS '_GE and_CC patients_NNS '_GE attitudes_NNS and_CC knowledge_NN ,_, and_CC the_DD perceptions_NNS of_II physicians_NNS and_CC healthcare_NN purchasers_NNS about_II economic_JJ factors_NNS ._.
P12137608A07
References_NNS of_II all_DD identified_VVNJ studies_NNS were_VBD searched_VVN for_II further_JJ trial_NN citations_NNS ._.
P12137612A21
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: There_EX is_VBZ insufficient_JJ evidence_NN available_JJ from_II randomised_VVNJ controlled_VVNJ trials_NNS to_TO determine_VVI the_DD relative_JJ effectiveness_NN of_II surgical_JJ and_CC conservative_JJ treatment_NN for_II acute_JJ injuries_NNS of_II the_DD lateral_JJ ligament_NN complex_NN of_II the_DD ankle_NN ._.
P12137619A12
They_PN may_VM also_RR result_VVB in_II a_DD greater_JJR improvement_NN in_II long_JJ term_NN outcomes_NNS such_II+ as_II menstrual_JJ loss_NN and_CC dysmenorrhoea_NN ._.
P12137624A05
Though_CS both_DD methods_NNS are_VBB widely_RR used_VVN ,_, the_DD advantages_NNS and_CC disadvantages_NNS of_II laparoscopic_JJ sterilisation_NN compared_VVN to_II mini-laparotomy_NN have_VHB not_RR been_VBN systematically_RR evaluated_VVN ._.
P12137627A10
MAIN_JJ RESULTS_NNS :_: The_DD timing_VVGN of_II support_NN :_: early_JJ versus_CC delayed_VVNJ Of_II the_DD seven_MC trials_NNS addressing_VVG the_DD timing_VVGN of_II support_NN ,_, data_NNS on_II mortality_NN were_VBD obtained_VVN for_II all_DD seven_MC trials_NNS (_( 284_MC participants_NNS )_) ._.
P12137632A39
Longer-term_NN use_NN of_II galantamine_NN has_VHZ not_RR been_VBN assessed_VVN in_II a_DD controlled_VVNJ fashion_NN ._.
P12137636A29
Such_DD education_NN may_VM be_VBB effective_JJ in_II increasing_VVGN the_DD short-term_NN use_NN of_II contraception_NN ._.
P12137642A07
Control_NN could_VM include_VVB an_DD opiate_JJ ,_, sedative_NN or_CC non-pharmacological_JJ treatment_NN ._.
P12137653A09
Random_JJ effects_NNS meta-analyses_NNS were_VBD performed_VVN where_CS data_NNS could_VM be_VBB pooled_VVN ._.
P12137656A17
There_EX were_VBD no_DD differences_NNS between_II ACDR_NN CPR_NN and_CC STR_NN for_II mortality_NN either_CC immediately_RR (_( RR_NN 0.98_MC [_( 95_MC %_SYM CI_NN 0.94_MC -_SYM 1.03_MC ]_) )_) or_CC at_II hospital_NN discharge_NN (_( RR_NN 0.99_MC [_( 95_MC %_SYM CI_NN 0.98_MC -_SYM 1.01_MC ]_) )_) ._.
P12137667A15
Exercise_NN capacity_NN improved_VVD in_II patients_NNS treated_VVN with_II intravenous_JJ epoprostenol_NN (_( Standardised_VVNJ Mean_NN Difference_NN )_) 0.69_MC ,_, 95_MC %_SYM Confidence_NN Intervals_NNS (_( CI_NN )_) 0.40_MC ,_, 0.97_MC ._.
P12137675A18
There_EX was_VBD an_DD effect_NN on_II some_DD verbal_JJ memory_NN functions_NNS (_( immediate_JJ recall_NN )_) ,_, on_II a_DD test_NN of_II abstract_JJ reasoning_VVGN and_CC a_DD test_NN of_II speed_NN and_CC accuracy_NN in_II relatively_RR young_JJ (_( 47_MC years_NNS of_II age_NN )_) surgically_RR menopausal_JJ women_NNS who_PNR had_VHD been_VBN given_VVN a_DD bolus_NN intramuscular_JJ injection_NN of_II 10_MC mg_NN E2_NN every_DD month_NN for_II 3_MC months_NNS ._.
P12137681A08
Studies_NNS reported_VVD mainly_RR goitre_NN rates_NNS and_CC urinary_JJ iodine_NN excretion_NN as_II outcome_NN measures_NNS ._.
P12137687A22
The_DD protocols_NNS of_II two_MC of_II the_DD studies_NNS mandated_VVD the_DD use_NN of_II early_JJ exchange_NN transfusion_NN ,_, limiting_VVG the_DD generalizability_NN of_II the_DD results_NNS ._.
P12137691A05
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD MEDLINE_NN ,_, Embase_NN ,_, Amed_NN ,_, Cinahl_NN ,_, CISCOM_NN and_CC the_DD Cochrane_NNP Controlled_VVNJ Trial_NN Register_NN ._.
P12137696A15
Seven_MC infants_NNS only_RR were_VBD randomised_VVN to_II treatment_NN with_II dopamine_NN and_CC seven_MC to_TO receive_VVI placebo_NN ._.
P12137705A05
The_DD manufacturers_NNS of_II rofecoxib_NN ,_, MSD_NN ,_, were_VBD also_RR approached_VVN by_II the_DD UK_NNP National_JJ Institute_NN for_II Clinical_JJ Excellence_NN to_TO submit_VVI additional_JJ evidence_NN to_TO inform_VVI it_PN 's_GE appraisal_NN on_II the_DD use_NN of_II cyclo-oxygenase_NN inhibitors_NNS for_II arthritis_NN ._.
P12137712A13
Continuous_JJ data_NNS were_VBD pooled_VVN using_VVG weighted_VVNJ mean_NN differences_NNS and_CC dichotomous_JJ data_NNS using_VVG relative_JJ risks_NNS ._.
P12137716A05
Additional_JJ RCTs_NNS were_VBD identified_VVN from_II the_DD Cochrane_NNP Airways_NNS Group_NN 's_GE registry_NN of_II COPD_NN RCTs_NNS using_VVG the_DD strategy_NN :_: [_( exp_NN ,_, lung_NN diseases_NNS ,_, obstructive_JJ ]_) and_CC [_( exp_NN ,_, rehabilitation_NN or_CC exp_NN ,_, exercise_NN therapy_NN ]_) and_CC [_( research_NN design_NN or_CC longitudinal_JJ studies_NNS or_CC evaluation_NN study_NN or_CC randomized_VVNJ controlled_VVNJ trial_NN ]_) ._.
P12140910A02
The_DD advanced_VVNJ practice_NN nursing_VVGJ model_NN at_II Mount_NN Sinai_NN Hospital_NN is_VBZ one_MC successful_JJ care_NN delivery_NN model_NN that_PNR fills_VVZ the_DD needs_NNS of_II both_CC CCI_NN patients_NNS and_CC the_DD nurses_NNS who_PNR work_VVB with_II them_PN ._.
P12149041A08
In_II primary_JJ prevention_NN ,_, the_DD data_NNS are_VBB not_RR as_RR convincing_VVG and_CC generalisations_NNS can_VM not_RR be_VBB made_VVN as_II+ to_II whether_CST ,_, and_CC in_II which_DD subgroup_NN ,_, drug_NN therapy_NN to_TO lower_VVI low_JJ density_NN lipoprotein_NN (_( LDL_NN )_) cholesterol_NN should_VM be_VBB initiated_VVN ._.
P12150693A03
In_II both_CC ST-segment_NN elevation_NN and_CC non-ST-segment_NN elevation_NN MI_NN ,_, aspirin_NN /_SYM clopidogrel_NN ,_, heparin_NN /_SYM low_JJ molecular_JJ weight_NN heparin_NN /_SYM direct_JJ thrombin_NN inhibitors_NNS ,_, beta-blockers_NNS and_CC angiotensin_NN converting_VVGJ enzyme_NN inhibitors_NNS are_VBB part_NN of_II the_DD routine_JJ regimens_NNS ._.
P12164804A07
For_II both_DD subsets_NNS ,_, protein_NN A_NN immunoadsorption_NN is_VBZ reportedly_RR successful_JJ ._.
P12169077A13
Publication_NN bias_NN was_VBD examined_VVN using_VVG Begg_NNP modified_VVNJ funnel_NN plots_NNS and_CC formally_RR tested_VVN using_VVG the_DD Egger_NNP weighted-linear_JJ regression_NN method_NN ._.
P12175274A06
A_DD booster_NN dose_NN of_II PNCRM7_NN elicited_VVD an_DD anamnestic_JJ response_NN to_II all_DD seven_MC serotypes_NNS ._.
P12187868A06
Amiodarone_NN has_VHZ been_VBN evaluated_VVN in_II numerous_JJ clinical_JJ trials_NNS in_II patients_NNS with_II heart_NN failure_NN and_CC appears_VVZ to_TO be_VBI safe_JJ and_CC effective_JJ in_II terms_NNS of_II conversion_NN to_II sinus_NN rhythm_NN ,_, maintenance_NN of_II sinus_NN rhythm_NN as_CC+ well_CC+ as_CC control_NN of_II ventricular_JJ rate_NN ._.
P12192737A25
Dietary_JJ surveys_NNS carried_VVN out_II in_II the_DD US_NNP population_NN indicate_VVB that_CST less_RR than_CSN 12_MC percent_NN of_II US_NNP children_NNS and_CC adults_NNS meet_VVB this_DD recommended_VVNJ level_NN of_II intake_NN (_( 104_MC )_) ._.
P12196062A06
The_DD prognosis_NN is_VBZ poor_JJ ,_, with_II a_DD mean_NN survival_NN time_NN of_II 2.8_MC years_NNS after_II diagnosis_NN if_CS untreated_VVN ._.
P12196870A35
(_( III-C_NN )_) Part_NN II_MC :_: New_JJ Technologies_NNS for_II Fetal_JJ Surveillance_NN in_II Labour_NN ._.
P12196882A23
The_DD clinician_NN is_VBZ advised_VVN to_TO examine_VVI the_DD breast_NN in_II the_DD postpartum_NN period_NN if_CS the_DD woman_NN is_VBZ not_RR breastfeeding_VVG ._.
P12197448A10
Further_RR randomized_VVNJ controlled_VVNJ trials_NNS with_II larger_JJR sample_NN sizes_NNS are_VBB required_VVN to_TO demonstrate_VVI the_DD efficacy_NN of_II a_DD combination_NN antidepressant_NN strategy_NN for_II patients_NNS with_II treatment-resistant_JJ depression_NN ._.
P12202465A08
Individual_JJ studies_NNS showed_VVD similar_JJ results_NNS ,_, reflected_VVN in_II the_DD P_NN values_NNS of_II the_DD test_NN of_II heterogeneity_NN (_( P_NN =_SYM 0.99_MC for_II vertebral_JJ and_CC 0.88_MC for_II nonvertebral_JJ fractures_NNS )_) ._.
P12202471A10
At_II the_DD lumbar_JJ spine_NN and_CC forearm_NN sites_NNS ,_, hydroxylated_VVNJ vitamin_NN D_NN doses_NNS above_II 50_MC microg_NN yield_VVB larger_JJR effects_NNS than_CSN lower_JJR doses_NNS ._.
P12207806A12
In_II most_DD populations_NNS studied_VVN ,_, 60_MC %_SYM of_II people_NNS who_PNR develop_VVB diabetes_NN have_VHB either_CC IGT_NN or_CC IFG_NN 5_MC years_NNS or_CC so_RR before_RR ,_, with_II the_DD other_JJ 40_MC %_SYM having_VVGN normal_JJ glucose_NN tolerance_NN at_II that_DD time_NN ._.
P12215733A08
Beta-blockers_NNS have_VHB been_VBN shown_VVN to_TO significantly_RR reduce_VVI sudden_JJ death_NN as_CC+ well_CC+ as_CC total_JJ mortality_NN ,_, while_CS the_DD effects_NNS of_II amiodarone_NN have_VHB been_VBN less_RR decisive_JJ ._.
P12222079A20
Strategies_NNS need_VVB to_TO be_VBI developed_VVN and_CC tested_VVN to_TO enhance_VVI motivation_NN and_CC to_TO target_VVI treatment_NN efforts_NNS at_II those_DD youth_NN who_PNR are_VBB most_RRT likely_RR to_TO benefit_VVI from_II services_NNS ._.
P12227125A09
One_MC study_NN involving_VVG high-risk_NN patients_NNS reported_VVD a_DD reduction_NN in_II ulcer_NN incidence_NN (_( OR_NN 0.28_MC ,_, 95_MC %_SYM confidence_NN interval_NN [_( CI_NN ]_) 0.13-0.59_MC )_) and_CC amputation_NN rate_NN (_( OR_NN 0.32_MC ,_, 95_MC %_SYM CI_NN 0.14-0.71_MC )_) after_II 1_MC year_NN ._.
P12229053A10
To_TO prepare_VVI for_II this_DD "_`` certainty_NN ,_, "_'' radiology_NN departments_NNS must_VM answer_VVB many_DD questions_NNS ._.
P12235735A03
Diabetic_JJ individuals_NNS with_II hypertension_NN have_VHB a_DD greater_JJR risk_NN of_II macrovascular_JJ and_CC microvascular_JJ disease_NN than_CSN normotensive_JJ diabetic_JJ individuals_NNS ._.
P12241126A10
However_RR ,_, all_PND have_VHB potential_JJ serious_JJ adverse_JJ events_NNS ._.
P12269960A10
The_DD mechanism_NN of_II any_DD anti-dyspeptic_JJ action_NN is_VBZ difficult_JJ to_TO define_VVI ,_, as_CS the_DD causes_NNS of_II non-ulcer_NN dyspepsia_NN are_VBB unclear_JJ ._.
P12350192A04
DATA_NNS SOURCES_NNS :_: Relevant_JJ articles_NNS were_VBD identified_VVN through_II searches_NNS of_II the_DD Cochrane_NNP Library_NN ,_, MEDLINE_NN ,_, and_CC EMBASE_NN (_( 1984-2001_MC )_) ,_, manual_JJ searches_NNS of_II bibliographies_NNS of_II known_VVNJ primary_JJ and_CC review_NN articles_NNS ,_, and_CC contact_NN with_II manufacturers_NNS ._.
P12354487A08
Combined_VVNJ oestrogen_NN /_SYM progestagen_NN HRT_NN was_VBD used_VVN in_II three_MC trials_NNS and_CC oestrogen_NN alone_JJ in_II one_MC ._.
P12360366A10
The_DD accrual_JJ of_II breast_NN cancer_NN cases_NNS appearing_VVG during_II the_DD fourth_JJ year_NN of_II observation_NN is_VBZ similar_JJ to_II that_PND found_VVN in_II previous_JJ studies_NNS ,_, and_CC remains_VVZ inferior_JJ to_II the_DD increases_NNS related_VVN to_II lifestyle_NN factors_NNS reported_VVN in_II other_JJ studies_NNS ._.
P12369881A02
The_DD potential_NN of_II this_DD drug_NN class_NN has_VHZ yet_RR to_TO be_VBI fully_RR explored_VVN ._.
P12371014A09
Electrophysiologic_JJ studies_NNS performed_VVN during_II the_DD antiarrhythmic_JJ surgical_JJ procedure_NN can_VM not_RR provide_VVB complete_JJ information_NN ,_, and_CC their_PNG use_NN is_VBZ thus_RR restricted_VVN to_II the_DD arrhythmogenic_JJ myocardial_JJ target_NN only_RR [_( 32_MC ,_, 45_MC ]_) ._.
P12381215A07
Antihypertensive_JJ agents_NNS have_VHB been_VBN extensively_RR studied_VVN in_II the_DD primary_JJ prevention_NN of_II stroke_NN ;_: however_RR ,_, relatively_RR few_JJ trials_NNS of_II antihypertensive_JJ agents_NNS in_II the_DD secondary_JJ prevention_NN of_II stroke_NN are_VBB available_JJ ._.
P12383060A08
Out_II+ of_II 76_MC eligible_JJ clinical_JJ trials_NNS ,_, 53_MC (_( 12_MC not_RR yet_RR published_VVN )_) involving_VVG 24089_MC patients_NNS met_VVD the_DD criteria_NNS for_II inclusion_NN ._.
P12386751A21
Catheter-directed_VVNJ thrombolysis_NN is_VBZ known_VVN to_TO improve_VVI lysis_NN rates_NNS ._.
P12390557A06
The_DD dyslipidemia_NN may_VM be_VBB associated_VVN with_II lipodystrophy_NN ,_, insulin_NN resistance_NN ,_, and_CC ,_, rarely_RR ,_, frank_JJ diabetes_NN mellitus_NN ._.
P12391943A10
Cost-effectiveness_NN base_NN case_NN estimates_NNS ranged_VVD from_II 2,415_MC Pounds_NNS savings_NNS to_II 49,476_MC Pounds_NNS additional_JJ cost_NN (_( 1997_MC prices_NNS )_) per_II unit_NN of_II effect_NN for_II donepezil_NN and_CC a_DD small_JJ savings_NNS for_II rivastigmine_NN ._.
P12398573A02
DATA_NNS SOURCES_NNS :_: A_DD MEDLINE_NN search_NN (_( 1966-September_NN 2001_MC )_) was_VBD conducted_VVN using_VVG the_DD following_VVGJ terms_NNS :_: pravastatin_NN ,_, lovastatin_NN ,_, simvastatin_NN ,_, atorvastatin_NN ,_, cerivastatin_NN ,_, fluvastatin_NN ,_, statins_NNS ,_, hydroxymethylglutaryl_NN coenzyme_NN A_NN reductase_NN inhibitor_NN ,_, acute_JJ coronary_JJ syndromes_NNS ,_, unstable_JJ angina_NN ,_, and_CC myocardial_JJ infarction_NN ._.
P12406054A04
Cigarette_NN smoking_VVGN appears_VVZ to_TO be_VBI the_DD most_RRT significant_JJ environmental_JJ risk_NN factor_NN ._.
P12407856A06
We_PN believe_VVB that_CST several_JJ aspects_NNS of_II the_DD new_JJ definition_NN need_VVB to_TO be_VBI discussed_VVN before_CS the_DD new_JJ criteria_NNS for_II MI_NN are_VBB used_VVN in_II clinical_JJ practice_NN in_II Italy_NNP ._.
P12408744A39
In_II November_NN 2001_MC ,_, Genentech_NN and_CC Novartis_NN stated_VVD that_CST an_DD amended_VVNJ BLA_NN would_VM be_VBB submitted_VVN to_II the_DD FDA_NN in_II the_DD fourth_JJ quarter_NN of_II 2002_MC ._.
P12411873A05
Radionuclide_NN imaging_VVGJ techniques_NNS appear_VVB to_TO be_VBI appropriate_JJ in_II risk_NN assessment_NN ,_, prognosis_NN and_CC evaluation_NN of_II therapy_NN in_II patients_NNS after_II acute_JJ myocardial_JJ infarction_NN ._.
P12415021A14
Increasing_VVG the_DD rate_NN of_II follow-up_NN to_II diagnostic_JJ evaluation_NN from_II the_DD base-case_NN estimate_NN of_II 77_MC %_SYM to_II 100_MC %_SYM decreased_VVD the_DD incremental_JJ cost_NN of_II UNHS_NN to_II $_SYM 38000_MC per_II additional_JJ infant_NN whose_PNR deafness_NN was_VBD diagnosed_VVN by_II 6_MC months_NNS ._.
P12419477A03
The_DD update_NN was_VBD made_VVN possible_JJ by_II a_DD series_NN of_II large_JJ ,_, cholesterol-lowering_VVGJ clinical_JJ trials_NNS ._.
P12424170A02
To_TO assess_VVI whether_CST results_NNS obtained_VVN in_II secondary_JJ care_NN can_VM be_VBB extrapolated_VVN to_II primary_JJ care_NN and_CC suggest_VVI how_CST future_JJ trials_NNS should_VM be_VBB designed_VVN to_TO provide_VVI more_RR rigorous_JJ evidence_NN ._.
P12428993A13
In_II elderly_JJ patients_NNS (_( arbitrarily_RR defined_VVN as_II aged_VVNJ >_SYM 75_MC years_NNS )_) ,_, the_DD management_NN of_II atrial_JJ fibrillation_NN varies_VVZ ;_: it_PN requires_VVZ an_DD individual_JJ approach_NN ,_, which_PNR largely_RR depends_VVZ on_II comorbid_JJ conditions_NNS ,_, underlying_VVG cardiac_JJ disease_NN ,_, and_CC patient_NN and_CC physician_NN preferences_NNS ._.
P12431942A12
Generalist_NN and_CC specialist_NN pediatricians_NNS prepared_VVD clinical_JJ cases_NNS ._.
P12434275A04
With_II the_DD exception_NN of_II allogeneic_JJ stem_NN cell_NN transplantation_NN ,_, no_DD treatment_NN modality_NN has_VHZ been_VBN proven_VVN to_TO be_VBI of_II benefit_NN over_II supportive_JJ care_NN ._.
P12435257A04
PATIENTS_NNS :_: A_DD total_NN of_II 4052_MC patients_NNS with_II AF_NN randomly_RR assigned_VVN to_TO receive_VVI therapeutic_JJ doses_NNS of_II oral_JJ anticoagulant_NN or_CC aspirin_NN with_II or_CC without_II low-dose_NN oral_JJ anticoagulants_NNS ._.
P12436944A03
These_DD numbers_NNS will_VM continue_VVB to_TO climb_VVI ,_, internationally_RR ,_, since_CS the_DD leading_VVGJ associated_VVNJ risk_NN for_II diabetes_NN development_NN ,_, obesity_NN ,_, has_VHZ reached_VVN epidemic_JJ proportions_NNS ,_, globally_RR ._.
P12440233A08
The_DD low_JJ density_NN lipoprotein_NN target_NN of_II <_SYM 100_MC mg_NN was_VBD present_JJ in_II only_RR 22_MC %_SYM of_II patients_NNS before_II enrollment_NN ,_, with_II improvement_NN of_II up_RR+ to_RR 57_MC %_SYM after_II the_DD follow-up_NN period_NN ._.
P12447156A02
Despite_II the_DD compelling_VVGJ scientific_JJ evidence_NN that_CST beta-blockers_NNS reduce_VVB hospitalizations_NNS and_CC mortality_NN in_II patients_NNS with_II heart_NN failure_NN ,_, this_DD lifesaving_VVGJ therapy_NN continues_VVZ to_TO be_VBI underutilized_VVN ._.
P12457213A12
For_II ulcer_NN bleedings_NNS ,_, endoscopic_JJ treatment_NN is_VBZ the_DD established_VVNJ first_JJ choice_NN ._.
P12472045A01
Stroke_NN is_VBZ the_DD leading_VVGJ cause_NN of_II serious_JJ long-term_NN disability_NN in_II the_DD United_VVNJ States_NNS ._.
P12479763A02
OBJECTIVE_NN :_: To_TO determine_VVI whether_CST treatment_NN with_II a_DD calcium_NN channel_NN blocker_NN or_CC an_DD angiotensin-converting_VVGJ enzyme_NN inhibitor_NN lowers_VVZ the_DD incidence_NN of_II coronary_JJ heart_NN disease_NN (_( CHD_NN )_) or_CC other_JJ cardiovascular_JJ disease_NN (_( CVD_NN )_) events_NNS vs_CC treatment_NN with_II a_DD diuretic_NN ._.
P12485545A12
We_PN describe_VVB a_DD classification_NN derived_VVN from_II these_DD studies_NNS that_PNR is_VBZ based_VVN on_II the_DD actual_JJ practice_NN of_II primary_JJ care_NN and_CC provides_VVZ a_DD starting_VVGJ point_NN for_II future_JJ epidemiologic_JJ and_CC interventional_JJ research_NN ._.
P12489289A11
Immunofluorescence_NN assays_NNS have_VHB been_VBN well_RR characterized_VVN and_CC validated_VVN in_II clinical_JJ trials_NNS ,_, however_RR they_PN are_VBB not_RR universally_RR available_JJ ._.
P12495903A14
Specific_JJ recommendations_NNS for_II supportive_JJ therapy_NN ,_, including_VVG iron_NN chelation_NN ,_, were_VBD issued_VVN ._.
P12501499A17
Eleven_MC published_VVNJ trials_NNS investigating_VVG the_DD effect_NN of_II diets_NNS in_II ulcerative_JJ colitis_NN show_VVB only_RR for_II elimination_NN diet_NN a_DD positive_JJ treatment_NN effect_NN ._.
P12505250A01
Little_JJ information_NN exists_VVZ to_TO quantify_VVI the_DD functional_JJ status_NN and_CC economic_JJ consequences_NNS of_II lipid-lowering_VVGJ therapy_NN in_II elderly_JJ patients_NNS ._.
P12507182A04
Evidence_NN based_VVNJ medicine_NN is_VBZ designed_VVN to_TO discover_VVI the_DD best_JJT evidence_NN available_JJ and_CC apply_VVI it_PN in_II daily_JJ practice_NN for_II treatment_NN of_II the_DD individual_JJ patient_NN ._.
P12512406A14
Although_CS a_DD complete_JJ tendon_NN rupture_NN with_II loading_VVGN after_II steroid_NN injection_NN has_VHZ been_VBN reported_VVN ,_, no_DD reliable_JJ proof_NN exists_VVZ of_II the_DD deleterious_JJ effects_NNS of_II peritendinous_JJ injections_NNS ;_: conclusions_NNS in_II literature_NN are_VBB based_VVN mainly_RR on_II uncontrolled_VVNJ case_NN reports_NNS that_PNR fail_VVB under_II scientific_JJ scrutiny_NN ,_, whereas_CS scientifically_RR rigorous_JJ studies_NNS have_VHB not_RR been_VBN performed_VVN ._.
P12513114A11
Most_RRT successful_JJ management_NN strategies_NNS combine_VVB pharmacological_JJ and_CC nonpharmacological_JJ (_( home_NN remedies_NNS ,_, massage_NN ,_, topical_JJ agents_NNS ,_, heat_NN and_CC cold_NN packs_NNS and_CC informal_JJ cognitive_JJ strategies_NNS )_) therapies_NNS ._.
P12518268A07
Patients_NNS should_VM be_VBB informed_VVN of_II these_DD side_NN effects_NNS in_II order_NN to_TO prevent_VVI excessive_JJ BWG_NN ,_, and_CC their_PNG blood_NN glucose_NN and_CC lipids_NNS should_VM be_VBB monitored_VVN before_II treatment_NN and_CC then_RR at_II regular_JJ intervals_NNS ._.
P12519539A02
Its_PNG pathogenesis_NN has_VHZ not_RR been_VBN elucidated_VVN yet_RR ,_, but_CC may_VM be_VBB related_VVN to_II vasospasm_NN ._.
P12519543A10
Participants_NNS '_GE ages_NNS ranged_VVD from_II 40_MC to_II 85_MC ,_, and_CC both_DD sexes_NNS were_VBD equally_RR represented_VVN ._.
P12519548A02
Manual_JJ therapy_NN practitioners_NNS are_VBB also_RR varied_VVN ,_, including_VVG physiotherapists_NNS ,_, respiratory_JJ therapists_NNS ,_, chiropractic_JJ and_CC osteopathic_JJ physicians_NNS ._.
P12519554A08
Where_CS insufficient_JJ data_NNS were_VBD presented_VVN original_JJ authors_NNS were_VBD contacted_VVN for_II further_JJ details_NNS ._.
P12519563A05
SEARCH_NN STRATEGY_NN :_: Searches_NNS were_VBD conducted_VVN in_II January_NN 2002_MC ._.
P12519569A03
SEARCH_NN STRATEGY_NN :_: We_PN searched_VVD the_DD following_VVGJ databases_NNS up_II+ to_II 2001_MC ,_, inclusive_JJ :_: Cochrane_NNP Drugs_NNS and_CC Alcohol_NN Review_NN Group_NN Register_NN ,_, the_DD Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN ,_, MEDLINE_NN ,_, EMBASE_NN ,_, Current_JJ Contents_NNS ,_, Psychlit_NN ,_, CORK_NN [_( www._NN state.vt.su_NN /_SYM adap_NN /_SYM cork_NN ]_) ,_, Alcohol_NN and_CC Drug_NN Council_NN of_II Australia_NNP (_( ADCA_NN )_) [_( www.adca.org.au_NN ]_) ,_, Australian_JJ Drug_NN Foundation_NN (_( ADF_NN -VIC_NN )_) [_( www.adf.org.au_NN ]_) ,_, Centre_NN for_II Education_NN and_CC Information_NN on_II Drugs_NNS and_CC Alcohol_NN (_( CEIDA_NN )_) [_( www.ceida.net.au_NN ]_) ,_, Australian_JJ Bibliographic_JJ Network_NN (_( ABN_NN )_) ,_, and_CC Library_NN of_II Congress_NN databases_NNS ,_, available_JJ NIDA_NN monographs_NNS and_CC the_DD College_NN on_II Problems_NNS of_II Drug_NN Dependence_NN Inc_NN ._.
P12519576A10
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: The_DD methodological_JJ quality_NN of_II the_DD studies_NNS was_VBD assessed_VVN using_VVG criteria_NNS for_II blinding_VVGN of_II randomization_NN ,_, blinding_VVGN of_II intervention_NN ,_, completeness_NN of_II follow-up_NN and_CC blinding_VVGN of_II outcome_NN assessment_NN ._.
P12519586A08
SELECTION_NN CRITERIA_NNS :_: All_DD relevant_JJ ,_, unconfounded_VVNJ ,_, randomized_VVNJ ,_, double-blind_JJ controlled_VVNJ studies_NNS ,_, in_II which_PNR extracts_NNS of_II Ginkgo_NN biloba_NN at_II any_DD strength_NN and_CC over_II any_DD period_NN were_VBD compared_VVN with_II placebo_NN for_II their_PNG effects_NNS on_II people_NNS with_II acquired_VVNJ cognitive_JJ impairment_NN ,_, including_VVG dementia_NN ,_, of_II any_DD degree_NN of_II severity_NN ._.
P12519590A06
All_DD searches_NNS were_VBD performed_VVN during_II April_NN and_CC May_NN 2001_MC ._.
P12519597A01
BACKGROUND_NN :_: Sickle_JJ cell_NN disease_NN is_VBZ an_DD inherited_VVNJ disorder_NN of_II haemoglobin_NN ,_, which_PNR results_VVZ in_II abnormal_JJ red_JJ blood_NN cells_NNS ._.
P12519607A02
Research_NN suggests_VVZ that_CST parenting_VVGN has_VHZ an_DD important_JJ role_NN to_TO play_VVI in_II helping_VVGN children_NNS to_TO become_VVI well_RR adjusted_VVNJ adults_NNS ,_, and_CC that_CST the_DD first_JJ few_JJ months_NNS and_CC years_NNS of_II a_DD child_NN 's_GE life_NN are_VBB especially_RR important_JJ in_II establishing_VVGN patterns_NNS of_II emotional_JJ ,_, cognitive_JJ and_CC social_JJ functioning_VVGN which_PNR will_VM in_II turn_NN influence_VVB the_DD child_NN 's_GE future_JJ development_NN and_CC in_II particular_NN ,_, their_PNG mental_JJ health_NN ._.
P12519612A02
Tap_NN water_NN is_VBZ commonly_RR used_VVN in_II the_DD community_NN for_II cleansing_VVGN wounds_NNS because_CS it_PN is_VBZ easily_RR accessible_JJ ,_, efficient_JJ and_CC cost_NN effective_JJ ,_, however_RR ,_, there_EX is_VBZ an_DD unresolved_VVNJ debate_NN about_II its_PNG use_NN ._.
P12519615A14
The_DD differences_NNS were_VBD similar_JJ among_II the_DD studies_NNS and_CC when_CS combined_VVN :_: Weighted_VVNJ Mean_NN Difference_NN (_( WMD_NN )_) 0.0_MC liters_NNS (_( 95_MC %_SYM Confidence_NN Interval_NN (_( 95_MC %_SYM CI_NN )_) -0.19_MC ,_, 0.19_MC )_) ._.
P12519624A01
BACKGROUND_NN :_: Immunization_NN rates_NNS for_II children_NNS and_CC adults_NNS are_VBB rising_VVG ,_, but_CC coverage_NN levels_NNS have_VHB not_RR reached_VVN national_JJ goals_NNS ._.
P12520824A10
Early_JJ and_CC sustained_VVNJ antiplatelet_NN use_NN after_II atherothrombotic_JJ stroke_NN reduces_VVZ stroke_NN recurrence_NN ._.
P12527564A07
There_EX is_VBZ a_DD great_JJ deal_NN of_II evidence_NN about_II a_DD wide_JJ variety_NN of_II clinician-based_VVNJ and_CC community-based_VVNJ efforts_NNS at_II smoking_VVGJ avoidance_NN or_CC cessation_NN ._.
P12530498A03
We_PN sought_VVD the_DD opinion_NN of_II pediatric_JJ cardiologists_NNS practicing_VVG in_II U.S._NNP fellowship_NN programs_NNS on_II the_DD subject_NN by_II means_NNS of_II a_DD multiple-choice_NN survey_NN ._.
P12534856A05
It_PN is_VBZ one_MC of_II the_DD causes_NNS of_II frequent_JJ hospital_NN readmissions_NNS ,_, reflecting_VVG acute_JJ decompensation_NN and_CC compromised_VVNJ quality_NN of_II life_NN for_II patients_NNS and_CC increased_VVNJ cost_NN and_CC resource_NN use_NN for_II the_DD healthcare_NN system_NN ._.
P12535389A09
The_DD second_JJ author_NN assessed_VVD the_DD quality_NN of_II trials_NNS and_CC extracted_VVD data_NNS independently_RR ._.
P12535396A12
MAIN_JJ RESULTS_NNS :_: There_EX are_VBB 17_MC included_VVNJ trials_NNS ._.
P12535398A26
The_DD apparent_JJ increase_NN in_II uterine_JJ hyperstimulation_NN is_VBZ of_II concern_NN ._.
P12535405A10
We_PN reviewed_VVD studies_NNS in_II scope_NN for_II criteria_NNS of_II outcome_NN relevance_NN (_( measurement_NN of_II at_RR+ least_RR one_MC of_II a_DD list_NN of_II behavioral_JJ or_CC biologic_JJ outcomes_NNS ,_, e.g._II ,_, unprotected_VVNJ sex_NN or_CC incidence_NN of_II HIV_NN infections_NNS )_) and_CC methodologic_JJ rigor_NN (_( randomized_VVNJ controlled_VVNJ trials_NNS or_CC certain_JJ strong_JJ quasi-experimental_JJ designs_NNS with_II comparison_NN groups_NNS )_) ._.
P12535410A01
BACKGROUND_NN :_: In_II nephrotic_JJ syndrome_NN protein_NN leaks_VVZ from_II the_DD blood_NN to_II the_DD urine_NN through_II the_DD glomeruli_NNS resulting_VVG in_II hypoproteinaemia_NN and_CC generalised_VVNJ oedema_NN ._.
P12535413A33
The_DD data_NN suggests_VVZ less_DD persisting_VVGJ pain_NN and_CC numbness_NN following_VVG laparoscopic_JJ repair_NN ._.
P12535419A16
There_EX was_VBD no_DD evidence_NN from_II these_DD studies_NNS that_CST this_DD increase_NN in_II uptake_NN of_II tests_NNS was_VBD related_VVN to_II informed_VVNJ decision_NN making_VVGN by_II consumers_NNS ._.
P12535424A21
In_II addition_NN ,_, meta-analysis_NN of_II available_JJ data_NNS from_II two_MC studies_NNS (_( Jacqz-Aigrain_NNP 1994_MC ,_, Anand_NNP 1999_MC )_) showed_VVD a_DD statistically_RR significantly_RR longer_JJR duration_NN of_II NICU_NN stay_NN in_II the_DD midazolam_NN group_NN compared_VVN to_II the_DD placebo_NN group_NN (_( WMD_NN 5.4_MC days_NNS ,_, 95_MC %_SYM CI_NN 0.4_MC ,_, 10.5_MC )_) ._.
P12535427A22
Both_PND of_II these_PND were_VBD conducted_VVN under_II open_JJ conditions_NNS and_CC had_VHD serious_JJ methodological_JJ problems_NNS ._.
P12535430A20
New_JJ Trials_NNS with_II longer_JJR follow_NN+ up_NN are_VBB required_VVN ._.
P12535436A20
There_EX was_VBD no_DD evidence_NN of_II any_DD publication_NN bias_NN ._.
P12535440A09
Types_NNS of_II outcome_NN measures_NNS :_: Primary_JJ :_: improvement_NN in_II the_DD Neuropathy_NN Disability_NN Score_NN or_CC Modified_VVNJ Rankin_NNP Scale_NN six_MC months_NNS after_II randomisation_NN Secondary_JJ :_: Neuropathy_NN Disability_NN Score_NN and/or_CC the_DD Modified_VVNJ Rankin_NNP Score_NN 12_MC months_NNS after_II randomisation_NN ._.
P12535443A21
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: The_DD evidence_NN available_JJ indicates_VVZ that_CST Open_JJ retropubic_JJ colposuspension_NN is_VBZ the_DD most_RRT effective_JJ treatment_NN modality_NN for_II stress_NN urinary_JJ incontinence_NN especially_RR in_II the_DD long_JJ term_NN ._.
P12535453A05
Such_DB an_DD approach_NN is_VBZ not_RR ,_, however_RR ,_, without_II cost_NN and_CC the_DD actual_JJ benefit_NN of_II the_DD adoption_NN of_II routine_JJ outcome_NN and_CC needs_NNS assessment_NN in_II the_DD day-to-day_NN care_NN of_II those_PND with_II schizophrenia_NN remains_VVZ unclear_JJ ._.
P12535460A15
The_DD final_JJ total_NN of_II participants_NNS included_VVN in_II the_DD meta-analysis_NN was_VBD 224_MC ._.
P12535468A13
Four_MC RCTs_NNS evaluated_VVD the_DD beta-blockers_NNS ,_, propranolol_NN and_CC pindolol_NN ,_, one_MC RCT_NN evaluated_VVD the_DD central_JJ nervous_JJ system_NN stimulant_NN ,_, methylphenidate_NN and_CC one_MC RCT_NN evaluated_VVD amantadine_NN ,_, a_DD drug_NN normally_RR used_VVN in_II parkinsonism_NN and_CC related_VVNJ disorders_NNS ._.
P12535472A15
The_DD risk_NN of_II a_DD carry-over_JJ effect_NN into_II the_DD second_JJ arm_NN meant_VVB that_CST these_DD results_NNS were_VBD not_RR analysed_VVN ._.
P12535476A08
The_DD manufacturers_NNS of_II amantadine_NN were_VBD contacted_VVN ._.
P12535479A20
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: Budesonide_NN is_VBZ effective_JJ in_II the_DD treatment_NN of_II collagenous_JJ colitis_NN ._.
P12535486A10
Quantitative_JJ data_NNS are_VBB presented_VVN using_VVG relative_JJ risks_NNS or_CC mean_NN differences_NNS together_RR with_II 95_MC per_II cent_MC confidence_NN limits_NNS ._.
P12535495A15
Quality_NN of_II life_NN was_VBD not_RR adequately_RR evaluated_VVN in_II the_DD studies_NNS ._.
P12535501A07
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: Trial_NN inclusion_NN and_CC methodological_JJ quality_NN was_VBD assessed_VVN by_II two_MC independent_JJ reviewers_NNS according_II+ to_II predetermined_VVNJ criteria_NNS ._.
P12535505A18
There_EX was_VBD no_DD significant_JJ difference_NN in_II readmission_NN rates_NNS between_II day_NN hospital_NN patients_NNS and_CC controls_NNS (_( n=667_NN ,_, 5_MC RCTs_NNS ,_, RR_NN 0.91_MC CI_NN 0.72_MC to_II 1.15_MC )_) ._.
P12535509A08
NPPV_NN resulted_VVD in_II decreased_VVNJ mortality_NN (_( Relative_JJ Risk_NN [_( RR_NN ]_) 0.41_MC ;_: 95_MC %_SYM Confidence_NN Intervals_NNS [_( CI_NN ]_) 0.26_MC ,_, 0.64_MC )_) ,_, decreased_VVNJ need_NN for_II intubation_NN (_( RR_NN 0.42_MC ;_: 95_MC %_SYM CI_NN 0.31_MC ,_, 0.59_MC )_) ,_, reduction_NN in_II treatment_NN failure_NN (_( RR_NN 0.51_MC ;_: 95_MC %_SYM CI_NN 0.39_MC ,_, 0.67_MC )_) ,_, rapid_JJ improvement_NN within_II the_DD first_JJ hour_NN in_II pH_NN (_( Weight_NN Mean_NN Difference_NN [_( WMD_NN ]_) 0.03_MC ;_: 95_MC %_SYM CI_NN 0.02_MC ,_, 0.04_MC )_) ,_, PaCO2_NN (_( WMD_NN -0.40_MC kPa_NN ;_: 95_MC %_SYM CI_NN -0.78_MC ,_, -0.03_MC )_) and_CC respiratory_JJ rate_NN (_( WMD_NN -3.08_MC bpm_NN ;_: 95_MC %_SYM CI_NN -4.26_MC ,_, -1.89_MC )_) ._.
P12540330A04
OUTCOMES_NNS MEASURED_VVN :_: To_TO prepare_VVI the_DD data_NNS ,_, systematic_JJ reviews_NNS were_VBD performed_VVN for_II low_JJ back_NN ,_, knee_NN ,_, neck_NN ,_, and_CC shoulder_NN pain_NN ._.
P12544987A10
Both_CC univariate_JJ and_CC multivariable_JJ regression_NN analyses_NNS showed_VVD a_DD consistent_JJ relative_JJ risk_NN reduction_NN in_II 28-day_NN mortality_NN rates_NNS for_II drotrecogin_NN alfa_NN (_( activated_VVNJ )_) ._.
P12552027A05
Studies_NNS of_II side_NN effects_NNS of_II anticonvulsants_NNS commonly_RR used_VVN to_TO treat_VVI seizures_NNS in_II children_NNS are_VBB also_RR reviewed_VVN ._.
P12554124A04
Osteoarthritis_NN (_( OA_NN )_) is_VBZ one_MC of_II the_DD chronic_JJ conditions_NNS for_II which_PNR HRT_NN has_VHZ been_VBN suggested_VVN to_TO provide_VVI beneficial_JJ outcomes_NNS ._.
P12563091A04
Therefore_RR ,_, a_DD predictive_JJ marker_NN of_II PE_NN emergence_NN is_VBZ critical_JJ ._.
P12570125A11
Therapeutic_JJ modalities_NNS such_II+ as_II new_JJ drugs_NNS ,_, e.g._II epoprostenol_NN ,_, treprostinil_NN and_CC bosentan_NN ,_, and_CC surgical_JJ interventions_NNS ,_, e.g._II transplantation_NN and_CC blade_NN septostomy_NN ,_, which_PNR were_VBD unavailable_JJ several_JJ decades_NNS ago_RR ,_, have_VHB had_VHD a_DD significant_JJ impact_NN on_II prognosis_NN and_CC outcome_NN ._.
P12574007A03
The_DD authors_NNS also_RR searched_VVD the_DD citations_NNS of_II selected_VVNJ studies_NNS and_CC contacted_VVD relevant_JJ authors_NNS and_CC manufacturers_NNS ._.
P12577161A02
Sepsis_NN is_VBZ the_DD systemic_JJ inflammatory_JJ response_NN to_II infection_NN ,_, often_RR associated_VVN with_II hypoperfusion_NN followed_VVN by_II tissue_NN injury_NN and_CC organ_NN failure_NN ._.
P12578514A09
CONCLUSIONS_NNS :_: Lipid_NN therapy_NN with_II statins_NNS can_VM reduce_VVB CVD_NN morbidity_NN and_CC mortality_NN as_CS demonstrated_VVN in_II a_DD number_NN of_II clinical_JJ trials_NNS ._.
P12587942A05
The_DD data_NN for_II its_PNG effective_JJ use_NN in_II the_DD medical_JJ phase_NN of_II therapy_NN for_II patients_NNS with_II acute_JJ coronary_JJ syndromes_NNS ,_, however_RR ,_, is_VBZ not_RR as_RR consistent_JJ ._.
P12595913A04
However_RR ,_, more_DD controlled_VVNJ studies_NNS addressing_VVG this_DD issue_NN are_VBB needed_VVN ._.
P12602664A06
The_DD combination_NN of_II a_DD leukotriene_NN receptor_NN antagonist_NN and_CC an_DD antihistamine_NN has_VHZ not_RR been_VBN proven_VVN to_TO be_VBI more_RR effective_JJ than_CSN either_DD agent_NN alone_JJ ._.
P12612871A07
RESULTS_NNS :_: Documentation_NN of_II low-density_NN lipoprotein_NN (_( LDL_NN )_) cholesterol_NN was_VBD significantly_RR lower_JJR in_II patients_NNS with_II CAD+HF_NN (_( 53_MC %_SYM )_) compared_VVN with_II those_PND with_II CAD_NN alone_JJ (_( 69_MC %_SYM )_) ._.
P12617510A13
Vaccinia_NN can_VM be_VBB transmitted_VVN from_II a_DD vaccinee_NN 's_GE unhealed_VVNJ vaccination_NN site_NN to_II other_JJ persons_NNS by_II close_JJ contact_NN and_CC can_VM lead_VVB to_II the_DD same_JJ adverse_JJ events_NNS as_CSN in_II the_DD vaccinee_NN ._.
P12622601A05
The_DD quality_NN of_II retrieved_VVNJ articles_NNS was_VBD rated_VVN as_II "_`` good_JJ ,_, "_'' "_`` fair_JJ ,_, "_'' or_CC "_`` poor_JJ ,_, "_'' and_CC sensitivity_NN ,_, specificity_NN ,_, and_CC diagnostic_JJ yield_NN of_II tests_NNS were_VBD calculated_VVN ._.
P12628892A11
CONCLUSION_NN :_: Based_VVN on_II surrogate_JJ markers_NNS ,_, heliox_NN may_VM offer_VVB mild-to-moderate_JJ benefits_NNS in_II patients_NNS with_II acute_JJ asthma_NN within_II the_DD first_JJ hour_NN of_II use_NN ,_, but_CC its_PNG advantages_NNS become_VVB less_RR apparent_JJ beyond_II 1_MC h_NN ,_, as_CS most_DD conventionally_RR treated_VVNJ patients_NNS improve_VVB to_II similar_JJ levels_NNS ,_, with_II or_CC without_II it_PN ._.
P12633191A10
DATA_NNS SYNTHESIS_NN :_: Randomized_VVNJ controlled_VVNJ trials_NNS have_VHB shown_VVN that_CST fecal_JJ occult_JJ blood_NN testing_VVGN can_VM reduce_VVB colorectal_JJ cancer_NN incidence_NN and_CC mortality_NN ._.
P12637112A16
Current_JJ evidence_NN supports_VVZ their_PNG use_NN as_II adjuncts_NNS to_II lifestyle_NN modifications_NNS in_II the_DD treatment_NN of_II obesity_NN ._.
P12641480A03
However_RR ,_, until_CS recently_RR ,_, there_EX has_VHZ been_VBN uncertainty_NN about_II the_DD consistency_NN of_II such_DD benefits_NNS across_II different_JJ patient_NN groups_NNS and_CC in_II particular_NN ,_, for_II older_JJR people_NNS and_CC in_II those_PND with_II a_DD history_NN of_II stroke_NN ._.
P12644345A06
The_DD Antithrombotic_JJ Trialists_NNS '_GE Collaboration_NN found_VVD a_DD 46_MC %_SYM reduction_NN in_II vascular_JJ events_NNS with_II antiplatelet_NN therapy_NN (_( mostly_RR aspirin_NN )_) ._.
P12646338A05
Also_RR ,_, in_II comparisons_NNS with_II simvastatin_NN 20_MC mg_NN and_CC pravastatin_NN 20_MC mg_NN ,_, 86_MC %_SYM of_II patients_NNS treated_VVN with_II rosuvastatin_NN 10_MC mg_NN achieved_VVD ATP_NN III_MC goals_NNS ,_, compared_VVN with_II 64_MC %_SYM of_II simvastatin-treated_VVNJ patients_NNS and_CC 49_MC %_SYM of_II pravastatin-treated_VVNJ patients_NNS (_( p_NN <_SYM 0.001_MC )_) ._.
P12656536A01
OBJECTIVES_NNS :_: The_DD recognition_NN that_CST alveolar_JJ overdistension_NN rather_II+ than_II peak_JJ inspiratory_JJ airway_NN pressure_NN is_VBZ the_DD primary_JJ determinant_NN of_II lung_NN injury_NN has_VHZ shifted_VVN our_PNG understanding_VVGN of_II the_DD pathogenesis_NN of_II ventilator-induced_VVNJ side_NN effects_NNS ._.
P12660659A07
Despite_II the_DD overall_JJ safety_NN and_CC efficacy_NN of_II these_DD agents_NNS ,_, many_DD patients_NNS undergoing_VVG statin_NN therapy_NN fail_VVB to_TO achieve_VVI the_DD treatment_NN goals_NNS specified_VVN in_II the_DD National_JJ Cholesterol_NN Education_NN Program_NN Adult_NN Treatment_NN Panel_NN III_MC guidelines_NNS ,_, often_RR because_II+ of_II suboptimal_JJ use_NN ,_, tolerability_NN problems_NNS ,_, or_CC lack_NN of_II compliance_NN ._.
P12662126A08
In_II approximately_RR 10_MC %_SYM of_II patients_NNS ,_, however_RR ,_, severe_JJ infusion-related_VVNJ reactions_NNS develop_VVB (_( e.g._II bronchospasm_NN ,_, hypotension_NN )_) ._.
P12664086A09
Sensitivity_NN analysis_NN suggests_VVZ that_CST this_DD effect_NN is_VBZ largely_RR dependent_JJ on_II the_DD results_NNS of_II a_DD single_JJ trial_NN (_( weighted_VVNJ mean_NN difference_NN :_: -0.9_MC kg_NN ;_: 95_MC %_SYM CI_NN :_: -2.0_MC to_II 0.2_MC kg_NN ,_, n=335_NN )_) ._.
P12667273A13
Prophylactic_JJ measures_NNS include_VVB rigorous_JJ infection_NN control_NN and_CC administration_NN of_II polyclonal_JJ (_( RSV-IGIV_NN [_( respiratory_JJ syncytial_JJ virus_NN -_: immunoglobulin_NN intravenous_JJ ]_) )_) and_CC monoclonal_JJ (_( palivizumab_NN )_) antibodies_NNS ._.
P12668909A11
This_DD review_NN discusses_VVZ the_DD diagnosis_NN and_CC management_NN of_II the_DD metabolic_JJ syndrome_NN and_CC examines_VVZ the_DD potential_NN of_II future_JJ treatment_NN options_NNS ._.
P12672771A17
Safety_NN data_NNS from_II 50_MC trials_NNS yielded_VVD estimates_NNS of_II 2.2-_MC to_II 3.6-fold_NN increases_NNS in_II odds_NNS of_II psychiatric_JJ ,_, autonomic_JJ ,_, or_CC gastrointestinal_JJ symptoms_NNS ,_, and_CC heart_NN palpitations_NNS ._.
P12678337A04
We_PN included_VVD any_DD randomized_VVNJ clinical_JJ trial_NN comparing_VVG different_JJ types_NNS of_II antibiotic_JJ prophylaxis_NN with_II placebo_NN or_CC no_DD intervention_NN in_II inpatients_NNS with_II cirrhosis_NN ._.
P12685059A06
Few_JJ diagnostic_JJ strategies_NNS have_VHB been_VBN assessed_VVN in_II ICU_NN patients_NNS with_II suspected_VVNJ PE_NN ._.
P12690649A13
In_II leukemia_NN and_CC lymphoma_NN ,_, the_DD coagulopathy_NN is_VBZ typically_RR acute_JJ DIC_NN that_PNR can_VM lead_VVB to_II systemic_JJ and_CC brain_NN hemorrhages_NNS ._.
P12692171A17
However_RR ,_, they_PN should_VM remind_VVB patients_NNS of_II the_DD importance_NN of_II communicating_VVGN test_NN results_NNS to_II family_NN members_NNS ,_, as_II part_NN of_II pretest_NN counseling_VVGN and_CC informed_VVNJ consent_NN discussions_NNS ._.
P12696988A09
We_PN put_VVB forward_RR recommendations_NNS for_II relevant_JJ outcome_NN measures_NNS ,_, timeframes_NNS ,_, endpoints_NNS and_CC epidemiologic_JJ data_NNS sources_NNS ._.
P12704479A02
Although_CS quality_NN indicators_NNS have_VHB been_VBN developed_VVN in_II other_JJ countries_NNS ,_, Canadian_JJ cardiovascular_JJ disease_NN indicators_NNS do_VDB not_RR exist_VVB ._.
P12708950A01
OBJECTIVE_NN :_: To_TO review_VVI the_DD pharmacology_NN ,_, pharmacokinetics_NNS ,_, efficacy_NN ,_, and_CC tolerability_NN of_II extended-release_NN (_( ER_NN )_) metoprolol_NN succinate_NN and_CC its_PNG role_NN in_II the_DD management_NN of_II chronic_JJ heart_NN failure_NN ._.
P12710848A02
The_DD systemic_JJ nature_NN of_II the_DD disease_NN is_VBZ reflected_VVN in_II the_DD fact_NN that_CST individuals_NNS with_II PAD_NN or_CC carotid_JJ artery_NN disease_NN are_VBB more_RR likely_RR to_TO have_VHI CAD_NN than_CSN those_PND without_II ._.
P12715671A07
We_PN also_RR searched_VVD the_DD Cochrane_NNP Controlled_VVNJ trials_NNS Register_VVB (_( Cochrane_NNP Library_NN issue_NN 1_MC ,_, 2000_MC )_) the_DD Science_NN Citation_NN Index_NN ,_, BIOSIS_NN ,_, CAB-Health_NN ,_, Health_NN star_NN and_CC Economic_JJ databases_NNS ._.
P12719677A02
A_DD search_NN was_VBD conducted_VVN of_II all_DD published_VVNJ literature_NN on_II conventional_JJ search_NN engines_NNS (_( PubMed_NN ,_, EMBASE_NN ,_, the_DD Cochrane_NNP Registry_NN ,_, CINAHL_NN ,_, LILACS_NN )_) and_CC alternative_JJ medicine_NN databases_NNS (_( Natural_JJ Medicines_NNS Comprehensive_JJ Database_NN ,_, Longwood_NNP Herbal_NN Taskforce_NN ,_, and_CC Alternative_JJ Medicine_NN Alert_NN )_) ,_, for_II all_DD studies_NNS of_II the_DD five_MC most_RRT commonly_RR used_VVNJ CAM_NN treatments_NNS of_II vaginitis_NN ._.
P12725011A05
There_EX are_VBB no_DD well-conducted_VVNJ ,_, randomized_VVNJ clinical_JJ trials_NNS to_TO guide_VVI practitioners_NNS ._.
P12729427A04
DATA_NNS SOURCES_NNS :_: Accuracy_NN and_CC complications_NNS of_II diagnostic_JJ tests_NNS were_VBD estimated_VVN by_II using_VVGN meta-analysis_NN and_CC literature_NN review_NN ._.
P12735123A17
Although_CS many_DD clinicians_NNS share_VVB a_DD nihilistic_JJ view_NN regarding_VVG the_DD potential_JJ usefulness_NN of_II mechanical_JJ ventilation_NN in_II elderly_JJ patients_NNS few_JJ data_NNS warrant_VVB this_DD negative_JJ prognostication_NN and_CC more_DD outcome_NN studies_NNS are_VBB needed_VVN to_TO delineate_VVI the_DD optimum_NN application_NN of_II this_DD element_NN of_II supportive_JJ care_NN ._.
P12738981A10
In_II the_DD properly_RR selected_VVNJ woman_NN with_II symptomatic_JJ fibroids_NNS ,_, the_DD result_NN from_II the_DD selected_VVNJ treatment_NN should_VM be_VBB an_DD improvement_NN in_II the_DD quality_NN of_II life_NN ._.
P12742289A04
METHODS_NNS :_: Both_CC MEDLINE_NN (_( 1966_MC to_II December_NN 2001_MC )_) and_CC EMBASE_NN (_( 1980_MC to_II December_NN 2001_MC )_) were_VBD searched_VVN ,_, with_II supplementation_NN by_II reference_NN list_NN searches_NNS ._.
P12749504A04
METHODS_NNS :_: The_DD English-language_NN literature_NN was_VBD searched_VVN using_VVG the_DD EMBASE_NN and_CC MEDLINE_NN databases_NNS ._.
P12751912A10
Furthermore_RR ,_, the_DD total_JJ cost_NN of_II a_DD screening_VVGJ programme_NN is_VBZ difficult_JJ to_TO define_VVI since_CS it_PN extends_VVZ well_RR beyond_II the_DD initial_JJ test_NN ._.
P12759325A09
DATA_NNS SYNTHESIS_NN :_: Data_NNS were_VBD combined_VVN from_II 42_MC clinical_JJ trials_NNS that_PNR included_VVD 192478_MC patients_NNS randomized_VVN to_II 7_MC major_JJ treatment_NN strategies_NNS ,_, including_VVG placebo_NN ._.
P12769045A05
DATA_NNS EXTRACTION_NN METHODS_NNS :_: Articles_NNS were_VBD categorized_VVN as_II Intervention_NN ,_, Population_NN (_( stage_NN distribution_NN )_) ,_, or_CC Validation_NN studies_NNS ._.
P12773077A12
For_II patients_NNS undergoing_VVG primary_JJ PCI_NN for_II the_DD management_NN of_II STEMI_NN ,_, the_DD available_JJ evidence_NN supports_VVZ the_DD use_NN of_II abciximab_NN ,_, albeit_CS further_JJ investigation_NN is_VBZ warranted_VVN ._.
P12777595A16
Many_JJ characteristics_NNS of_II families_NNS have_VHB changed_VVN during_II the_DD past_NN 3_MC to_II 5_MC decades_NNS ._.
P12778842A01
Depression_NN and_CC bipolar_JJ disorder_NN are_VBB frequently_RR chronic_JJ disorders_NNS ,_, with_II onset_NN often_RR beginning_VVGN in_II childhood_NN ._.
P12781904A04
In_II the_DD Heart_NN Outcomes_NNS Prevention_NN Evaluation_NN (_( HOPE_NN )_) study_NN ,_, ramipril_NN treatment_NN in_II high-risk_NN patients_NNS was_VBD associated_VVN with_II a_DD 20_MC %_SYM reduction_NN in_II the_DD risk_NN for_II myocardial_JJ infarction_NN ;_: mean_NN reduction_NN in_II blood_NN pressure_NN was_VBD 3_MC mm_NN Hg_NN for_II systolic_JJ blood_NN pressure_NN and_CC 1_MC mm_NN Hg_NN for_II diastolic_JJ blood_NN pressure_NN ._.
P12784781A09
The_DD odds_NNS ratios_NNS for_II stenting_VVGN vs_CC CABG_NN were_VBD 0.82_MC (_( 95_MC %_SYM confidence_NN interval-CI_NN 0.57-1.18_MC ,_, p_NN =_SYM 0.3_MC )_) for_II the_DD occurrence_NN of_II death_NN ,_, non-fatal_JJ myocardial_JJ infarction_NN or_CC stroke_NN ,_, 4.6_MC (_( 95_MC %_SYM CI_NN 3.5-5.9_MC ,_, p_NN <_SYM 0.00001_MC )_) for_II repeat_NN revascularization_NN ,_, and_CC 2.3_MC (_( 95_MC %_SYM CI_NN 1.8-2.8_MC ,_, p_NN <_SYM 0.00001_MC )_) for_II symptomatic_JJ angina_NN ._.
P12788842A03
Observational_JJ studies_NNS suggest_VVB a_DD protective_JJ role_NN of_II estrogen_NN ,_, whereas_CS recent_JJ randomized_VVNJ controlled_VVNJ trials_NNS report_VVB a_DD negative_JJ role_NN for_II oral_JJ estrogen_NN in_II primary_JJ and_CC secondary_JJ prevention_NN of_II cardiovascular_JJ events_NNS ._.
P12793924A07
High-risk_NN categories_NNS include_VVB congenital_JJ and_CC acquired_VVNJ immunodeficiency_NN ,_, younger_JJR age_NN ,_, transfusion_NN of_II blood_NN donated_VVN by_II family_NN members_NNS ,_, and_CC transfusion_NN with_II fresh_JJ whole_JJ blood_NN ._.
P12796751A01
BACKGROUND_NN :_: Coronary_JJ stent_NN placement_NN has_VHZ replaced_VVN balloon_NN angioplasty_NN as_II the_DD percutaneous_JJ coronary_JJ intervention_NN (_( PCI_NN )_) method_NN of_II choice_NN ,_, primarily_RR because_II+ of_II its_PNG lower_JJR restenosis_NN rate_NN ._.
P12800564A35
When_CS historical_JJ data_NNS are_VBB not_RR available_JJ ,_, the_DD Six_MC Sigma_NN team_NN must_VM collect_VVB baseline_NN data_NNS as_II one_MC of_II their_PNG earliest_JJT tasks_NNS ._.
P12804385A15
In_II the_DD bupropion_NN trials_NNS ,_, 18_MC had_VHD a_DD placebo_NN arm_NN ,_, two_MC of_II which_PNR tested_VVD long-term_NN use_NN to_TO prevent_VVI relapse_NN ._.
P12804392A22
Clinicians_NNS should_VM weigh_VVB the_DD moderate_JJ benefits_NNS of_II antibiotic_JJ treatment_NN against_II the_DD potential_NN for_II adverse_JJ effects_NNS ._.
P12804400A08
Analysis_NN was_VBD on_II an_DD intention-to-treat_NN basis_NN ._.
P12804406A27
Combined_VVNJ oestrogen_NN and_CC progesterone_NN appeared_VVD to_TO reduce_VVI the_DD likelihood_NN of_II cure_NN or_CC improvement_NN ._.
P12804410A17
Subgroups_NNS of_II patients_NNS may_VM gain_VVB benefit_NN ,_, but_CC it_PN appears_VVZ difficult_JJ to_TO predict_VVI responders_NNS ._.
P12804416A17
REVIEWER_NN 'S_GE CONCLUSIONS_NNS :_: We_PN did_VDD not_RR find_VVB convincing_VVGJ evidence_NN that_CST BCAA_NN had_VHD a_DD significant_JJ beneficial_JJ effect_NN on_II patients_NNS with_II hepatic_JJ encephalopathy_NN ._.
P12804421A18
Since_CS no_DD clear_JJ rationale_NN exists_VVZ for_II biphasic_JJ pills_NNS and_CC since_RR extensive_JJ evidence_NN is_VBZ available_JJ for_II monophasic_JJ pills_NNS ,_, the_DD latter_NN are_VBB preferred_VVN ._.
P12804425A02
OBJECTIVES_NNS :_: To_TO determine_VVI the_DD benefit_NN of_II methylxanthines_NNS compared_VVN to_II placebo_NN for_II COPD_NN exacerbations_NNS ._.
P12804428A14
The_DD rehabilitation_NN program_NN was_VBD required_VVN to_TO be_VBI multidisciplinary_JJ ,_, i.e._CC ,_, it_PN had_VHD to_TO consist_VVI of_II a_DD physician_NN 's_GE consultation_NN plus_II either_CC a_DD psychological_JJ ,_, social_JJ or_CC vocational_JJ intervention_NN ,_, or_CC a_DD combination_NN of_II these_PND ._.
P12804436A02
OBJECTIVES_NNS :_: To_TO determine_VVI whether_CST there_EX is_VBZ evidence_NN to_TO support_VVI the_DD use_NN of_II KMC_NN in_II LBW_NN infants_NNS as_II an_DD alternative_NN to_II conventional_JJ care_NN after_II the_DD initial_JJ period_NN of_II stabilization_NN with_II conventional_JJ care_NN ._.
P12804442A20
Subgroup_NN analyses_NNS failed_VVD to_TO identify_VVI a_DD disproportionate_JJ benefit_NN of_II treatment_NN according_II+ to_II the_DD allergen_NN administered_VVN ._.
P12804447A09
An_DD update_NN search_NN was_VBD conducted_VVN on_II 12th_JJ August_NN 2002_MC ._.
P12804453A06
The_DD Cochrane_NNP Effective_JJ Practice_NN and_CC Organisation_NN of_II Care_NN Specialised_VVNJ Register_NN ,_, the_DD Cochrane_NNP Rehabilitation_NN Specialist_NN Register_NN ;_: Cochrane_NNP Controlled_VVNJ Trials_NNS Register_NN (_( CCTR_NN )_) ;_: MEDLINE_NN (_( 1966-2000_MC )_) ;_: EMBASE_NN (_( 1980-2000_MC )_) ,_, Cumulative_JJ Index_NN to_II Nursing_VVGN and_CC Allied_NN Health_NN Literature_NN (_( CINAHL_NN )_) (_( 1982-2000_MC )_) :_: Science_NN Citation_NN Index_NN (_( 1982-2000_MC )_) ;_: Social_JJ Science_NN Citation_NN Index_NN (_( 1982-2000_MC )_) ;_: Best_JJT Evidence_NN (_( 1991-2000_MC )_) ;_: HMIC_NN (_( 1979-2000_MC )_) ;_: PsycINFO_NN (_( 1967-2000_MC )_) ;_: ASSIA_NN (_( 1987-2000_MC )_) ;_: Ageline_NN (_( 1978-2000_MC )_) ;_: AgeInfo_NN (_( 1971-2000_MC )_) ;_: Sociological_JJ Abstracts_NNS (_( 1963-2000_MC )_) ;_: System_NN for_II Information_NN on_II Grey_JJ Literature_NN (_( SIGLE_NN )_) (_( 1980-2000_MC )_) ;_: UK_NNP National_JJ Research_NN Registers_NNS Project_NN Database_NN (_( Issue_NN 12001_MC )_) ;_: Architecture_NN Publication_NN Index_NN (_( 1977-2000_MC )_) ._.
P12804456A24
These_DD results_NNS were_VBD not_RR sensitive_JJ to_II the_DD assumption_NN made_VVN because_CS the_DD overall_JJ benefit_NN estimated_VVN was_VBD still_RR significant_JJ when_CS the_DD correlation_NN was_VBD assumed_VVN to_TO be_VBI less_RR than_CSN 0.1_MC ._.
P12804461A13
The_DD reviewers_NNS assumed_VVD that_CST people_NNS who_PNR died_VVD or_CC dropped_VVD out_II had_VHD no_DD improvement_NN and_CC tested_VVD the_DD sensitivity_NN of_II the_DD final_JJ results_NNS to_II this_DD assumption_NN ._.
P12804466A08
SELECTION_NN CRITERIA_NNS :_: All_DD randomised_VVNJ and_CC quasi-randomised_VVNJ trials_NNS involving_VVG agents_NNS that_PNR reduce_VVB gastric_JJ acidity_NN compared_VVN to_II placebo_NN or_CC a_DD comparator_NN treatment_NN ._.
P12804469A20
The_DD incidence_NN of_II decreased_VVNJ urine_NN output_NN (_( <_SYM 1cc_NN /_SYM kg_NN /_SYM hr_NN )_) was_VBD lower_JJR in_II the_DD ibuprofen_NN group_NN as_CS compared_VVN to_II the_DD indomethacin_NN group_NN [_( NNT_NN 9_MC (_( 95_MC %_SYM CI_NN 5-14_MC )_) ]_) ._.
P12804475A10
We_PN entered_VVD and_CC analyzed_VVD data_NNS with_II RevMan_NN 4.1_MC ._.
P12804481A11
MAIN_JJ RESULTS_NNS :_: 18_MC trials_NNS involving_VVG 1891_MC people_NNS were_VBD included_VVN ._.
P12804486A29
Neuropsychiatric_JJ and_CC cognitive_JJ adverse_JJ events_NNS occur_VVB more_RR frequently_RR on_II anticholinergics_NNS than_CSN on_II placebo_NN and_CC are_VBB a_DD more_RR common_JJ reason_NN for_II withdrawal_NN than_CSN lack_NN of_II efficacy_NN ._.
P12804493A04
Several_JJ surgical_JJ techniques_NNS have_VHB been_VBN developed_VVN to_TO regenerate_VVI periodontal_JJ tissues_NNS including_VVG guided_VVNJ tissue_NN regeneration_NN (_( GTR_NN )_) ,_, bone_NN grafting_VVGN (_( BG_NN )_) and_CC the_DD use_NN of_II enamel_NN matrix_NN derivative_NN (_( EMD_NN )_) ._.
P12804498A11
The_DD data_NNS selected_VVN would_VM reflect_VVB cognitive_JJ ,_, behavioural_JJ ,_, physical_JJ and_CC psychological_JJ domains_NNS of_II AD_NN ._.
P12804502A13
Substantial_JJ statistical_JJ heterogeneity_NN was_VBD observed_VVN (_( p_NN <_SYM 0.001_MC )_) ._.
P12804506A08
DATA_NNS COLLECTION_NN AND_CC ANALYSIS_NN :_: Two_MC trials_NNS (_( 418_MC subjects_NNS )_) met_VVD the_DD inclusion_NN criteria_NNS for_II this_DD review_NN ._.
P12804510A01
BACKGROUND_NN :_: Therapeutic_JJ exercise_NN is_VBZ used_VVN as_II one_MC modality_NN to_TO treat_VVI people_NNS with_II osteoarthritis_NN (_( OA_NN )_) ._.
P12806450A11
Participants_NNS in_II the_DD studies_NNS were_VBD primiparous_JJ women_NNS ._.
P12812622A03
Because_CS there_EX is_VBZ no_DD cure_NN for_II this_DD costly_JJ disease_NN ,_, goals_NNS of_II therapy_NN include_VVB ;_: slowing_VVGN progression_NN ,_, increasing_VVGN patient_NN survival_NN ,_, minimizing_VVGN symptoms_NNS ,_, improving_VVGN patient_NN functional_JJ capacity_NN ,_, and_CC decreasing_VVGN ER_NN visits_NNS ,_, hospital_NN admissions_NNS ,_, and_CC readmissions_NNS ._.
P12816555A02
This_DD final_JJ article_NN reviews_VVZ the_DD role_NN of_II long-term_NN HRT_NN in_II stroke_NN ,_, Alzheimer_NNP 's_GE disease_NN (_( AD_NN )_) ,_, and_CC overall_JJ mortality_NN as_CC+ well_CC+ as_CC strategies_NNS to_TO guide_VVI decision-making_VVGN for_II the_DD individual_JJ patient_NN ._.
P12820712A30
Therefore_RR ,_, for_II patients_NNS with_II sufficient_JJ cardiopulmonary_JJ reserve_NN who_PNR can_VM be_VBB clinically_RR staged_VVN as_II IA_NN or_CC IB_NN ,_, either_CC by_II good_JJ quality_NN CT_NN with_II contrast_NN or_CC increasingly_RR with_II 18-FDG_NN PET_NN ,_, the_DD initial_JJ tissue_NN diagnosis_NN may_VM be_VBB at_II the_DD time_NN of_II surgery_NN ,_, when_CS a_DD frozen_VVNJ section_NN preceding_VVG a_DD complete_JJ lobectomy_NN with_II lymph_NN node_NN sampling_VVGN will_VM combine_VVB diagnosis_NN and_CC therapy_NN ._.
P12825147A03
The_DD pharmacologic_JJ options_NNS are_VBB divided_VVN into_II initiators_NNS versus_CC conditioners_NNS and_CC central-_JJ or_CC peripheral-acting_VVGJ drugs_NNS ._.
P12829553A01
OBJECTIVES_NNS :_: To_TO determine_VVI the_DD combination_NN of_II drugs_NNS and_CC vitamins_NNS ,_, and_CC their_PNG doses_NNS ,_, for_II use_NN in_II a_DD single_JJ daily_JJ pill_JJ to_TO achieve_VVI a_DD large_JJ effect_NN in_II preventing_VVGN cardiovascular_JJ disease_NN with_II minimal_JJ adverse_JJ effects_NNS ._.
P12834569A03
Current_JJ positive_JJ inotropes_NNS (_( eg_II ,_, dobutamine_NN and_CC phosphodiesterase_NN inhibitors_NNS )_) provide_VVB symptomatic_JJ relief_NN ,_, but_CC newer_JJR agents_NNS may_VM have_VHB a_DD better_JJR adverse_JJ effect_NN profile_NN ._.
P12841826A03
OBJECTIVE_NN :_: To_TO provide_VVI a_DD concise_JJ state-of-the-art_NN review_NN of_II the_DD most_RRT commonly_RR used_VVNJ automated_VVNJ signal_NN detection_NN procedures_NNS ,_, including_VVG the_DD underlying_VVGJ statistical_JJ concepts_NNS ,_, performance_NN characteristics_NNS ,_, and_CC outstanding_VVGJ limitations_NNS ,_, and_CC issues_NNS to_TO be_VBI resolved_VVN ._.
P12848590A04
Erlotinib_NN is_VBZ undergoing_VVG clinical_JJ development_NN as_II an_DD oral_JJ tablet_NN by_II an_DD alliance_NN between_II OSI_NN Pharmaceuticals_NNS ,_, Genentech_NN and_CC Roche_NNP ._.
P12852701A02
The_DD fixed-dose_NN combination_NN of_II trandolapril_NN and_CC verapamil_NN extended_VVNJ release_NN (_( ER_NN )_) is_VBZ approved_VVN for_II the_DD treatment_NN of_II hypertension_NN only_RR ._.
P12853542A16
CONCLUSIONS_NNS :_: This_DD meta-analysis_NN of_II 3_MC months_NNS of_II NIPPV_NN in_II patients_NNS with_II stable_JJ COPD_NN showed_VVD that_CST ventilatory_JJ support_NN did_VDD not_RR improve_VVB lung_NN function_NN ,_, gas_NN exchange_NN ,_, or_CC sleep_NN efficiency_NN ._.
P12858126A05
Among_II available_JJ dyslipidemic_JJ therapies_NNS ,_, although_CS statins_NNS remain_VVB the_DD mainstay_NN for_II lowering_VVGN low-density_NN lipoprotein_NN cholesterol_NN and_CC clinical_JJ events_NNS ,_, niacin_NN is_VBZ currently_RR the_DD most_RRT effective_JJ agent_NN for_II increasing_VVGN low_JJ high-density_NN lipoprotein_NN cholesterol_NN levels_NNS ._.
P12862115A27
There_EX is_VBZ need_VVB to_TO combine_VVI data_NNS collection_NN methods_NNS ,_, such_II+ as_II interview_NN surveys_NNS ,_, hospital_NN records_NNS ,_, police_NN records_NNS ,_, focus_NN group_NN discussions_NNS and_CC key_JJ informant_NN interviews_NNS ._.
P12879083A08
Nine_MC trials_NNS evaluated_VVD protein_NN and_CC energy_NN supplementation_NN (_( five_MC oral_JJ and_CC four_MC nasogastric_JJ feeding_VVGN )_) ,_, and_CC a_DD further_JJ three_MC trials_NNS tested_VVD oral_JJ protein_NN supplementation_NN ._.